# ESC Guidelines: Cardiac Pacing CRT (2021)

**Source**: `2021_Cardiac_Pacing_CRT.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 94

---

## Table of Contents

- [ehab364-1](#ehab364-1) *(p. 6)*
- [ehab364-2](#ehab364-2) *(p. 8)*
- [ehab364-2.1](#ehab364-21) *(p. 8)*
- [ehab364-2.2](#ehab364-22) *(p. 8)*
- [ehab364-2.3](#ehab364-23) *(p. 8)*
- [ehab364-2.3.1](#ehab364-231) *(p. 8)*
- [tblfn1](#tblfn1) *(p. 8)*
- [ehab364-2.3.2](#ehab364-232) *(p. 9)*
- [ehab364-2.3.3](#ehab364-233) *(p. 13)*
- [ehab364-3](#ehab364-3) *(p. 13)*
- [ehab364-3.1](#ehab364-31) *(p. 13)*
- [tblfn2](#tblfn2) *(p. 13)*
- [tblfn3](#tblfn3) *(p. 13)*
- [tblfn4](#tblfn4) *(p. 13)*
- [tblfn5](#tblfn5) *(p. 13)*
- [tblfn6](#tblfn6) *(p. 13)*
- [tblfn7](#tblfn7) *(p. 13)*
- [tblfn8](#tblfn8) *(p. 13)*
- [tblfn9](#tblfn9) *(p. 13)*
- [tblfn10](#tblfn10) *(p. 13)*
- [tblfn11](#tblfn11) *(p. 13)*
- [tblfn12](#tblfn12) *(p. 13)*
- [tblfn13](#tblfn13) *(p. 13)*
- [tblfn15](#tblfn15) *(p. 13)*
- [tblfn16](#tblfn16) *(p. 13)*
- [ehab364-3.2](#ehab364-32) *(p. 14)*
- [ehab364-3.3](#ehab364-33) *(p. 14)*
- [ehab364-3.4](#ehab364-34) *(p. 15)*
- [ehab364-3.4.1](#ehab364-341) *(p. 15)*
- [ehab364-3.4.2](#ehab364-342) *(p. 15)*
- [ehab364-3.4.3](#ehab364-343) *(p. 16)*
- [ehab364-3.4.4](#ehab364-344) *(p. 16)*
- [ehab364-3.4.4.1](#ehab364-3441) *(p. 16)*
- [ehab364-3.4.4.2](#ehab364-3442) *(p. 16)*
- [ehab364-3.4.5](#ehab364-345) *(p. 16)*
- [ehab364-3.4.6](#ehab364-346) *(p. 16)*
- [ehab364-3.5](#ehab364-35) *(p. 16)*
- [ehab364-4](#ehab364-4) *(p. 16)*
- [ehab364-4.1](#ehab364-41) *(p. 16)*
- [tblfn17](#tblfn17) *(p. 17)*
- [ehab364-4.2](#ehab364-42) *(p. 18)*
- [ehab364-4.3](#ehab364-43) *(p. 18)*
- [tblfn18](#tblfn18) *(p. 18)*
- [tblfn19](#tblfn19) *(p. 18)*
- [tblfn20](#tblfn20) *(p. 18)*
- [tblfn21](#tblfn21) *(p. 18)*
- [tblfn22](#tblfn22) *(p. 18)*
- [tblfn23](#tblfn23) *(p. 18)*
- [ehab364-4.3.1](#ehab364-431) *(p. 19)*
- [ehab364-4.3.2](#ehab364-432) *(p. 19)*
- [ehab364-4.3.3](#ehab364-433) *(p. 19)*
- [tblfn24](#tblfn24) *(p. 19)*
- [tblfn25](#tblfn25) *(p. 19)*
- [tblfn26](#tblfn26) *(p. 19)*
- [tblfn27](#tblfn27) *(p. 19)*
- [tblfn28](#tblfn28) *(p. 19)*
- [tblfn29](#tblfn29) *(p. 19)*
- [tblfn30](#tblfn30) *(p. 19)*
- [tblfn31](#tblfn31) *(p. 19)*
- [ehab364-4.3.4](#ehab364-434) *(p. 20)*
- [ehab364-4.3.5](#ehab364-435) *(p. 20)*
- [tblfn32](#tblfn32) *(p. 20)*
- [tblfn33](#tblfn33) *(p. 20)*
- [tblfn34](#tblfn34) *(p. 20)*
- [tblfn35](#tblfn35) *(p. 20)*
- [tblfn36](#tblfn36) *(p. 20)*
- [tblfn37](#tblfn37) *(p. 20)*
- [ehab364-4.3.6](#ehab364-436) *(p. 21)*
- [ehab364-4.3.7](#ehab364-437) *(p. 21)*
- [ehab364-4.4](#ehab364-44) *(p. 21)*
- [tblfn38](#tblfn38) *(p. 21)*
- [tblfn39](#tblfn39) *(p. 21)*
- [tblfn40](#tblfn40) *(p. 21)*
- [tblfn41](#tblfn41) *(p. 21)*
- [tblfn42](#tblfn42) *(p. 21)*
- [tblfn43](#tblfn43) *(p. 21)*
- [tblfn44](#tblfn44) *(p. 21)*
- [tblfn45](#tblfn45) *(p. 21)*
- [tblfn46](#tblfn46) *(p. 21)*
- [tblfn47](#tblfn47) *(p. 21)*
- [tblfn48](#tblfn48) *(p. 21)*
- [ehab364-4.5](#ehab364-45) *(p. 22)*
- [ehab364-5](#ehab364-5) *(p. 23)*
- [ehab364-5.1](#ehab364-51) *(p. 23)*
- [ehab364-5.1.1](#ehab364-511) *(p. 23)*
- [ehab364-5.1.1.1](#ehab364-5111) *(p. 23)*
- [tblfn49](#tblfn49) *(p. 23)*
- [tblfn50](#tblfn50) *(p. 23)*
- [tblfn51](#tblfn51) *(p. 23)*
- [ehab364-5.1.1.2](#ehab364-5112) *(p. 24)*
- [ehab364-5.1.2](#ehab364-512) *(p. 24)*
- [ehab364-5.2](#ehab364-52) *(p. 26)*
- [ehab364-5.2.1](#ehab364-521) *(p. 26)*
- [ehab364-5.2.1.1](#ehab364-5211) *(p. 26)*
- [ehab364-5.2.1.2](#ehab364-5212) *(p. 26)*
- [ehab364-5.2.1.3](#ehab364-5213) *(p. 26)*
- [ehab364-5.2.1.4](#ehab364-5214) *(p. 26)*
- [tblfn52](#tblfn52) *(p. 26)*
- [tblfn53](#tblfn53) *(p. 26)*
- [tblfn54](#tblfn54) *(p. 26)*
- [ehab364-5.2.2](#ehab364-522) *(p. 27)*
- [ehab364-5.2.2.1](#ehab364-5221) *(p. 27)*
- [ehab364-5.2.2.2](#ehab364-5222) *(p. 27)*
- [tblfn55](#tblfn55) *(p. 27)*
- [tblfn56](#tblfn56) *(p. 27)*
- [tblfn57](#tblfn57) *(p. 27)*
- [tblfn58](#tblfn58) *(p. 27)*
- [ehab364-5.3](#ehab364-53) *(p. 28)*
- [ehab364-5.3.1](#ehab364-531) *(p. 28)*
- [ehab364-5.3.1.1](#ehab364-5311) *(p. 28)*
- [ehab364-5.3.1.2](#ehab364-5312) *(p. 28)*
- [ehab364-5.3.1.3](#ehab364-5313) *(p. 29)*
- [ehab364-5.3.1.4](#ehab364-5314) *(p. 29)*
- [ehab364-5.3.1.5](#ehab364-5315) *(p. 29)*
- [ehab364-5.3.2](#ehab364-532) *(p. 29)*
- [tblfn59](#tblfn59) *(p. 29)*
- [tblfn60](#tblfn60) *(p. 29)*
- [tblfn61](#tblfn61) *(p. 29)*
- [ehab364-5.4](#ehab364-54) *(p. 30)*
- [ehab364-5.4.1](#ehab364-541) *(p. 31)*
- [ehab364-5.4.2](#ehab364-542) *(p. 32)*
- [ehab364-5.5](#ehab364-55) *(p. 32)*
- [ehab364-5.5.1](#ehab364-551) *(p. 32)*
- [ehab364-5.5.2](#ehab364-552) *(p. 32)*
- [ehab364-6](#ehab364-6) *(p. 32)*
- [ehab364-6.1](#ehab364-61) *(p. 32)*
- [tblfn62](#tblfn62) *(p. 32)*
- [tblfn63](#tblfn63) *(p. 32)*
- [tblfn64](#tblfn64) *(p. 32)*
- [tblfn65](#tblfn65) *(p. 32)*
- [tblfn66](#tblfn66) *(p. 32)*
- [tblfn67](#tblfn67) *(p. 32)*
- [ehab364-6.2](#ehab364-62) *(p. 33)*
- [tblfn68](#tblfn68) *(p. 34)*
- [tblfn69](#tblfn69) *(p. 34)*
- [tblfn70](#tblfn70) *(p. 34)*
- [ehab364-6.3](#ehab364-63) *(p. 35)*
- [ehab364-6.3.1](#ehab364-631) *(p. 35)*
- [ehab364-6.3.2](#ehab364-632) *(p. 35)*
- [ehab364-6.3.3](#ehab364-633) *(p. 36)*
- [ehab364-6.4](#ehab364-64) *(p. 37)*
- [tblfn71](#tblfn71) *(p. 37)*
- [tblfn72](#tblfn72) *(p. 37)*
- [tblfn73](#tblfn73) *(p. 37)*
- [tblfn74](#tblfn74) *(p. 37)*
- [tblfn75](#tblfn75) *(p. 37)*
- [tblfn76](#tblfn76) *(p. 37)*
- [tblfn77](#tblfn77) *(p. 37)*
- [ehab364-6.5](#ehab364-65) *(p. 38)*
- [ehab364-6.6](#ehab364-66) *(p. 38)*
- [tblfn78](#tblfn78) *(p. 38)*
- [tblfn79](#tblfn79) *(p. 38)*
- [tblfn80](#tblfn80) *(p. 38)*
- [ehab364-6.7](#ehab364-67) *(p. 39)*
- [tblfn81](#tblfn81) *(p. 39)*
- [tblfn82](#tblfn82) *(p. 39)*
- [tblfn83](#tblfn83) *(p. 39)*
- [ehab364-7](#ehab364-7) *(p. 40)*
- [ehab364-7.1](#ehab364-71) *(p. 40)*
- [ehab364-7.2](#ehab364-72) *(p. 40)*
- [ehab364-7.2.1](#ehab364-721) *(p. 40)*
- [ehab364-7.2.2](#ehab364-722) *(p. 42)*
- [ehab364-7.2.2.1](#ehab364-7221) *(p. 42)*
- [ehab364-7.2.2.2](#ehab364-7222) *(p. 42)*
- [ehab364-7.2.2.3](#ehab364-7223) *(p. 42)*
- [tblfn84](#tblfn84) *(p. 42)*
- [ehab364-7.3](#ehab364-73) *(p. 43)*
- [ehab364-7.4](#ehab364-74) *(p. 43)*
- [tblfn85](#tblfn85) *(p. 43)*
- [tblfn86](#tblfn86) *(p. 43)*
- [tblfn87](#tblfn87) *(p. 43)*
- [ehab364-8](#ehab364-8) *(p. 44)*
- [ehab364-8.1](#ehab364-81) *(p. 44)*
- [ehab364-8.2](#ehab364-82) *(p. 44)*
- [ehab364-8.2.1](#ehab364-821) *(p. 44)*
- [tblfn88](#tblfn88) *(p. 44)*
- [tblfn89](#tblfn89) *(p. 44)*
- [tblfn90](#tblfn90) *(p. 44)*
- [tblfn91](#tblfn91) *(p. 44)*
- [tblfn92](#tblfn92) *(p. 44)*
- [ehab364-8.2.2](#ehab364-822) *(p. 45)*
- [ehab364-8.2.3](#ehab364-823) *(p. 45)*
- [ehab364-8.3](#ehab364-83) *(p. 46)*
- [tblfn93](#tblfn93) *(p. 46)*
- [tblfn94](#tblfn94) *(p. 46)*
- [tblfn95](#tblfn95) *(p. 46)*
- [tblfn96](#tblfn96) *(p. 47)*
- [tblfn97](#tblfn97) *(p. 47)*
- [ehab364-8.4](#ehab364-84) *(p. 48)*
- [ehab364-8.4.1](#ehab364-841) *(p. 48)*
- [ehab364-8.4.1.1](#ehab364-8411) *(p. 48)*
- [ehab364-8.4.2](#ehab364-842) *(p. 48)*
- [ehab364-8.4.2.1](#ehab364-8421) *(p. 48)*
- [tblfn98](#tblfn98) *(p. 48)*
- [tblfn99](#tblfn99) *(p. 48)*
- [tblfn100](#tblfn100) *(p. 48)*
- [tblfn101](#tblfn101) *(p. 48)*
- [tblfn102](#tblfn102) *(p. 48)*
- [tblfn103](#tblfn103) *(p. 48)*
- [tblfn104](#tblfn104) *(p. 48)*
- [tblfn105](#tblfn105) *(p. 48)*
- [tblfn106](#tblfn106) *(p. 48)*
- [ehab364-8.4.3](#ehab364-843) *(p. 49)*
- [ehab364-8.4.3.1](#ehab364-8431) *(p. 49)*
- [ehab364-8.4.4](#ehab364-844) *(p. 49)*
- [ehab364-8.5](#ehab364-85) *(p. 49)*
- [ehab364-8.5.1](#ehab364-851) *(p. 49)*
- [ehab364-8.5.2](#ehab364-852) *(p. 49)*
- [tblfn107](#tblfn107) *(p. 49)*
- [tblfn108](#tblfn108) *(p. 49)*
- [tblfn109](#tblfn109) *(p. 49)*
- [ehab364-8.5.3](#ehab364-853) *(p. 50)*
- [ehab364-8.5.4](#ehab364-854) *(p. 50)*
- [ehab364-8.6](#ehab364-86) *(p. 50)*
- [ehab364-8.6.1](#ehab364-861) *(p. 50)*
- [ehab364-8.6.2](#ehab364-862) *(p. 50)*
- [tblfn110](#tblfn110) *(p. 50)*
- [tblfn111](#tblfn111) *(p. 50)*
- [tblfn112](#tblfn112) *(p. 50)*
- [tblfn113](#tblfn113) *(p. 50)*
- [tblfn114](#tblfn114) *(p. 50)*
- [tblfn115](#tblfn115) *(p. 50)*
- [tblfn116](#tblfn116) *(p. 50)*
- [tblfn117](#tblfn117) *(p. 50)*
- [ehab364-8.6.3](#ehab364-863) *(p. 51)*
- [ehab364-8.6.4](#ehab364-864) *(p. 51)*
- [ehab364-8.6.5](#ehab364-865) *(p. 51)*
- [ehab364-8.6.6](#ehab364-866) *(p. 51)*
- [tblfn118](#tblfn118) *(p. 51)*
- [tblfn119](#tblfn119) *(p. 51)*
- [tblfn120](#tblfn120) *(p. 51)*
- [tblfn121](#tblfn121) *(p. 51)*
- [tblfn122](#tblfn122) *(p. 51)*
- [tblfn123](#tblfn123) *(p. 51)*
- [tblfn124](#tblfn124) *(p. 51)*
- [ehab364-8.6.6.1](#ehab364-8661) *(p. 52)*
- [ehab364-8.7](#ehab364-87) *(p. 52)*
- [ehab364-9](#ehab364-9) *(p. 52)*
- [ehab364-9.1](#ehab364-91) *(p. 52)*
- [ehab364-9.2](#ehab364-92) *(p. 52)*
- [ehab364-9.3](#ehab364-93) *(p. 52)*
- [tblfn125](#tblfn125) *(p. 52)*
- [tblfn126](#tblfn126) *(p. 52)*
- [tblfn127](#tblfn127) *(p. 52)*
- [tblfn128](#tblfn128) *(p. 52)*
- [ehab364-9.4](#ehab364-94) *(p. 53)*
- [ehab364-9.5](#ehab364-95) *(p. 53)*
- [tblfn129](#tblfn129) *(p. 53)*
- [tblfn130](#tblfn130) *(p. 53)*
- [ehab364-9.6](#ehab364-96) *(p. 54)*
- [ehab364-9.7](#ehab364-97) *(p. 54)*
- [ehab364-9.8](#ehab364-98) *(p. 54)*
- [ehab364-10](#ehab364-10) *(p. 55)*
- [ehab364-10.1](#ehab364-101) *(p. 55)*
- [tblfn131](#tblfn131) *(p. 55)*
- [tblfn132](#tblfn132) *(p. 55)*
- [tblfn133](#tblfn133) *(p. 55)*
- [ehab364-10.2](#ehab364-102) *(p. 56)*
- [ehab364-10.2.1](#ehab364-1021) *(p. 56)*
- [ehab364-10.2.2](#ehab364-1022) *(p. 56)*
- [ehab364-10.2.3](#ehab364-1023) *(p. 56)*
- [ehab364-10.2.4](#ehab364-1024) *(p. 56)*
- [tblfn134](#tblfn134) *(p. 56)*
- [ehab364-10.2.5](#ehab364-1025) *(p. 57)*
- [ehab364-11](#ehab364-11) *(p. 57)*
- [ehab364-11.1](#ehab364-111) *(p. 57)*
- [ehab364-11.2](#ehab364-112) *(p. 59)*
- [tblfn135](#tblfn135) *(p. 59)*
- [tblfn136](#tblfn136) *(p. 59)*
- [tblfn137](#tblfn137) *(p. 59)*
- [tblfn138](#tblfn138) *(p. 59)*
- [ehab364-11.3](#ehab364-113) *(p. 60)*
- [ehab364-11.4](#ehab364-114) *(p. 61)*
- [ehab364-11.5](#ehab364-115) *(p. 61)*
- [tblfn139](#tblfn139) *(p. 61)*
- [tblfn140](#tblfn140) *(p. 61)*
- [ehab364-11.6](#ehab364-116) *(p. 62)*
- [ehab364-11.7](#ehab364-117) *(p. 62)*
- [tblfn141](#tblfn141) *(p. 62)*
- [tblfn142](#tblfn142) *(p. 62)*
- [tblfn143](#tblfn143) *(p. 62)*
- [tblfn144](#tblfn144) *(p. 62)*
- [tblfn145](#tblfn145) *(p. 62)*
- [tblfn1145](#tblfn1145) *(p. 62)*
- [ehab364-12](#ehab364-12) *(p. 63)*
- [ehab364-13](#ehab364-13) *(p. 63)*
- [tblfn147](#tblfn147) *(p. 63)*
- [tblfn148](#tblfn148) *(p. 63)*
- [tblfn150](#tblfn150) *(p. 63)*
- [tblfn151](#tblfn151) *(p. 63)*
- [tblfn152](#tblfn152) *(p. 63)*
- [tblfn149](#tblfn149) *(p. 64)*
- [ehab364-14](#ehab364-14) *(p. 65)*
- [tblfn153](#tblfn153) *(p. 65)*
- [tblfn154](#tblfn154) *(p. 65)*
- [tblfn155](#tblfn155) *(p. 65)*
- [ehab364-15](#ehab364-15) *(p. 66)*
- [ehab364-16](#ehab364-16) *(p. 67)*
- [tblfn156](#tblfn156) *(p. 69)*
- [tblfn157](#tblfn157) *(p. 69)*
- [tblfn158](#tblfn158) *(p. 69)*
- [tblfn159](#tblfn159) *(p. 69)*
- [tblfn160](#tblfn160) *(p. 69)*
- [tblfn161](#tblfn161) *(p. 69)*
- [tblfn162](#tblfn162) *(p. 69)*
- [tblfn163](#tblfn163) *(p. 69)*
- [ehab364-17](#ehab364-17) *(p. 70)*
- [ehab364-18](#ehab364-18) *(p. 70)*
- [ehab364-19](#ehab364-19) *(p. 70)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC)
With the special contribution of the European Heart Rhythm
Association (EHRA)
Authors/Task Force Members: Michael Glikson * (Chairperson) (Israel),
Jens Cosedis Nielsen* (Chairperson) (Denmark), Mads Brix Kronborg (Task Force
Coordinator) (Denmark), Yoav Michowitz (Task Force Coordinator) (Israel),
Angelo Auricchio (Switzerland), Israel Moshe Barbash (Israel), Jose´ A. Barrabe´s
(Spain), Giuseppe Boriani (Italy), Frieder Braunschweig (Sweden), Michele Brignole
(Italy), Haran Burri (Switzerland), Andrew J. S. Coats (United Kingdom),
Jean-Claude Deharo (France), Victoria Delgado (Netherlands), Gerhard-Paul Diller
(Germany), Carsten W. Israel (Germany), Andre Keren (Israel), Reinoud E. Knops
(Netherlands), Dipak Kotecha (United Kingdom), Christophe Leclercq (France),
* Corresponding authors: Michael Glikson, Jesselson Integrated Heart Center, Shaare Zedek Medical Center and Hebrew University Faculty of Medicine, Jerusalem, Israel,
Tel: þ972 2 6555975, Email: mglikson@szmc.org.il.
Jens Cosedis Nielsen, Department of Clinical Medicine, Aarhus University and Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark,
Tel: þ45 78 45 20 39, Email: jenniels@rm.dk.
Author/Task Force Member afﬁliations: listed in Author information.
ESC Clinical Practice Guidelines Committee (CPG): listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of
Cardiovascular Imaging (EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure
Association (HFA).
Councils: Council for Cardiology Practice, Council on Basic Cardiovascular Science, Council on Cardiovascular Genomics, Council on Hypertension, Council on Stroke.
Working Groups: Adult Congenital Heart Disease, Cardiac Cellular Electrophysiology, Cardiovascular Regenerative and Reparative Medicine, Cardiovascular Surgery, eCardiology, Myocardial and Pericardial Diseases.
Patient Forum
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to
Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC
Guidelines exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
This article has been co-published with permission in the European Heart Journal and EP Europace. V
C the European Society of Cardiology 2021. All rights reserved.
The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article. For permissions,
please email journals.permissions@oup.com.
ESC GUIDELINES
doi:10.1093/eurheartj/ehab364


<!-- PAGE 2 -->

### Page 2

.........................................................
Be´la Merkely (Hungary), Christoph Starck (Germany), Ingela Thyle´n (Sweden),
Jose´ Maria Tolosana (Spain), ESC Scientific Document Group
Document Reviewers: Francisco Leyva (CPG Review Coordinator) (United Kingdom), Cecilia Linde
(CPG Review Coordinator) (Sweden), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Elena Arbelo
(Spain), Riccardo Asteggiano (Italy), Gonzalo Baron-Esquivias (Spain), Johann Bauersachs (Germany),
Mauro Bifﬁ(Italy), Ulrika Birgersdotter-Green (United States of America ), Maria Grazia Bongiorni (Italy),
Michael A. Borger (Germany), Jelena Celutkien _e (Lithuania), Maja Cikes (Croatia), Jean-Claude Daubert
(France), Inga Drossart (Belgium), Kenneth Ellenbogen (United States of America), Perry M. Elliott
(United Kingdom), Larissa Fabritz (United Kingdom), Volkmar Falk (Germany), Laurent Fauchier (France),
Francisco Fernandez-Avile´s (Spain), Dan Foldager (Denmark), Fredrik Gadler (Sweden), Pastora Gallego
Garcia De Vinuesa (Spain), Bulent Gorenek (Turkey), Jose M. Guerra (Spain), Kristina Hermann Haugaa
(Norway), Jeroen Hendriks (Netherlands), Thomas Kahan (Sweden), Hugo A. Katus (Germany),
Aleksandra Konradi (Russia), Konstantinos C. Koskinas (Switzerland), Hannah Law (United Kingdom),
Basil S. Lewis (Israel), Nicholas John Linker (United Kingdom), Maja-Lisa Løchen (Norway), Joost Lumens
(Netherlands), Julia Mascherbauer (Austria), Wilfried Mullens (Belgium), Klaudia Vivien Nagy (Hungary),
Eva Prescott (Denmark), Pekka Raatikainen (Finland), Amina Rakisheva (Kazakhstan), Tobias Reichlin
(Switzerland), Renato Pietro Ricci (Italy), Evgeny Shlyakhto (Russia), Marta Sitges (Spain), Miguel Sousa-Uva
(Portugal), Richard Sutton (Monaco), Piotr Suwalski (Poland), Jesper Hastrup Svendsen (Denmark),
Rhian M. Touyz (United Kingdom), Isabelle C. Van Gelder (Netherlands), Kevin Vernooy (Netherlands),
Johannes Waltenberger (Germany), Zachary Whinnett (United Kingdom), Klaus K. Witte (United Kingdom)
All experts involved in the development of these guidelines have submitted declarations of interest.
These have been compiled in a report and published in a supplementary document simultaneously to the guidelines. The report is also available on the ESC website www.escardio.org/guidelines
For the Supplementary Data which include background information and detailed discussion of the data that have provided the basis for the guidelines see European Heart Journal online
...................................................................................................................................................................................................
Keywords
Guidelines • cardiac pacing • cardiac resynchronization therapy • pacemaker • heart failure • syncope •
atrial ﬁbrillation • conduction system pacing • pacing indications • alternate site pacing • complications •
pacing in TAVI • bradycardia • temporary pacing
Table of contents
1 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.1 Evidence review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.2 Relationships with industry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.3 What is new in these guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.3.1 New concepts and new sections . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.3.2 New recommendations in 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.3.3 Changes in cardiac pacing and cardiac resynchronization therapy guideline recommendations since 2013 . . . . . . . . . . . . . . . . 11
3 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
3.1 Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
3.2 Natural history . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
3.3 Pathophysiology and classification of bradyarrhythmias considered for permanent cardiac pacing therapy . . . . . . . . . . . . . . . . 12
3.4 Types and modes of pacing: general description . . . . . . . . . . . . . . . 13
3.4.1 Endocardial pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
3.4.2 Epicardial pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
3.4.3 Cardiac resynchronization therapy (endo-and/or epicardial) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.4.4 Alternative methods (conduction system pacing,
leadless pacing) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.4.4.1 Conduction system pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.4.4.2 Leadless pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.4.5 Pacing modes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.4.6 Rate-responsive pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.5 Sex differences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
4 Evaluation of the patient with suspected or documented bradycardia or conduction system disease . . . . . . . . . . . . . . . . . . . . . . . . . . 14
4.1 History and physical examination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
4.2 Electrocardiogram . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
4.3 Non-invasive evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
4.3.1 Ambulatory electrocardiographic monitoring . . . . . . . . . . . . . 16
4.3.2 Exercise testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
4.3.3 Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
4.3.4 Laboratory tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
4.3.5 Genetic testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17


<!-- PAGE 3 -->

### Page 3

.............................................................................................................................................................................
4.3.6 Sleep evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
4.3.7 Tilt testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
4.4 Implantable monitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
4.5 Electrophysiology study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
5 Cardiac pacing for bradycardia and conduction system disease . . . . . 21
5.1 Pacing for sinus node dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
5.1.1 Indications for pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
5.1.1.1 Sinus node dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
5.1.1.2 Bradycardia—tachycardia form of sinus node dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
5.1.2 Pacing mode and algorithm selection . . . . . . . . . . . . . . . . . . . . . 22
5.2 Pacing for atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
5.2.1 Indications for pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
5.2.1.1 First-degree atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . 24
5.2.1.2 Second-degree type I atrioventricular block
(Mobitz type I or Wenckebach) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
5.2.1.3 Second-degree Mobitz type II, 2:1, and advanced atrioventricular block (also named high-grade atrioventricular block, where the P:QRS ratio is 3:1 or higher), third-degree atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
5.2.1.4 Paroxysmal atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . 24
5.2.2 Pacing mode and algorithm selection . . . . . . . . . . . . . . . . . . . . . 25
5.2.2.1 Dual-chamber vs. ventricular pacing . . . . . . . . . . . . . . . . . . . . 25
5.2.2.2 Atrioventricular block in the case of permanent atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
5.3 Pacing for conduction disorders without atrioventricular block . . . 26
5.3.1 Indications for pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
5.3.1.1 Bundle branch block and unexplained syncope . . . . . . . . . . . 26
5.3.1.2 Bundle branch block, unexplained syncope, and abnormal electrophysiological study . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
5.3.1.3 Alternating bundle branch block . . . . . . . . . . . . . . . . . . . . . . . . 27
5.3.1 Bundle branch block without symptoms . . . . . . . . . . . . . . . . . . . 27
5.3.1.4 Patients with neuromuscular diseases . . . . . . . . . . . . . . . . . . . 27
5.3.2 Pacing mode and algorithm selection . . . . . . . . . . . . . . . . . . . . . 27
5.4 Pacing for reflex syncope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
5.4.1 Indications for pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
5.4.2 Pacing mode and algorithm selection . . . . . . . . . . . . . . . . . . . . . 30
5.5 Pacing for suspected (undocumented) bradycardia . . . . . . . . . . . . 30
5.5.1 Recurrent undiagnosed syncope . . . . . . . . . . . . . . . . . . . . . . . . . 30
5.5.2 Recurrent falls . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
6 Cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
6.1 Epidemiology, prognosis, and pathophysiology of heart failure suitable for cardiac resynchronization therapy by biventricular pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
6.2 Indication for cardiac resynchronization therapy: patients in sinus rhythm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
6.3 Patients in atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
6.3.1 Patients with atrial fibrillation and heart failure who are candidates for cardiac resynchronization therapy . . . . . . . . . . . 33
6.3.2 Patients with uncontrolled heart rate who are candidates for atrioventricular junction ablation (irrespective of QRS duration) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
6.3.3 Emerging novel modalities for CRT: role of conduction system pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
6.4 Patients with conventional pacemaker or implantable cardioverter defibrillator who need upgrade to cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
6.5 Pacing in patients with reduced left ventricular ejection fraction and a conventional indication for antibradycardia pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
6.6 Benefit of adding implantable cardioverter defibrillator in patients with indications for cardiac resynchronization therapy . . . . 36
6.7 Factors influencing the efficacy of cardiac resynchronization therapy: role of imaging techniques . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
7 Alternative pacing strategies and sites . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
7.1 Septal pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
7.2 His bundle pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
7.2.1 Implantation and follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
7.2.2 Indications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
7.2.2 Pacing for bradycardia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
7.2.2 Pace and ablate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
7.2.2 Role in cardiac resynchronization therapy . . . . . . . . . . . . . . 40
7.3 Left bundle branch area pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
7.4 Leadless pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
8 Indications for pacing in specific conditions . . . . . . . . . . . . . . . . . . . . . . . . 42
8.1 Pacing in acute myocardial infarction . . . . . . . . . . . . . . . . . . . . . . . . . 42
8.2 Pacing after cardiac surgery and heart transplantation . . . . . . . . . 42
8.2.1 Pacing after coronary artery bypass graft and valve surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
8.2.2 Pacing after heart transplantation . . . . . . . . . . . . . . . . . . . . . . . . 43
8.2.3 Pacing after tricuspid valve surgery . . . . . . . . . . . . . . . . . . . . . . . 43
8.3 Pacing after transcatheter aortic valve implantation . . . . . . . . . . . . 44
8.4 Cardiac pacing and cardiac resynchronization therapy in congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
8.4.1 Sinus node dysfunction and bradycardia—tachycardia syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
8.4.1.1 Indications for pacemaker implantation . . . . . . . . . . . . . . . . . 46
8.4.2 Congenital atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . . 46
8.4.2.1 Indications for pacemaker implantation . . . . . . . . . . . . . . . . . 46
8.4.3 Post-operative atrioventricular block . . . . . . . . . . . . . . . . . . . . . 47
8.4.3.1 Indications for pacemaker implantation . . . . . . . . . . . . . . . . . 47
8.4.4 Cardiac resynchronization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
8.5 Pacing in hypertrophic cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . 47
8.5.1 Bradyarrhythmia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
8.5.2 Pacing for the management of left ventricular outflow tract obstruction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
8.5.3 Pacemaker implantation following septal myectomy and alcohol septal ablation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
8.5.4 Cardiac resynchronization therapy in end-stage hypertrophic cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
8.6 Pacing in rare diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
8.6.1 LongQT syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
8.6.2 Neuromuscular diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
8.6.3 Dilated cardiomyopathy with lamin A/C mutation . . . . . . . . 49
8.6.4 Mitochondrial cytopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
8.6.5 Infiltrative and metabolic diseases . . . . . . . . . . . . . . . . . . . . . . . . 49
8.6.6 Inflammatory diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
8.6.6.1 Sarcoidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
8.7 Cardiac pacing in pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
9 Special considerations on device implantations and perioperative management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
9.1 General considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
9.2 Antibiotic prophylaxis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
9.3 Operative environment and skin antisepsis . . . . . . . . . . . . . . . . . . . 50
ESC Guidelines
3


<!-- PAGE 4 -->

### Page 4

..........................................................................................................................................................................
9.4 Management of anticoagulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
9.5 Venous access . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
9.6 Lead considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
9.7 Lead position . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
9.8 Device pocket . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
10 Complications of cardiac pacing and cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
10.1 General complications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
10.2 Specific complications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
10.2.1 Lead complications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
10.2.2 Haematoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
10.2.3 Infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
10.2.4 Tricuspid valve interference . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
10.2.5 Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
11 Management considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
11.1 Magnetic resonance imaging in patients with implanted cardiac devices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
11.2 Radiation therapy in pacemaker patients . . . . . . . . . . . . . . . . . . . . . 57
11.3 Temporary pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
11.4 Peri-operative management in patients with cardiovascular implantable electronic devices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
11.5 Cardiovascular implantable electronic devices and sports activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
11.6 When pacing is no longer indicated . . . . . . . . . . . . . . . . . . . . . . . . . 60
11.7 Device follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
12 Patient-centred care and shared decision-making in cardiac pacing and cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . 61
13 Quality indicators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
14 Key messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
15 Gaps in evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
16 ‘What to do’ and ‘what not to do’ messages from the guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
17 Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
18 Author Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
19 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
Tables of Recommendations
Recommendations for non-invasive evaluation . . . . . . . . . . . . . . . . . . . . . . 16
Recommendation for ambulatory electrocardiographic monitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Recommendations for exercise testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Recommendations regarding imaging before implantation . . . . . . . . . . . 18
Recommendations for laboratory tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Recommendations for genetic testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Recommendation for sleep evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Recommendation for tilt testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Recommendation for implantable loop recorders . . . . . . . . . . . . . . . . . . . 19
Recommendations for electrophysiology study . . . . . . . . . . . . . . . . . . . . . 21
Recommendations for pacing in sinus node dysfunction . . . . . . . . . . . . . 24
Recommendations for pacing for atrioventricular block . . . . . . . . . . . . . 25
Recommendations for pacing in patients with bundle branch block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Recommendations for pacing for reflex syncope . . . . . . . . . . . . . . . . . . . . 30
Recommendations for cardiac pacing in patients with suspected (undocumented) syncope and unexplained falls . . . . . . 30
Recommendations for cardiac resynchronization therapy in patients in sinus rhythm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Recommendations for cardiac resynchronization therapy in patients with persistent or permanent atrial fibrillation . . . . . . . . . . . . . . 35
Recommendation for upgrade from right ventricular pacing to cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Recommendation for patients with heart failure and atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Recommendations for adding a defibrillator with cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Recommendations for using His bundle pacing . . . . . . . . . . . . . . . . . . . . . . 41
Recommendations for using leadless pacing (leadless pacemaker) . . . . 42
Recommendations for cardiac pacing after acute myocardial infarction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Recommendations for cardiac pacing after cardiac surgery and heart transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Recommendations for cardiac pacing after transcatheter aortic valve implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Recommendations for cardiac pacing in patients with congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Recommendations for pacing in hypertrophic obstructive cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Recommendations for cardiac pacing in rare diseases . . . . . . . . . . . . . . . 48
Recommendation for patients with LMNA gene mutations . . . . . . . . . . 49
Recommendations for pacing in Kearns—Sayre syndrome . . . . . . . . . . 49
Recommendations for pacing in cardiac sarcoidosis . . . . . . . . . . . . . . . . . 50
Recommendations regarding device implantations and peri-operative management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
Recommendations for performing magnetic resonance imaging in pacemaker patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
Recommendations regarding temporary cardiac pacing . . . . . . . . . . . . . 59
Recommendation when pacing is no longer indicated . . . . . . . . . . . . . . . 60
Recommendations for pacemaker and cardiac resynchronization therapy-pacemaker follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
Recommendation regarding patient-centred care in cardiac pacing and cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
List of tables
Table 1 Classes of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Table 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Table 3 New concepts and sections in current guidelines . . . . . . . . . . . . . 8
Table 4 New recommendations in 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Table 5 Changes in cardiac pacing and cardiac resynchronization therapy guideline recommendations since 2013 . . . . . . . . . . . . . . . . . . . . . 11
Table 6 Drugs that may cause bradycardia or conduction disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Table 7 Intrinsic and extrinsic causes of bradycardia . . . . . . . . . . . . . . . . . 16
Table 8 Choice of ambulatory electrocardiographic monitoring depending on symptom frequency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Table 9 Advantages and disadvantages of a ‘backup’ ventricular lead with His bundle pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Table 10 Predictors for permanent pacing after transcatheter aortic valve implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45


<!-- PAGE 5 -->

### Page 5

..........................................................................................................................................................................
Table 11 Management of anticoagulation in pacemaker procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
Table 12 Complications of pacemaker and cardiac resynchronization therapy implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
Table 13 Frequency of follow-up for routine pacemaker and cardiac resynchronization therapy, either in person alone or combined with remote device management . . . . . . . . . . . . . . . . . . . . . . . . 60
Table 14 Topics and content that may be included in patient education . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Table 15 A selection of the developed quality indicators for patients undergoing cardiovascular implantable electronic device implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
List of figures
Figure 1 Central Illustration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 2 Classification of documented and suspected bradyarrhythmias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 3 Initial evaluation of patients with symptoms suggestive of bradycardia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 4 Evaluation of bradycardia and conduction disease algorithm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Figure 5 Optimal pacing mode and algorithm selection in sinus node dysfunction and atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . . 23
Figure 6 Decision algorithm for patients with unexplained syncope and bundle branch block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
Figure 7 Decision pathway for cardiac pacing in patients with reflex syncope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
Figure 8 Summary of indications for pacing in patients >40 years of age with reflex syncope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Figure 9 Indication for atrioventricular junction ablation in patients with symptomatic permanent atrial fibrillation or persistent atrial fibrillation unsuitable for atrial fibrillation ablation . . . . . . . . . . . . . . . . . . . 34
Figure 10 Patient’s clinical characteristics and preference to be considered for the decision-making between cardiac resynchronization therapy pacemaker or defibrillator . . . . . . . . . . . . . . . 38
Figure 11 Three patients with different types of transitions in
QRS morphology with His bundle pacing and decrementing pacing output . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
Figure 12 Management of conduction abnormalities after transcatheter aortic valve implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Figure 13 Integrated management of patients with pacemaker and cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
Figure 14 Flowchart for evaluating magnetic resonance imaging in pacemaker patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
Figure 15 Pacemaker management during radiation therapy . . . . . . . . . 58
Figure 16 Example of shared decision-making in patients considered for pacemaker/CRT implantation . . . . . . . . . . . . . . . . . . . . . . . 62
Abbreviations and acronyms
AF
Atrial ﬁbrillation
APAF
Ablate and Pace in Atrial Fibrillation
(trial)
ATP
Antitachycardia pacing
AV
Atrioventricular
AVB
Atrioventricular block
AVJ
Atrioventricular junction
AVN
Atrioventricular node
BBB
Bundle branch block
BLOCK-HF
Biventricular versus RV pacing in patients with AV block (trial)
b.p.m.
Beats per minute
BRUISE CONTROL
Bridge or Continue Coumadin for
Device Surgery Randomized Controlled
Trial
BRUISE CONTROL-2
Randomized Controlled Trial of
Continued Versus Interrupted Direct
Oral Anti-Coagulant at the Time of
Device Surgery
CABG
Coronary artery bypass graft
CARE-HF
CArdiac REsynchronization in Heart
Failure (trial)
CHD
Congenital heart disease
CI
Conﬁdence interval
CIED
Cardiovascular implantable electronic device
CMR
Cardiovascular magnetic resonance
COMPANION
COmparison of Medical therapy, PAcing aNd deﬁbrillatION (trial)
CPAP
Continuous positive airway pressure
CRT
Cardiac resynchronization therapy
CRT-D
Deﬁbrillator with cardiac resynchronization therapy
CRT-P
Cardiac resynchronization therapypacemaker
CSM
Carotid sinus massage
CSS
Carotid sinus syndrome
CT
Computed tomography
DANPACE
DANish Multicenter Randomized
Trial on Single Lead Atrial PACing vs.
Dual Chamber Pacing in Sick Sinus
Syndrome
DDD
Dual-chamber, atrioventricular pacing
ECG
Electrocardiogram/electrocardiographic
Echo-CRT
Echocardiography Guided Cardiac
Resynchronization Therapy (trial)
EF
Ejection fraction
EHRA
European Heart Rhythm Association
EMI
Electromagnetic interference
EORP
EurObservational Research Programme
EPS
Electrophysiology study
ESC
European Society of Cardiology
EuroHeart
European Uniﬁed Registries On Heart
Care Evaluation and Randomized Trials
HBP
His bundle pacing
HCM
Hypertrophic cardiomyopathy
HF
Heart failure
HFmrEF
Heart failure with mildly reduced ejection fraction
HFpEF
Heart failure with preserved ejection fraction
ESC Guidelines
5


<!-- PAGE 6 -->

### Page 6

............................................................................................................................................................................
HFrEF
Heart failure with reduced ejection fraction
HOT-CRT
His-optimized cardiac resynchronization therapy
HR
Hazard ratio
HV
Hisventricular interval (time from the beginning of the H deﬂection to the earliest onset of ventricular depolarization recorded in any lead,
electrophysiology study of the heart)
ICD
Implantable cardioverter-deﬁbrillator
ILR
Implantable loop recorder
LBBB
Left bundle branch block
LGE
Late gadolinium contrast enhanced
LQTS
Long QT syndrome
LV
Left ventricular
LVEF
Left ventricular ejection fraction
MADIT-CRT
Multicenter Automatic Deﬁbrillator
Implantation with Cardiac
Resynchronization Therapy (trial)
MI
Myocardial infarction
MIRACLE
Multicenter Insync RAndomized Clinical
Evaluation (trial)
MOST
MOde Selection Trial in Sinus-Node
Dysfunction
MRI
Magnetic resonance imaging
MUSTIC
MUltisite STimulation In
Cardiomyopathies (trial)
NOAC
Non-vitamin K antagonist oral anticoagulant
NYHA
New York Heart Association
OAC
Oral anticoagulant
OMT
Optimal medical therapy
OR
Odds ratio
PATH-CHF
PAcing THerapies in Congestive Heart
Failure (trial)
PCCD
Progressive cardiac conduction disease
PCI
Percutaneous coronary intervention
PET
Positron emission tomography
PM
Pacemaker
RA
Right atrium/atrial
RAFT
ResynchronizationDeﬁbrillation for
Ambulatory Heart Failure Trial
RBBB
Right bundle branch block
RCT
Randomized controlled trial
RESET-CRT
Re-evaluation of Optimal Resynchronisation Therapy in Patients with
Chronic Heart Failure (trial)
REVERSE
REsynchronization reVErses Remodelling in Systolic left vEntricular dysfunction
(trial)
RV
Right ventricular/right ventricle
RVA
Right ventricular apical
RVOT
Right ventricular outﬂow tract
RVS
Right ventricular septum
S. aureus
Staphylococcus aureus
SAR
Speciﬁc absorption rate
SAS
Sleep apnoea syndrome
SCD
Sudden cardiac death
SND
Sinus node dysfunction
SR
Sinus rhythm
TAVI
Transcatheter aortic valve implantation
VKA
Vitamin K antagonist
WRAP-IT
World-wide Randomized Antibiotic
Envelope Infection Prevention Trial
1 Preamble
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision-making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver, as appropriate.
A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other societies and organizations. Because of their impact on clinical practice,
quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (https://www.escardio.org/Guidelines).
The ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.
In addition to the publication of Clinical Practice Guidelines, the ESC
carries out the EurObservational Research Programme of international registries of cardiovascular diseases and interventions which are essential to assess diagnostic/therapeutic processes, use of resources, and adherence to guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world,
based on high-quality data collected during routine clinical practice.
Furthermore, the ESC has developed and embedded in this document a set of quality indicators (QIs), which are tools to evaluate the level of implementation of the guidelines and may be used by the
ESC, hospitals, healthcare providers, and professionals to measure clinical practice as well as in educational programmes, alongside the key messages from the guidelines, to improve quality of care and clinical outcomes.
The Members of this Task Force were selected by the ESC, including representation from its relevant ESC subspecialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management of a given condition according to ESC Clinical Practice Guidelines
Committee (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the riskbenefit ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to pre-defined scales, as outlined below.
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as


<!-- PAGE 7 -->

### Page 7

....................................
real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/
guidelines) and have been compiled in a report and published in a supplementary document simultaneously with the guidelines.
This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arose during the writing period were notified to the
ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of new guidelines. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions, the guidelines are signed-off by all the experts involved in the Task Force. The finalized document is signed-off by the CPG for publication in the European Heart
Journal. The guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.
The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recommendations including condensed pocket guideline versions, summary slides, summary cards for non-specialists, and an electronic version
Table 1
Classes of recommendations
©ESC 2021
Classes of recommendations
Class I 
Evidence and/or general agreement 
that a given treatment or procedure is 
Is recommended or is indicated
Wording to use
Class III 
Evidence or general agreement that the 
given treatment or procedure is not 
useful/effective, and in some cases 
may be harmful.
Is not recommended
   Class IIb established by evidence/opinion.
May be considered
   Class IIa
Weight of evidence/opinion is in 
Should be considered
Class II 
Table 2
Levels of evidence
Level of 
evidence A
Data derived from multiple randomized clinical trials 
or meta-analyses. 
Level of 
evidence B
Data derived from a single randomized clinical trial or large non-randomized studies. 
Level of 
evidence C
Consensus of opinion of the experts and/or small studies, 
retrospective studies, registries.
©ESC 2021
ESC Guidelines
7


<!-- PAGE 8 -->

### Page 8

.........................................................................................
for digital applications (smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access to the full text version of the guidelines, which is freely available via the ESC website and hosted on the EHJ website. The
National Cardiac Societies of the ESC are encouraged to endorse,
adopt, translate, and implement all ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.
Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription.
2 Introduction
Pacing is an important part of electrophysiology and of cardiology in general. Whereas some of the situations requiring pacing are clear and have not changed over the years, many others have evolved and have been the subject of extensive recent research, such as pacing after syncope (section 5), pacing following transcatheter aortic valve implantation (TAVI; section 8), cardiac resynchronization therapy (CRT) for heart failure (HF) and for prevention of pacing-induced cardiomyopathy (section 6), and pacing in various infiltrative and inflammatory diseases of the heart, as well as in different cardiomyopathies (section 8).
Other novel topics include new diagnostic tools for decision-making on pacing (section 4), as well as a whole new area of pacing the His bundle and the left bundle branch (section 7). In addition, attention has increased in other areas, such as how to systematically minimize procedural risk and avoid complications of cardiac pacing (section 9), how to manage patients with pacemakers in special situations, such as when magnetic resonance imaging (MRI) or irradiation are needed (section
11), how to follow patients with a pacemaker with emphasis on the use of remote monitoring, and how to include shared decision-making in caring for this patient population (section 12).
The last pacing guidelines of the European Society of Cardiology
(ESC) were published in 2013; therefore, a new set of guidelines was felt to be timely and necessary.
To address these topics, a Task Force was established to create the new guidelines. As well as receiving the input of leading experts in the field of pacing, the Task Force was enhanced by representatives from the Association for Acute CardioVascular Care, the Heart
Failure Association, the European Association of Cardiothoracic
Surgery, the European Association of Percutaneous Cardiovascular
Interventions, the ESC Working Group on Myocardial and
Pericardial Diseases, as well as the Association of Cardiovascular
Nursing & Allied Professions.
2.1 Evidence review
This document is divided into sections, each with a section coordinator and several authors. They were asked to thoroughly review the recent literature on their topics, and to come up with recommendations and grade them by classification as well as by level of evidence.
Where data seemed controversial, a methodologist (Dipak Kotecha)
was asked to evaluate the strength of the evidence and to assist in determining the class of recommendation and level of evidence. All recommendations were voted on by all authors of the document and were accepted only if supported by at least 75% of the co-authors.
The leaders (Jens Cosedis Nielsen and Michael Glikson) and the coordinators of this document (Yoav Michowitz and Mads Brix
Kronborg) were responsible for alignment of the recommendations between sections, and several members of the writing committee were responsible for overlap with other ESC Guidelines, such as the
HF guidelines and the valvular heart disease guidelines.
2.2 Relationships with industry
All work in this document was voluntary and all co-authors were required to declare and prove that they do not have conflicts of interests, as defined recently by the Scientific Guideline Committee of the
ESC and the ESC board.
2.3 What is new in these guidelines
2.3.1
New concepts and new sections
Table 3
New concepts and sections in current guidelines
Concept/section
Section
New section on types and modes of pacing, including conduction system pacing and leadless pacing
3.4
New section on sex differences in pacing
3.5
New section on evaluation of patients for pacing
4
Expanded and updated section on CRT
6
New section on alternative pacing strategies and sites
7
Expanded and updated section on pacing in speciﬁc conditions, including detailed new sections on post TAVI,
postoperative and pacing in the presence of tricuspid valve diseases, and operations
8
A new section on implantation and perioperative management, including perioperative anticoagulation
9
An expanded revised section on CIED complications
10
A new section on various management considerations,
including MRI, radiotherapy, temporary pacing, perioperative management, sport activity, and follow up
11
A new section on patient-centred care
12
CIED = cardiovascular implantable electronic device; CRT = cardiac resynchronization therapy; MRI = magnetic resonance imaging; TAVI = transcatheter aortic valve implantation.
ESC 2021
..............................................................................


<!-- PAGE 9 -->

### Page 9

2.3.2
New recommendations in 2021
Table 4
New recommendations in 2021
Recommendations
Classa
Levelb
Evaluation of the patient with suspected or documented bradycardia or conduction system disease
Monitoring
In patients with infrequent (less than once a month) unexplained syncope or other symptoms suspected to be caused by bradycardia, in whom a comprehensive evaluation did not demonstrate a cause, long-term ambulatory monitoring with an ILR is recommended.
I
A
Ambulatory electrocardiographic monitoring is recommended in the evaluation of patients with suspected bradycardia to correlate rhythm disturbances with symptoms.
I
C
Carotid massage
Once carotid stenosis is ruled outc, carotid sinus massage is recommended in patients with syncope of unknown origin compatible with a reﬂex mechanism or with symptoms related to pressure/manipulation of the carotid sinus area.
I
B
Tilt test
Tilt testing should be considered in patients with suspected recurrent reﬂex syncope.
IIa
B
Exercise test
Exercise testing is recommended in patients who experience symptoms suspicious of bradycardia during or immediately after exertion.
I
C
In patients with suspected chronotropic incompetence, exercise testing should be considered to conﬁrm the diagnosis.
IIa
B
In patients with intra-ventricular conduction disease or AVB of unknown level, exercise testing may be considered to expose infranodal block.
IIb
C
Imaging
Cardiac imaging is recommended in patients with suspected or documented symptomatic bradycardia to evaluate the presence of structural heart disease, to determine left ventricular systolic function, and to diagnose potential causes of conduction disturbances.
I
C
Multimodality imaging (CMR, CT, PET) should be considered for myocardial tissue characterization in the diagnosis of speciﬁc pathologies associated with conduction abnormalities needing pacemaker implantation, particularly in patients younger than 60 years.
IIa
C
Continued
Laboratory tests
In addition to preimplant laboratory tests,d speciﬁc laboratory tests are recommended in patients with clinical suspicion for potential causes of bradycardia (e.g. thyroid function tests,
Lyme titre, digitalis level, potassium, calcium, and pH) to diagnose and treat these conditions.
I
C
Sleep evaluation
Screening for SAS is recommended in patients with symptoms of SAS and in the presence of severe bradycardia or advanced AVB during sleep.
I
C
Electrophysiological study
In patients with syncope and bifascicular block,
EPS should be considered when syncope remains unexplained after non-invasive evaluation or when an immediate decision about pacing is needed due to severity, unless empirical pacemaker implantation is preferred (especially in elderly and frail patients).
IIa
B
In patients with syncope and sinus bradycardia,
EPS may be considered when non-invasive tests have failed to show a correlation between syncope and bradycardia.
IIb
B
Genetics
Genetic testing should be considered in patients with early onset (age <50 years) of progressive cardiac conduction disease.
IIa
C
Genetic testing should be considered in family members following the identiﬁcation of a pathogenic genetic variant that explains the clinical phenotype of cardiac conduction disease in an index case.
IIa
C
Cardiac pacing for bradycardia and conduction system disease
Pacing is indicated in symptomatic patients with the bradycardia-tachycardia form of SND to correct bradyarrhythmias and enable pharmacological treatment, unless ablation of the tachyarrhythmia is preferred.
I
B
Pacing is indicated in patients with atrial arrhythmia (mainly AF) and permanent or paroxysmal third- or high-degree AVB irrespective of symptoms.
I
C
In patients with SND and DDD PM, minimization of unnecessary ventricular pacing through programming is recommended.
I
A
Dual chamber cardiac pacing is indicated to reduce recurrent syncope in patients aged >40
years with severe, unpredictable, recurrent syncope who have:
• spontaneous documented symptomatic asystolic pause/s >3 s or asymptomatic pause/s
>6 s due to sinus arrest or AVB; or
• cardioinhibitory carotid sinus syndrome; or
• asystolic syncope during tilt testing.
I
A
Continued
............................................................................................................................................................................
ESC Guidelines
9


<!-- PAGE 10 -->

### Page 10

In patients with recurrent unexplained falls, the same assessment as for unexplained syncope should be considered.
IIa
C
AF ablation should be considered as a strategy to avoid pacemaker implantation in patients with
AF-related bradycardia or symptomatic preautomaticity pauses, after AF conversion, taking into account the clinical situation.
IIa
C
In patients with the bradycardia-tachycardia variant of SND, programming of atrial ATP may be considered.
IIb
B
Dual-chamber cardiac pacing may be considered to reduce syncope recurrences in patients with the clinical features of adenosine-sensitive syncope.
IIb
B
Cardiac resynchronization therapy
In patients who are candidates for an ICD and who have CRT indication, implantation of a
CRT-D is recommended.
I
A
In patients who are candidates for CRT, implantation of a CRT-D should be considered after individual risk assessment and using shared decision-making.
IIa
B
In patients with symptomatic AF and an uncontrolled heart rate who are candidates for AVJ
ablation (irrespective of QRS duration), CRT
rather than standard RV pacing should be considered in patients with HFmrEF.
IIa
C
In patients with symptomatic AF and an uncontrolled heart rate who are candidates for AVJ
ablation (irrespective of QRS duration), RV pacing should be considered in patients with HFpEF.
IIa
B
In patients with symptomatic AF and an uncontrolled heart rate who are candidates for AVJ
ablation (irrespective of QRS duration), CRT
may be considered in patients with HFpEF.
IIb
B
Alternate site pacing
His bundle pacing
In patients treated with HBP, device programming tailored to speciﬁc requirements of His bundle pacing is recommended.
I
C
In CRT candidates in whom coronary sinus lead implantation is unsuccessful, HBP should be considered as a treatment option along with other techniques such as surgical epicardial lead.
IIa
B
In patients treated with HBP, implantation of a right ventricular lead used as “backup” for pacing should be considered in speciﬁc situations (e.g.
pacemaker-dependency, high-grade AVB, infranodal block, high pacing threshold, planned AVJ
ablation), or for sensing in case of issues with detection (e.g. risk of ventricular undersensing or oversensing of atrial/His potentials).
IIa
C
Continued
HBP with a ventricular backup lead may be considered in patients in whom a “pace-and-ablate”
strategy for rapidly conducted supraventricular arrhythmia is indicated, particularly when intrinsic QRS is narrow.
IIb
C
HBP may be considered as an alternative to right ventricular pacing in patients with AVB and LVEF
>40%, who are anticipated to have >20% ventricular pacing.
IIb
C
Leadless pacing
Leadless pacemakers should be considered as an alternative to transvenous pacemakers when no upper extremity venous access exists or when risk of device pocket infection is particularly high, such as previous infection and patients on haemodialysis.
IIa
B
Leadless pacemakers may be considered as an alternative to standard single lead ventricular pacing, taking into consideration life expectancy and using shared decision-making.
IIb
C
Indications for pacing in speciﬁc conditions
Pacing in acute myocardial infarction
Implantation of a permanent pacemaker is indicated with the same recommendations as in a general population (section 5.2) when AVB does not resolve within a waiting period of at least 5
days after MI.
I
C
In selected patients with AVB in context of anterior wall MI and acute HF, early device implantation (CRT-D/CRT-P) may be considered.
IIb
C
Pacing in cardiac surgery
1) High-degree or complete AVB after cardiac surgery. A period of clinical observation for at least 5 days is indicated in order to assess whether the rhythm disturbance is transient and resolves. However, in the case of complete AVB
with low or no escape rhythm when resolution is unlikely, this observation period can be shortened.
I
C
SND after cardiac surgery and heart transplantation. Before permanent pacemaker implantation,
a period of observation for up to 6 weeks should be considered.
IIa
C
Chronotropic incompetence after heart transplantation. Cardiac pacing should be considered for chronotropic incompetence persisting more than 6 weeks after heart transplantation to improve quality of life.
IIa
C
Continued
............................................................................................................................................................................


<!-- PAGE 11 -->

### Page 11

Surgery for valvular endocarditis and intraoperative complete AVB. Immediate epicardial pacemaker implantation should be considered in patients with surgery for valvular endocarditis and complete AVB if one of the following predictors of persistence is present: preoperative conduction abnormality, Staphylococcus aureus infection, intracardiac abscess, tricuspid valve involvement, or previous valvular surgery.
IIa
C
Patients requiring pacing at the time of tricuspid valve surgery. Transvalvular leads should be avoided and epicardial ventricular leads used.
During tricuspid valve surgery, removal of preexisting transvalvular leads should be considered and preferred over sewing-in the lead between the annulus and a bio-prosthesis or annuloplasty ring. In the case of an isolated tricuspid annuloplasty based on an individual risk-beneﬁt analysis,
a pre-existing right ventricular lead may be left in place without jailing it between ring and annulus.
IIa
C
Patients requiring pacing after biological tricuspid valve replacement/tricuspid valve ring repair.
When ventricular pacing is indicated, transvenous implantation of a coronary sinus lead or minimally invasive placement of an epicardial ventricular lead should be considered and preferred over a transvenous transvalvular approach.
IIa
C
Patients requiring pacing after mechanical tricuspid valve replacement. Implantation of a transvalvular right ventricular lead should be avoided.
III
C
Pacing in transcatheter aortic valve implantation
Permanent pacing is recommended in patients with complete or high-degree AVB that persists for 24 - 48 h after TAVI.
I
B
Permanent pacing is recommended in patients with new onset alternating BBB after TAVI.
I
C
Earlye permanent pacing should be considered in patients with pre-existing RBBB who develop any further conduction disturbance during or after TAVI.f
IIa
B
Ambulatory ECG monitoringg or an electrophysiology studyh should be considered for patients with new LBBB with QRS >150 ms or
PR >240 ms with no further prolongation during
>48 h after TAVI.
IIa
C
Continued
Ambulatory ECG monitoringg or electrophysiology studyh may be considered for TAVI patients with pre-existing conduction abnormality who develop further prolongation of QRS or PR
>20 ms.
IIb
C
Prophylactic permanent pacemaker implantation is not indicated before TAVI in patients with
RBBB and no indication for permanent pacing.
III
C
Various syndromes
In patients with neuromuscular diseases such as myotonic dystrophy type 1 and any second- or third-degree AVB or HV >_70 ms, with or without symptoms, permanent pacing is indicated.i
I
C
In patients with LMNA gene mutations, including
Emery-Dreifuss and limb girdle muscular dystrophies who fulﬁl conventional criteria for pacemaker implantation or who have prolonged PR
with LBBB, ICD implantation with pacing capabilities should be considered if at least 1-year survival is expected.
IIa
C
In patients with Kearns-Sayre syndrome who have PR prolongation, any degree of AVB, bundle branch block, or fascicular block, permanent pacing should be considered.
IIa
C
In patients with neuromuscular disease such as myotonic dystrophy type 1 with PR >_240 ms or
QRS duration >_120 ms, permanent pacemaker implantation may be considered.i
IIb
C
In patients with Kearns-Sayre Syndrome without cardiac conduction disorder, permanent pacing may be considered prophylactically.
IIb
C
Sarcoidosis
In patients with cardiac sarcoidosis who have permanent or transient AVB, implantation of a device capable of cardiac pacing should be considered.i
IIa
C
In patients with sarcoidosis and indication for permanent pacing who have LVEF <50%, implantation of a CRT-D should be considered.
IIa
C
Special considerations on device implantations and perioperative management
Administration of preoperative antibiotic prophylaxis within 1 h of skin incision is recommended to reduce risk of CIED infection.
I
A
Chlorhexidine alcohol instead of povidoneiodine alcohol should be considered for skin antisepsis.
IIa
B
Continued
.......................................................................................................................................................
ESC Guidelines
11


<!-- PAGE 12 -->

### Page 12

For venous access, the cephalic or axillary vein should be considered as ﬁrst choice.
IIa
B
For implantation of coronary sinus leads, quadripolar leads should be considered as ﬁrst choice.
IIa
C
To conﬁrm target ventricular lead position, use of multiple ﬂuoroscopic views should be considered.
IIa
C
Rinsing the device pocket with normal saline solution before wound closure should be considered.
IIa
C
In patients undergoing a reintervention CIED
procedure, the use of an antibiotic-eluting envelope may be considered.
IIb
B
Pacing of the mid-ventricular septum may be considered in patients with a high risk of perforation (elderly, previous perforation).
IIb
C
In pacemaker implantations in patients with possible pocket issues such as increased risk of erosion due to low body mass index, Twiddler’s syndrome or aesthetic reasons, a submuscular device pocket may be considered.
IIb
C
Heparin-bridging of anticoagulated patients is not recommended.
III
A
Permanent pacemaker implantation is not recommended in patients with fever. Pacemaker implantation should be delayed until the patient has been afebrile for at least 24 h.
III
B
Management considerations
Remote monitoring
Remote device management is recommended to reduce number of in-ofﬁce follow-up in patients with pacemakers who have difﬁculties to attend in-ofﬁce visits (e.g. due to reduced mobility or other commitments or according to patient preference).
I
A
Remote monitoring is recommended in case of a device component that has been recalled or is on advisory, to enable early detection of actionable events in patients, particularly those who are at increased risk (e.g. in case of pacemakerdependency).
I
C
Continued
In-ofﬁce routine follow-up of single- and dualchamber pacemakers may be spaced by up to 24
months in patients on remote device management.
IIa
A
Temporary pacing
Temporary transvenous pacing is recommended in cases of haemodynamic-compromising bradyarrhythmia refractory to intravenous chronotropic drugs.
I
C
Transcutaneous pacing should be considered in cases of haemodynamic compromising bradyarrhythmia when temporary transvenous pacing is not possible or available.
IIa
C
Temporary transvenous pacing should be considered when immediate pacing is indicated and pacing indications are expected to be reversible,
such as in the context of myocardial ischaemia,
myocarditis, electrolyte disturbances, toxic exposure, or after cardiac surgery.
IIa
C
Temporary transvenous pacing should be considered as a bridge to permanent pacemaker implantation, when this procedure is not immediately available or possible due to concomitant infection.
IIa
C
For long-term temporary transvenous pacing, an active ﬁxation lead inserted through the skin and connected to an external pacemaker should be considered.
IIa
C
Miscellaneous
When pacing is no longer indicated, a decision on the management strategy should be based on an individual risk-beneﬁt analysis in a shared decision-making process together with the patient.
I
C
MRI may be considered in pacemaker patients with abandoned transvenous leads if no alternative imaging modality is available.
IIb
C
Continued
.....................................................................................................................................


<!-- PAGE 13 -->

### Page 13

..........................
2.3.3
Changes in cardiac pacing and cardiac resynchronization therapy guideline recommendations since 2013
3 Background
3.1 Epidemiology
The prevalence and incidence of pacemaker implantation are unknown in many countries, yet several estimations have been published based on the analysis of large observational studies and databases. There is considerable variability in reported pacemaker implant rates between European countries, ranging from <25
Patient-centred care
In patients considered for pacemaker or CRT,
the decision should be based on the best available evidence with consideration of individual risk-beneﬁts of each option, the patients preferences, and goals of care, and it is recommended to follow an integrated care approach and use the principles of patientcentred care and shared decision making in the consultation.
I
C
AF = atrial ﬁbrillation; ATP = antitachycardia pacing; AV = atrioventricular; AVB
= atrioventricular block; AVJ = atrioventricular junction; BBB = bundle branch block; BMI = body mass index; CIED = cardiovascular implantable electronic device; CMR = cardiovascular magnetic resonance; CRT = cardiac resynchronization therapy; CRT-D = deﬁbrillator with cardiac resynchronization therapy;
CRT-P = cardiac resynchronization therapy-pacemaker; CSM = carotid sinus massage; CT = computed tomography; DDD = dual-chamber, atrioventricular pacing; ECG = electrocardiogram; EPS = electrophysiology study; HBP = His bundle pacing; HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HV =
Hisventricular interval; ICD = implantable cardioverter-deﬁbrillator; ILR =
implantable loop recorder; LBBB = left bundle branch block; LV = left ventricular;
LVEF = left ventricular ejection fraction; MI = myocardial infarction; MRI = magnetic resonance imaging; OMT = optimal medical therapy; PET = positron emission tomography; PR = PR interval; QRS = Q, R, and S waves; RBBB = right bundle branch block; RV = right ventricular; SAS = sleep apnoea syndrome; SND
= sinus node dysfunction; SR = sinus rhythm; TAVI = transcatheter aortic valve implantation.
aClass of recommendation.
bLevel of evidence.
cCSM should not be undertaken in patients with previous transient ischaemic attack, stroke, or known carotid stenosis. Carotid auscultation should be performed before carotid sinus massage. If a carotid bruit is present, carotid ultrasound should be performed to exclude carotid disease dComplete blood counts, prothrombin time, partial thromboplastin time, serum creatinine, and electrolytes.
eImmediately after procedure or within 24 h.
fTransient high-degree AVB, PR prolongation, or QRS axis change.
gAmbulatory continuous ECG monitoring (implantable or external) for 730
days.
hElectrophysiology study with HV >_70 ms may be considered positive for permanent pacing.
iWhenever pacing is indicated in neuromuscular disease, an ICD should be considered according to relevant guidelines.
ESC 2021
............................
Table 5
Changes in cardiac pacing and cardiac resynchronization therapy guideline recommendations since 2013
2013
2021
Classa
Cardiac pacing for bradycardia and conduction system disease
In patients with syncope, cardiac pacing may be considered to reduce recurrent syncope when asymptomatic pause(s) >6 s due to sinus arrest are documented.
IIa
IIb
Continued
Cardiac resynchronization therapy
Patients who have received a conventional pacemaker or an ICD and who subsequently develop symptomatic HF with LVEF <_35% despite OMT
and who have a signiﬁcantb proportion of RV
pacing should be considered for upgrade to
CRT.
I
IIa
CRT rather than RV pacing is recommended for patients with HFrEF (<40%) regardless of NYHA
class who have an indication for ventricular pacing and high-degree AVB in order to reduce morbidity. This includes patients with AF.
IIa
I
CRT should be considered for symptomatic patients with HF in SR with LVEF <_35%, a QRS
duration of 130149 ms, and LBBB QRS morphology despite OMT, to improve symptoms and reduce morbidity and mortality.
I
IIa
In patients with symptomatic AF and uncontrolled heart rate who are candidates for AVJ
ablation (irrespective of QRS duration), CRT is recommended in patients with HFrEF.
IIa
I
Speciﬁc indications for pacing
In patients with congenital heart disease, pacing may be considered for persistent postoperative bifascicular block associated with transient complete AVB.
IIa
IIb
Management considerations
In patients with MRI-conditional pacemaker systemsc, MRI can be performed safely following manufacturer instructions.
IIa
I
In patients with non-MRI-conditional pacemaker systems, MRI should be considered if no alternative imaging mode is available and if no epicardial leads, abandoned or damaged leads, or lead adaptors/extenders are present.
IIb
IIa
AF = atrial ﬁbrillation; AVB = atrioventricular block; AVJ = atrioventricular junction; CRT = cardiac resynchronization therapy; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter-deﬁbrillator; LBBB =
left bundle branch block; LVEF = left ventricular ejection fraction; MRI = magnetic resonance imaging; NYHA = New York Heart Association; OMT = optimal medical therapy; RV = right ventricular; SR = sinus rhythm.
aClass of recommendation.
bA limit of 20% RV pacing for considering interventions for pacing-induced HF is supported by observational data. However, there are no data to support that any percentage of RV pacing can be considered as deﬁning a true limit below which
RV pacing is safe and beyond which RV pacing is harmful.
cCombination of MRI conditional generator and lead(s) from the same manufacturer.
ESC 2021
....................................................................................................................................................
ESC Guidelines
13


<!-- PAGE 14 -->

### Page 14

....................................................................
pacemaker implantations per million people in Azerbaijan, Bosnia and
Herzegovina, and Kyrgyzstan, to >1000 implantations per million people in France, Italy, and Sweden.1 These differences may result from under- or overtreatment with pacemaker therapy in some countries, or from variations in sociodemographic characteristics and pathological conditions. There is a continuous growth in the use of pacemakers due to the increasing life expectancy and ageing of populations.28 The estimated number of patients globally undergoing pacemaker implantation has increased steadily up to an annual implant rate of 1 million devices.2 Degeneration of the cardiac conduction system and changes in intercellular conduction can be manifestations of cardiac pathology or non-cardiac disease, and are most prevalent in older patients. Therefore, most bradycardias requiring cardiac pacing are observed in the elderly,
with >80% of pacemakers being implanted in patients above the age of 65 years.
3.2 Natural history
High-degree atrioventricular block (AVB) and sinus node dysfunction
(SND) are the most common indications for permanent pacemaker therapy. Conservatively treated (i.e. non-paced) patients with highdegree
AVB
have notably poorer survival compared with pacemaker-treated patients.912 In contrast, SND follows an unpredictable course, and there is no evidence to show that pacemaker therapy results in improved prognosis.1315
Improving life expectancy is not, however, the only objective of pacemaker therapy. Quality of life is an essential metric for measuring a patient’s clinical status and outcome, and provides a holistic picture of clinical treatment effectiveness.16 Studies have been unanimous in finding improved quality of life in patients receiving pacing therapy.1722
3.3 Pathophysiology and classification of bradyarrhythmias considered for permanent cardiac pacing therapy
Definitions of various conduction disturbances are presented in
Supplementary Table 1.
Sinus bradycardia can be considered physiological in response to specific situations, such as in well-conditioned athletes, young individuals, and during sleep. Pathological bradyarrhythmias are dependent on their underlying cause and can be broadly categorized into intrinsic and extrinsic aetiologies. Advanced age and age-related degenerative changes are important intrinsic causes of modifications in electrical impulse initiation and propagation of the conduction
Preimplant evaluation
Minimizing complication risk
Pacing for bradycardia
Pacing in patients with rare diseases
Pacing in patients after cardiac surgery 
High risk reflex syncope
HBP in bradycardia or CRT
Pacing in TAVI
patients
CRT indications
Leadless pacing
New in these guidelines
Figure 1 The 2021 ESC Guidelines on cardiac pacing and CRT present new and updated recommendations for these treatments in relevant patient populations.


<!-- PAGE 15 -->

### Page 15

...........................................................................
system. In addition, genetic mutations have been linked to conduction disorders (see section 4.3.5), and atrial cardiomyopathy23 may be a specific disease that can result in supraventricular tachyarrhythmia,
SND, and atrioventricular node (AVN) disease.24
It is essential to differentiate reversible from non-reversible causes of bradycardia. Potential reversible causes of bradycardia include adverse drug effects, myocardial infarction (MI), toxic exposure, infections, surgery, and electrolyte disorders. In a study including 277 patients referred to the emergency department with bradycardia, electrolyte disorders were the underlying cause in 4%, intoxication in 6%, acute MI in 14%, and adverse drug effects in 21%.25
In the case of non-reversible pathological causes of slow heart rate, the presence and severity of symptoms play an essential role in the consideration for permanent antibradycardia pacemaker therapy. This may be challenging in patients with competing mechanisms for their symptoms. In general, candidates for pacing therapy can be broadly classified into two groups: patients with persistent bradycardia and patients with intermittent [with or without electrocardiographic (ECG) documentation] bradycardia. Persistent bradycardia usually indicates an intrinsic disease in the sinus node tissue or the atrioventricular (AV) conduction system, whereas intermittent bradycardia can be a result of a wide variety of intrinsic and extrinsic pathological processes, as illustrated in Figure 2.2631
3.4 Types and modes of pacing: general description
3.4.1
Endocardial pacing
Endocardial lead-based pacemakers consist of a pulse generator commonly placed in the pectoral region and transvenous lead(s)
implanted into the myocardium with the ability to sense cardiac activity and provide therapeutic cardiac stimulation. Since the introduction of transvenous endocardial pacemakers in the 1960s, major technological advances have improved their efficacy and safety. In general, pacemaker implantation is considered a low-risk procedure,
yet it is not exempt from device- and procedure-related complications and malfunction. Pacemaker implantation is covered in detail in a recent European Heart Rhythm Association (EHRA) consensus document.34
3.4.2
Epicardial pacing
Some clinical scenarios dictate implantation of an epicardial pacemaker system. These include patients with congenital anomalies and no venous access to the heart or with an open shunt between the right and left sides of the circulation, recurrent device infections,
occluded veins, and—most commonly today—in conjunction with open cardiac surgery. Epicardial leads are currently implanted using various (minimally invasive) thoracotomy or thoracoscopy and robotic techniques.35
Patient with bradycardia-related symptoms
Persistent bradycardia
Y
N
Sinus node disease
Documented arrhythmia
(ECG/Holter/monitor)
AV block
Sinus rhythm
Atrial fibrillation
Intrinsic
Paroxysmal AV block
Sino-atrial block and sinus arresta
Atrial fibrillation with slow ventricular condition
Extrinsic (functional)
Vagally induced sinus arrest or AV block
Adenosine hypersensitivityb
Idiopathic AV block
BBB
Reflex syncope
Carotid sinus
Tilt-induced
Unexplained syncope
(suspected)
Y
N
Figure 2 Classification of documented and suspected bradyarrhythmias. AV = atrioventricular; BBB = bundle branch block; ECG = electrocardiogram.
aIncluding the bradycardiatachycardia form of sick sinus syndrome. bDeharo et al.32 Figure adapted from Brignole et al.33
ESC Guidelines
15


<!-- PAGE 16 -->

### Page 16

.............................................................................................................................................................................
3.4.3
Cardiac resynchronization therapy (endo- and/or epicardial)
Cardiac dyssynchrony is a difference in the timing of electrical and mechanical activation of the ventricles, which can result in impaired cardiac efficiency. CRT delivers biventricular pacing to correct electromechanical dyssynchrony in order to increase cardiac output.36 In multiple trials, CRT has shown a significant morbidity and mortality benefit in specific patient groups with reduced left ventricular ejection fraction (LVEF).3740
3.4.4
Alternative methods (conduction system pacing,
leadless pacing)
3.4.4.1 Conduction system pacing
Compared with right ventricular (RV) pacing, His bundle pacing
(HBP) provides a more physiological simultaneous electrical activation of the ventricles via the HisPurkinje system. HBP can restore conduction in a subset of patients with high-degree AVB, and shorten
QRS duration in some patients with left bundle branch block (LBBB)
or right bundle branch block (RBBB).4144 More studies are ongoing and required to evaluate whether HBP has clinical benefits over CRT
or RV pacing. In addition, left bundle branch area pacing is being studied as a pacing modality for patients in whom the conduction disease is too distal for HBP (see section 7.3).
3.4.4.2 Leadless pacing
Miniaturized, intracardiac leadless pacemakers have been introduced.
These devices are inserted percutaneously through the femoral vein and implanted directly in the RV wall using customized catheterbased delivery systems. The first-generation leadless pacemakers have been proven to provide effective single-chamber pacing therapy.4550 Albeit a promising technology, potential difficulty with leadless pacemaker retrieval at the end of service is a limitation. Thus far, there are no randomized controlled data available to compare clinical outcomes between leadless pacing and single-chamber transvenous pacing.
3.4.5
Pacing modes
Technological advances in pacemaker therapy have resulted in a wide variety of pacing modalities. Pacemakers can sense the heart’s intrinsic electrical activity and restore the rate and AV sequence of cardiac activation. Abnormal cardiac automaticity and conduction may be treated by single-lead atrial sensing/pacing, single-lead ventricular sensing/pacing, single leads that pace the right ventricle (RV) and sense both the atrium and ventricle, and dual-lead systems that sense and pace the right atrium (RA) and RV. For common pacing modes,
refer to Supplementary Table 2. The choice of the optimal pacing mode in the presence of conduction disturbances is driven by the underlying morbidity, the impact of pacing therapy on morbidity, and the potential harmful effect of the chosen pacing modality. The choice of pacing modes in specific situations is discussed in section 5.
3.4.6
Rate-responsive pacing
The sinus node modulates the heart rate during different types and loads of exercise (i.e. physical exercise, emotions, postural change,
and fever) proportional to the metabolic demand. Rate-responsive pacemaker systems strive to produce an appropriate compensatory heart rate during emotional or physical activity by sensing body motion/acceleration, minute ventilation, intracardiac impedance, or other surrogates of physical and mental stress, and are indicated in cases of chronotropic incompetence.5157 Dual-sensing rate-responsive pacing (e.g. accelerometer and minute ventilation) may be used in selected patients.58 A brief overview of the most commonly used rate-responsive pacing sensors is given in Supplementary Table 3.
3.5 Sex differences
Pacing indications and complication rates differ between male and female patients. In male patients, primary pacemaker implantation is more often indicated for AVB and less so for SND and atrial fibrillation (AF) with bradycardia.59,60 In female patients, the rate of procedure-related adverse events is significantly higher, corrected for age and type of device. This higher rate is driven mostly by pneumothorax, pericardial effusion, and pocket haematomas.5961
Possible explanations for this are a smaller body size in women and anatomical differences, such as smaller vein diameters and RV
diameters.
4 Evaluation of the patient with suspected or documented bradycardia or conduction system disease
4.1 History and physical examination
A careful history and physical examination are essential for the evaluation of patients with suspected or documented bradycardia
(Figure 3). Current guidelines emphasize the importance of the history and physical examination in the initial evaluation, particularly for identifying patients with structural heart disease.62,63
A complete history should include family history, comprehensive cardiovascular risk assessment, and recent/historical diagnoses that may cause bradycardia. The history should be focused on frequency,
severity, and duration of symptoms that might suggest bradycardia or conduction system disease. The relationship of symptoms to physical activity, emotional distress, positional changes, medical treatment
(Table 6), and typical triggers (e.g. urination, defecation, cough, prolonged standing, and shaving) should be explored too, as well as pulse rate if measured during an episode.
Family history may be especially important in young patients with progressive cardiac conduction disease either isolated or in association with cardiomyopathies and/or myopathies.64,65
Physical examination should focus on manifestations of bradycardia and signs of underlying structural heart disease or systemic disorders (Table 7). Symptomatic slow peripheral pulses should be confirmed with cardiac auscultation or ECG to ensure that other rhythms are not misrepresented as bradycardia (e.g. premature ventricular contractions).
Autonomic regulation disorders are important in the differential diagnosis of syncope or near syncope, and, therefore, orthostatic changes in heart rate and blood pressure may help in the evaluation of the patients.


<!-- PAGE 17 -->

### Page 17

Initial evaluation of patients with symptoms suggestive of bradycardia (SND or AV block)
History
Physical examination
Cardiac imaging
ECG
Cardiovascular risk
Complete history focusing on symptoms
Family history
Medical treatment
Figure 3 Initial evaluation of patients with symptoms suggestive of bradycardia. AVB = atrioventricular block; ECG = electrocardiogram; SND = sinus node dysfunction.
Table 6
Drugs that may cause bradycardia or conduction disorders
Sinus node bradycardia
AVB
Beta-blockers
1
1
Antihypertensives
Non-dihydropyridine calcium channel blockers
1
1
Methyldopa
1
–
Clonidine
1
–
Antiarrhythmics
Amiodarone
1
1
Dronedarone
1
1
Sotalol
1
1
Flecainide
1
1
Propafenone
1
1
Procainamide
–
1
Disopyramide
1
1
Adenosine
1
1
Digoxin
1
1
Ivabradine
1
–
Psychoactive and neuroactive drugs
Donepezil
1
1
Lithium
1
1
Opioid analgesics
1
–
Phenothiazine
1
1
Phenytoin
1
1
Selective serotonin reuptake inhibitors
–
1
Tricyclic antidepressants
–
1
Carbamazepine
1
1
Continued
ESC 2021
Table 6
Continued
Sinus node bradycardia
AVB
Others
Muscle relaxants
1
–
Cannabis
1
–
Propofol
1
–
Ticagrelor
1
1
High-dose corticosteroids
1
–
Chloroquine
–
1
H2 antagonists
1
1
Proton pump inhibitors
1
–
Chemotherapy
Arsenic trioxide
1
1
Bortezomib
1
1
Capecitabine
1
–
Cisplatin
1
–
Cyclophosphamide
1
1
Doxorubicin
1
–
Epirubicin
1
–
5-ﬂuorouracil
1
1
Ifosfamide
1
–
Interleukin-2
1
–
Methotrexate
1
–
Mitroxantrone
1
1
Paclitaxel
1
–
Rituximab
1
1
Thalidomide
1
1
Anthracycline
–
1
Taxane
–
1
AVB = atrioventricular block.
........................................................................................................
ESC Guidelines
17


<!-- PAGE 18 -->

### Page 18

Carotid sinus massage (CSM) can be helpful in any patient >_40
years old with symptoms suggestive of carotid sinus syndrome (CSS):
syncope or near syncope elicited by tight collars, shaving, or turning the head.66,67 Methodology and response to CSM are described in section 4.1 in the Supplementary data. Diagnosis of CSS requires both the reproduction of spontaneous symptoms during CSM and clinical features of spontaneous syncope compatible with a
reflex mechanism.6870
4.2 Electrocardiogram
Together with the history and physical examination, the resting ECG
is an essential component of the initial evaluation of patients with documented or suspected bradycardia. A 12-lead ECG or a rhythm strip during the symptomatic episode provides the definitive diagnosis.
For those in whom physical examination suggests a bradycardia, a
12-lead ECG is useful to confirm the rhythm, rate, nature, and extent of conduction disturbance (Supplementary Table 1). Furthermore, an
ECG may provide information about structural heart or systemic illness (e.g. LV hypertrophy, Q waves, prolonged QT interval, and low voltage) that predict adverse outcomes in symptomatic patients.62
4.3 Non-invasive evaluation
Table 7
Intrinsic and extrinsic causes of bradycardia
Sinus bradycardia or SND
AVJ
disturbances
Intrinsic
Idiopathic (ageing, degenerative)
1
1
Infarction/ischaemia
1
1
Cardiomyopathies
1
1
Genetic disorders
1
1
Inﬁltrative diseases
Sarcoidosis
1
1
Amyloidosis
1
1
Haemochromatosis
1
1
Collagen vascular diseases
Rheumatoid arthritis
1
1
Scleroderma
1
1
Systemic lupus erythematosus
1
1
Storage diseases
1
1
Neuromuscular diseases
1
1
Infectious diseases
Endocarditis (perivalvular abscess)
–
1
Chagas disease
1
1
Myocarditis
–
1
Lyme disease
–
1
Diphtheria
–
1
Toxoplasmosis
–
1
Congenital heart diseases
1
1
Cardiac surgery
Coronary artery bypass grafting
1
1
Valve surgery (including transcatheter aortic valve replacement)
1
1
Maze operation
1
–
Heart transplant
1
1
Radiation therapy
1
1
Intended or iatrogenic AVB
–
1
Sinus tachycardia ablation
1
–
Extrinsic
Physical training (sports)
1
1
Vagal reﬂex
1
1
Drug effects
1
1
Idiopathic paroxysmal AVB
–
1
Electrolyte imbalance
Hypokalaemia
1
1
Hyperkalaemia
1
1
Hypercalcaemia
1
1
Hypermagnesaemia
1
1
Metabolic disorders
Hypothyroidism
1
1
Anorexia
1
1
Hypoxia
1
1
Acidosis
1
1
Continued
Table 7
Continued
Sinus bradycardia or SND
AVJ
disturbances
Hypothermia
1
1
Neurological disorders
Increased intracranial pressure
1
1
Central nervous system tumours
1
1
Temporal epilepsy
1
1
Obstructive sleep apnoea
1
1
AV = atrioventricular; AVB = atrioventricular block; AVJ = atrioventricular junction; SND = sinus node dysfunction.
Adapted from Mangrum et al.71 and Da Costa et al.72a
Recommendations for non-invasive evaluation
Recommendations
Classa
Levelb
Once carotid stenosis is ruled out,c CSM is recommended in patients with syncope of unknown origin compatible with a reﬂex mechanism or with symptoms related to pressure/manipulation of the carotid sinus area.6870
I
B
CSM = carotid sinus massage.
aClass of recommendation.
bLevel of evidence.
cCSM should not be undertaken in patients with previous transient ischaemic attack, stroke, or known carotid stenosis. Carotid auscultation should be performed before CSM. If a carotid bruit is present, carotid ultrasound should be performed to exclude the presence of carotid disease.
ESC 2021
ESC 2021
............................................................................................................................................................................


<!-- PAGE 19 -->

### Page 19

...................................................................................
4.3.1
Ambulatory electrocardiographic monitoring
The intermittent nature of most symptomatic bradycardia secondary to conduction system disease often requires prolonged ambulatory
ECG monitoring to correlate rhythm disturbances with symptoms.
This monitoring allows detection of interruption of AV conduction by either primary disease of the conductive system, a vagal or neurocardiogenic mechanism, or reflex AV block.72,72a
Ambulatory ECG identifies defects of sinus automaticity, which includes sinus pauses, sinus bradycardia, bradycardiatachycardia syndrome, asystole post-conversion of atrial flutter or AF, and chronotropic incompetence.
Different versions of ambulatory ECG monitoring have been reviewed recently in a
comprehensive expert consensus
(Supplementary Table 4).73 Ambulatory ECG selection depends on the frequency and nature of the symptoms (Table 8).
4.3.2
Exercise testing
Exercise testing may be useful in selected patients with suspected bradycardia during or shortly after exertion. Symptoms occurring during exercise are likely to be due to cardiac causes, whereas symptoms occurring after exercise are usually caused by a reflex mechanism.
Exercise testing can be used to diagnose symptomatic chronotropic incompetence, defined as an inability to increase the heart rate commensurate with the increased metabolic demands of physical activity.74,75 The most commonly used definition of chronotropic incompetence has been failure to reach 80% of the expected heart rate reserve. Expected heart rate reserve is defined as the difference between the age-predicted maximal heart rate (220  age) and the resting heart rate. However, some medical treatments and comorbidities cause exercise intolerance and make the diagnosis of chronotropic incompetence by exercise testing more difficult.
In patients with exercise-related symptoms, the development or progression of AVB may occasionally be the underlying cause.
Tachycardia-related exercise-induced second-degree and complete
AVB have been shown to be located distal to the AVN and predict progression to permanent AVB.7678 Usually, these patients show intraventricular conduction abnormalities on the resting ECG, but a normal resting ECG has also been described in such cases.77,79
Exercise testing may expose advanced infranodal AVB in the presence of conduction system disease of uncertain location.
In rare cases, conduction disturbances induced by exercise are caused by myocardial ischaemia or coronary vasospasm, and exercise testing may reproduce the symptoms.80,81
There are no data supporting an indication for exercise testing in patients without exercise-related symptoms. Exercise testing may be useful in selected patients to distinguish AVN from conduction disturbances in the HisPurkinje system below the AVN in the setting of conduction disturbance at an unclear level.
4.3.3
Imaging
In patients with suspected or documented symptomatic bradycardia,
the use of cardiac imaging is recommended to evaluate the presence of structural heart disease, to determine LV systolic function, and to diagnose potential reversible causes of conduction disturbances
(Table 7).
Echocardiography is the most commonly available imaging technique for evaluation of the above factors. It can also be used in the
Table 8
Choice of ambulatory electrocardiographic monitoring depending on symptom frequency
Frequency of symptom
Daily
24-h Holter ECG or in-hospital telemetric monitoring
Every 4872 h
244872 h Holter ECG
Every week
7-day Holter ECG/external loop recorder/
external patch recorder
Every month
External loop recorder/external patch recorder/handheld ECG recorder
<1 per month
ILR
ECG = electrocardiogram; ILR = implantable loop recorder.
Adapted from Brignole et al.33
ESC 2021
Recommendation for ambulatory electrocardiographic monitoring
Recommendation
Classa
Levelb
Ambulatory ECG monitoring is recommended in the evaluation of patients with suspected bradycardia to correlate rhythm disturbances with symptoms.73
I
C
ECG = electrocardiogram.
aClass of recommendation.
bLevel of evidence.
ESC 2021
Recommendations for exercise testing
Recommendations
Classa
Levelb
Exercise testing is recommended in patients who experience symptoms suspicious of bradycardia during or immediately after exertion.62,7480
I
C
In patients with suspected chronotropic incompetence, exercise testing should be considered to conﬁrm the diagnosis.74,75
IIa
B
In patients with intraventricular conduction disease or AVB of unknown level, exercise testing may be considered to expose infranodal block.76,77,79
IIb
C
AVB = atrioventricular block.
aClass of recommendation.
bLevel of evidence.
ESC 2021
..........................................................................................
ESC Guidelines
19


<!-- PAGE 20 -->

### Page 20

....................................................................................................................
context of haemodynamic instability. When coronary artery disease is suspected, coronary computed tomography (CT), angiography, or stress imaging is recommended.82 Cardiovascular magnetic resonance (CMR) and nuclear imaging techniques provide information on tissue characterization (inflammation, fibrosis/scar) and should be considered before pacemaker implantation when specific aetiologies associated with conduction abnormalities are suspected (specially in young patients). Late gadolinium contrast enhanced (LGE) and T2
CMR techniques allow the diagnosis of specific causes of conduction disturbances (i.e. sarcoidosis and myocarditis). Late gadolinium contrast enhancement CMR helps in the decision-making of individuals with arrhythmic events; the presence of large areas of LGE (scar/fibrosis) has been linked to an increased risk of ventricular arrhythmias regardless of LVEF and may indicate the need for an implantable cardioverter-defibrillator (ICD).8385 T2 CMR sequences are suited for the detection of myocardial inflammation (i.e. oedema and hyperaemia) as a potential cause of transitory conduction abnormalities that may not need permanent pacemaker implantation.86 Similarly,
positron emission tomography (PET) combined with CMR or CT
helps in the diagnosis of inflammatory activity status of infiltrative cardiomyopathies (i.e. sarcoidosis).87,88
4.3.4
Laboratory tests
Laboratory tests, including full blood counts, prothrombin time, partial thromboplastin time, renal function, and electrolyte measurements, are warranted as part of pre-procedural planning for pacemaker implantation.
Bradycardia or AVB may be secondary to other conditions
(Table 7). When suspected, laboratory data are useful for identifying and treating these conditions (e.g. thyroid function, Lyme titre to diagnose myocarditis in a young person with AVB, endocarditis,
hyperkalaemia, digitalis levels, and hypercalcaemia).8994
4.3.5
Genetic testing
Most cardiac conduction disorders are due to either ageing or structural abnormalities of the cardiac conduction system caused by underlying structural heart disease. Genes responsible for inherited cardiac diseases associated with cardiac conduction disorders have been identified.65,95,96
Genetic mutations have been linked to a range of abnormalities that may present in isolated forms of cardiac conduction disorder or in association with cardiomyopathy, congenital cardiac anomalies, or extra-cardiac disorders. Most genetically mediated cardiac conduction disorders have an autosomal dominant mode of inheritance65,95
(Supplementary Table 5).
Progressive cardiac conduction disease
(PCCD)
may be diagnosed in the presence of unexplained progressive conduction abnormalities in young (<50 years) individuals with structurally normal hearts in the absence of skeletal myopathies, especially if there is a family history of PCCD.97 Common PCCD-associated genes are
SCN5A and TRPM4 for isolated forms and LMNA for PCCD associated with HF.
The diagnosis of PCCD in an index patient is based on clinical data including history, family history, and 12-lead ECG. The potential presence of congenital heart disease (CHD) and/or cardiomyopathy must be investigated with cardiac imaging.
Early-onset PCCD, either isolated or with concomitant structural heart disease, should prompt consideration of PCCD genetic testing,
particularly in patients with a positive family history of conduction abnormalities, pacemaker implants, or sudden death.97
A consensus panel has endorsed mutation-specific genetic testing for family members and appropriate relatives after the identification of a PCCD causative mutation in an index case. Such testing can be deferred in asymptomatic children because of the age-dependent nature of cardiac conduction diseases and incomplete penetrance.65
However, every case should be individually evaluated depending of the risk of the detected mutation.
Asymptomatic family members who are positive for the family’s
PCCD-associated mutation should be regularly followed for development of cardiac conduction disease-related symptoms, deterioration of cardiac conduction, and beginning of HF.
Recommendations regarding imaging before implantation
Recommendations
Classa
Levelb
Cardiac imaging is recommended in patients with suspected or documented symptomatic bradycardia to evaluate the presence of structural heart disease, to determine LV systolic function, and to diagnose potential causes of conduction disturbances.
I
C
Multimodality imaging (CMR, CT, or PET) should be considered for myocardial tissue characterization in the diagnosis of speciﬁc pathologies associated with conduction abnormalities needing pacemaker implantation, particularly in patients younger than 60 years.8386,88
IIa
C
CMR = cardiovascular magnetic resonance; CT = computed tomography; LV =
left ventricular; PET = positron emission tomography.
aClass of recommendation.
bLevel of evidence.
Recommendations for laboratory tests
Recommendations
Classa
Levelb
In addition to pre-implantation laboratory tests,c speciﬁc laboratory tests are recommended in patients with clinical suspicion for potential underlying causes of reversible bradycardia (e.g.
thyroid function tests, Lyme titre, digitalis level,
potassium, calcium, and pH) to diagnose and treat these conditions.9094
I
C
aClass of recommendation.
bLevel of evidence.
cComplete blood counts, prothrombin time, partial thromboplastin time, serum creatinine, and electrolytes.
ESC 2021
ESC 2021
...................................................


<!-- PAGE 21 -->

### Page 21

............................................
4.3.6
Sleep evaluation
Nocturnal bradyarrhythmias are common in the general population.
In most circumstances, these are physiological, vagally mediated asymptomatic events, which do not require intervention.98100
Patients with sleep apnoea syndrome (SAS) have a higher prevalence of sleep-related bradycardia (both sinus and conduction system related) during apnoeic episodes.101,102 SAS-induced hypoxaemia is a key mechanism leading to an increased vagal tone and bradycardic rhythm disorders.101,102 Another rare mechanism of sleep-related bradycardia (usually in the form of prolonged sinus arrest) is rapid eye movement sleep-related bradycardia, unrelated to apnoea. This mechanism can also be diagnosed by polysomnography.103 Although most cases quoted in the literature have been treated with pacemakers, the evidence for this is scant, and there is no consensus on how to treat these patients.103
Treatment with continuous positive airway pressure (CPAP) alleviates obstructive sleep apnoea-related symptoms and improves cardiovascular outcomes. Appropriate treatment reduces episodes of bradycardia by 7289%,104 and patients are unlikely to develop symptomatic bradycardia at long-term follow-up.104106 Therefore,
patients with asymptomatic nocturnal bradyarrhythmias or cardiac conduction diseases should be evaluated for SAS. If the diagnosis is confirmed, treatment of sleep apnoea with CPAP and weight loss can be effective in improving bradyarrhythmias occurring during sleep,
and permanent pacing should be avoided. In patients with known or suspected SAS and symptomatic bradyarrhythmias not associated with sleep, a more complex assessment of the risks associated with bradyarrhythmias vs. the benefit of cardiac pacing is needed.
4.3.7
Tilt testing
Tilt testing should be considered to confirm a diagnosis of reflex syncope in patients in whom this diagnosis was suspected but not confirmed by initial evaluation.62,107 The endpoint of tilt testing is the reproduction of symptoms along with the characteristic circulatory pattern of the reflex syncope. The methodology and classification of responses are described in section 4.2 in the Supplementary data and in Supplementary Figure 1.
A positive cardioinhibitory response to tilt testing predicts, with high probability, asystolic spontaneous syncope; this finding is relevant for therapy when cardiac pacing is considered (see section 5.4).
Conversely, the presence of a positive vasodepressor, a mixed response, or even a negative response does not exclude asystole during spontaneous syncope.62
4.4 Implantable monitors
Patients with infrequent symptoms of bradycardia (less than once per month) need a longer duration of ECG monitoring. For these patients, the implantable loop recorder (ILR) is an ideal diagnostic tool given its capacity for prolonged monitoring (up to 3 years) and without the need for active patient participation (Table 8).
In patients with unexplained syncope after the initial evaluation and infrequent symptoms (less than once a month), several studies have demonstrated a higher efficacy of initial ILR implantation compared with a conventional strategy. Many conditions diagnosed by
ILR are bradycardia mediated.108112 For further discussion on the diagnostic roles of ILR and ambulatory ECG, and indications for their use, refer to the ESC Guidelines for the diagnosis and management of syncope.62
Recommendations for genetic testing
Recommendations
Classa
Levelb
Genetic testing should be considered in patients with early onset (age <50 years) of progressive cardiac conduction disease.c 65,97
IIa
C
Genetic testing should be considered in family members following the identiﬁcation of a pathogenic genetic variant that explains the clinical phenotype of cardiac conduction disease in an index case.65
IIa
C
aClass of recommendation.
bLevel of evidence.
cProgressive cardiac conduction disease: prolonged P wave duration, PR interval,
and QRS widening with axis deviation.96
ESC 2021
Recommendation for sleep evaluation
Recommendation
Classa
Levelb
Screening for SAS is recommended in patients with symptoms of SAS and in the presence of severe bradycardia or advanced AVB during sleep.101106
I
C
AVB = atrioventricular block; SAS = sleep apnoea syndrome.
aClass of recommendation.
bLevel of evidence.
ESC 2021
Recommendation for tilt testing
Recommendation
Classa
Levelb
Tilt testing should be considered in patients with suspected recurrent reﬂex syncope.62
IIa
B
aClass of recommendation.
bLevel of evidence.
Recommendation for implantable loop recorders
Recommendation
Classa
Levelb
In patients with infrequent (less than once a month) unexplained syncope or other symptoms suspected to be caused by bradycardia, in whom a comprehensive evaluation did not demonstrate a cause, long-term ambulat ory monitoring with an ILR is recommended.108112
I
A
ILR = implantable loop recorder.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC 2021
................................................................................................................................
ESC Guidelines
21


<!-- PAGE 22 -->

### Page 22

..............................
4.5 Electrophysiology study
The development of non-invasive ambulatory ECG technologies has reduced the need for the electrophysiology study (EPS) as a diagnostic test. EPS is generally an adjunctive tool in the evaluation of patients with syncope in whom bradycardia is suspected but has not been documented after non-invasive evaluation (Figure 4). The goal of an
EPS in the context of bradycardia evaluation is to identify abnormal sinus node function or the anatomical location of the cardiac conduction disorders (in the AVN or in the HisPurkinje system distal to the AVN).
In patients with syncope and sinus bradycardia, the pre-test probability of bradycardia-related syncope increases when there is a sinus bradycardia (<50 b.p.m.) or sinoatrial block. Observational studies have shown a relationship between prolonged sinus node recovery time with syncope and the effect of pacing on symptoms.113,114
In patients with syncope and bifascicular block, a prolonged
Hisventricular interval (HV) >_70 ms, or HV >_100 ms after pharmacological stress (ajmaline, procainamide, flecainide, or disopyramide),
or induction of second- or third-degree AVB by atrial pacing or by
History, physical examination, 12-lead ECG and cardiac imaging
Patient with symptoms suggestive of bradycardia or conduction system disease
Early onset of progressive cardiac conduction disease or family history inherited cardiac conduction disorder
Clinical suspicion for potential causes of bradycardia
Syncope and bifascicular block
Suspected scar or infiltrative cardiomyopathy
Suspected recurrent reflex syncope
Bradycardia or cardiac conduction disorders during sleep
Exercise induced symptoms
Genetic test
Laboratory test
EPS or ET for exercisedinduced block or empirical pacemaker in elderly and frail patients
Further imaging
(CMR,CT,
PET etc.)
CSM/ tilt test
Polysomnography
/sleep study
ET
Diagnostic
N
Y
SND
(See section 5.1)
CCD without
AV block
(See section 5.3)
AV block
(See section 5.2)
Reflex syncope
(See section 5.4)
Symptoms
<1 per month
AECG
monitoring
ILR
Nondiagnostic
Clinical follow-up
(non-diagnostic)
Figure 4 Evaluation of bradycardia and conduction disease algorithm. AECG = ambulatory electrocardiographic monitoring; AV = atrioventricular;
CCD = cardiac conduction disease (or disorder); CMR = cardiovascular magnetic resonance; CSM = carotid sinus massage; CT = computed tomography;
ECG = electrocardiogram; EPS = electrophysiology study; ET = exercise test; ILR = implantable loop recorder; PET = positron emission tomography;
SND = sinus node dysfunction.


<!-- PAGE 23 -->

### Page 23

..........................................................................................................................................................................
pharmacological stress, identifies a group at higher risk of developing
AVB.115122
The efficacy of EPS for the diagnosis of syncope is highest in patients with sinus bradycardia, bifascicular block, and suspected tachycardia,62 and lowest in patients with syncope, a normal ECG, no structural heart disease, and no palpitations. Therefore, EPS is preferred over ILR in patients with syncope who have a high pre-test probability for significant conduction disease (e.g. abnormal ECG,
BBB, ischaemic heart disease, or scar-related cardiomyopathy). For patients with a low pre-test probability (no structural heart disease,
normal ECG), ILR is preferred over EPS. EPS is also preferred when there is a high likelihood that another syncopal episode will be dangerous or life-threatening and an immediate diagnosis is likely if EPS is performed.
A negative EPS does not exclude an arrhythmic syncope, and further evaluation is warranted. Approximately one-third of patients with a negative EPS in whom an ILR is implanted develop AVB at follow-up.123
5 Cardiac pacing for bradycardia and conduction system disease
5.1 Pacing for sinus node dysfunction
SND, also known as sick sinus syndrome, comprises a wide spectrum of sinoatrial dysfunctions, ranging from sinus bradycardia, sinoatrial block, and sinus arrest to bradycardiatachycardia syndrome.124,125
An additional manifestation of SND is an inadequate chronotropic response to exercise, reported as chronotropic incompetence.
5.1.1
Indications for pacing
5.1.1.1 Sinus node dysfunction
In general, pacing for asymptomatic SND has never been shown to affect prognosis, as opposed to pacing for AVB. Therefore, SND can be considered as an appropriate indication for permanent pacing only when bradycardia due to SND is symptomatic.126 Patients with
SND may manifest symptoms attributable to bradyarrhythmia and/or symptoms of accompanying atrial tachyarrhythmias in the bradycardiatachycardia form of the disease. Symptoms may be present either at rest or at the end of the tachyarrhythmic episode (conversion pause also named pre-automaticity pause), or develop during exercise, and may range from mild fatigue to light-headedness, dizzy spells, near-syncope, to syncope. Dyspnoea on exertion may be related to chronotropic incompetence. Syncope is a common manifestation of SND and has been reported in 50% of patients who receive a pacemaker for SND.127
Establishing a correlation between symptoms and bradyarrhythmia is a crucial step in decision-making. However, age, concomitant heart disease, and other comorbidities may pose difficulties in establishing a clear causeeffect relationship between SND and symptoms.
The effect of cardiac pacing on the natural history of bradyarrhythmias was evaluated in non-randomized studies undertaken at the beginning of the pacemaker era, which suggested a symptomatic improvement with cardiac pacing.128131 This was confirmed by one randomized controlled trial (RCT)14 in which 107 patients (aged 73
± 11 years) with symptomatic SND were randomized to no treatment, oral theophylline, or dual-chamber (DDD) rate-responsive pacemaker therapy. In this study, the occurrence of syncope and HF
was lower in the pacemaker group during a follow-up of 19 ± 14
months.
In patients presenting with exercise intolerance in whom chronotropic incompetence has been identified, the usefulness of cardiac pacing is uncertain, and the decision to implant a pacemaker in such patients should be made on a case by case basis.
In some cases, symptomatic bradyarrhythmias may be related to transient, potentially reversible, or treatable conditions (section 4,
Table 7). In such cases, correction of these factors is required,
whereas permanent pacing is not indicated. In clinical practice, it is crucial to distinguish physiological bradycardia (due to autonomic influences or training effects) from inappropriate bradycardia that requires permanent cardiac pacing. For example, sinus bradycardia,
even when it is 4050 b.p.m. while at rest or as slow as 30 b.p.m.
while sleeping, particularly in trained athletes, could be accepted as a physiological finding that does not require cardiac pacing.
Asymptomatic bradycardia (due to either sinus pauses or AVB episodes) is not uncommon and warrants interpretation in the clinical context of the patient: in healthy subjects, pauses >2.5 s are uncommon, but this per se does not necessarily constitute a clinical disorder;
asymptomatic bradyarrhythmias are common in athletes.132 In the absence of published trials, no recommendations for bradycardia detected in asymptomatic patients can be made. On the other hand,
in patients investigated for syncope in whom asymptomatic pause(s)
>6 s due to sinus arrest are eventually documented, pacing may be indicated. Indeed, such patients constituted a small minority of those included in an observational study and a randomized trial on pacing in reflex syncope.133,134 In patients presenting with sleep-related asymptomatic intermittent bradycardia (sinus bradycardia or AVB),
sleep apnoea and rapid eye movement sleep-related bradycardia should be considered as possible causes.
Recommendations for electrophysiology study
Recommendations
Classa
Levelb
In patients with syncope and bifascicular block,
EPS should be considered when syncope remains unexplained after non-invasive evaluation or when an immediate decision about pacing is needed due to severity, unless empirical pacemaker implantation is preferred (especially in elderly and frail patients).115121
IIa
B
In patients with syncope and sinus bradycardia,
EPS may be considered when non-invasive tests have failed to show a correlation between syncope and bradycardia.113,114
IIb
B
EPS = electrophysiology study.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC Guidelines
23


<!-- PAGE 24 -->

### Page 24

.......................................................................................................................................................................
5.1.1.2 Bradycardiatachycardia form of sinus node dysfunction
The bradycardiatachycardia variant of SND is the most common form, and is characterized by progressive, age-related, degenerative fibrosis of the sinus node tissue and atrial myocardium.
Bradyarrhythmias can be associated with various forms of atrial tachyarrhythmias, including AF.125 In this form of SND, the bradyarrhythmias may correspond to atrial pauses due to sinoatrial blocks or may be due to overdrive suppression after an atrial tachyarrhythmia.135
Atrial tachyarrhythmias may be present at the time of diagnosis,
typically with sinus arrest and asystolic pauses at the termination of atrial tachyarrhythmias or after device implant. Control of atrial tachyarrhythmias in patients presenting with high ventricular rates may be difficult before implant, as drugs prescribed for rate control may worsen bradyarrhythmias. Ablation of the atrial tachyarrhythmia,
mainly AF, has been proposed in lieu of pacing and continuing medications for selected patients,136138 but no data are available from
RCTs to show whether catheter ablation of AF is non-inferior to cardiac pacing with respect to bradycardia-related symptoms in patients with bradycardiatachycardia syndrome.139 If drug treatment is chosen, bradyarrhythmias during drug treatment for rate or rhythm control may be managed by dose reduction or discontinuation as an alternative to cardiac pacing, but in many cases bradyarrhythmias persist.
5.1.2
Pacing mode and algorithm selection
In patients with SND, controlled studies found that DDD was superior to single-chamber ventricular pacing in reducing the incidence of
AF. These studies also showed some effect of DDD pacing on the occurrence of stroke.140,141 Dual-chamber pacing reduces the risk of pacemaker syndrome, which may occur in more than a quarter of patients with SND.21,142 Pacemaker syndrome is associated with a reduction in quality of life and usually justifies the preference for
DDD vs. ventricular rate-modulated pacing in SND, when reasonable.143 Potential exceptions are very elderly and/or frail patients with infrequent pauses who have limited functional capacity and/or a short expected survival. In these patients, the benefit of DDD(R) vs.
VVIR pacing is expected to have limited or no clinical impact, and the incremental risk of complications related to the second atrial lead required in DDD(R) implants should also be considered when choosing the pacing mode. In patients with SND treated with a DDD
pacemaker, programming of the AV interval and specific algorithms for minimizing RV pacing may further reduce the risk of AF and particularly of persistent AF.144 Dual-chamber pacing is safer and more sustainable than atrial-only pacing modes used in the past,127 even though single-lead atrial pacing was found to be superior to singlelead ventricular pacing.145,146 The results of studies that evaluated different pacing modes in bradyarrhythmias, including in some cases both SND and AVB, are shown in Supplementary Table 6.
With regard to the choice between DDD(R) and atrial pacing atrial sensing inhibited-response rate-adaptive (AAIR) pacing, an RCT
with only 177 patients suggested a reduced risk of AF with AAIR.147
However, the most recent DANish Multicenter Randomized Trial on
Single Lead Atrial PACing vs. Dual Chamber Pacing in Sick Sinus
Syndrome (DANPACE), which enrolled 1415 patients followed for a mean of 5.4 years, found no difference between DDD(R) and AAIR
pacing in all-cause mortality.127 The DANPACE trial also found a higher incidence of paroxysmal AF [hazard ratio (HR) 1.27] and a two-fold increased risk of pacemaker reoperation with AAIR, with
AVB developing in 0.61.9% of patients every year.127 These findings support the routine use of DDD(R) rather than AAIR pacing in patients with SND.
In view of these data, DDD(R) is the pacing mode of first choice in
SND (Figure 5). Unnecessary RV pacing should be systematically avoided in patients with SND, because it may cause AF and deterioration of HF, particularly if systolic function is impaired or borderline.144,148 This can be achieved by programming of the AV interval or using specific algorithms for minimizing RV pacing. Programming an excessively long AV interval to avoid RV pacing in patients with prolonged AV conduction may be disadvantageous from a haemodynamic point of view by causing diastolic mitral regurgitation, which may lead to symptoms and/or AF.144,149,150
Pacing algorithms for minimizing ventricular pacing are often used in SND.144,151 A meta-analysis of algorithms for minimizing RV pacing failed to show a significant effect compared with conventional DDD
pacing in patients with normal ventricular function with regard to endpoints such as incidence of persistent/permanent AF, all-cause hospitalization, and all-cause mortality.152 However, the rationale for reducing unnecessary RV pacing remains strong and is coupled with the benefits of extending device longevity.151,152 Some manufacturerspecific algorithms are more effective in minimizing ventricular pacing,
but may confer disadvantages in allowing decoupling between atria and ventricles.153,154 Rarely, algorithms designed to minimize ventricular pacing can cause life-threatening ventricular arrhythmias that are pause dependent or pause triggered.155158 No direct comparison of these algorithms has been performed so far, but pooled data from randomized trials do not show clear-cut superiority of any specific algorithm in improving clinical outcome.152,159
In patients with severely reduced LVEF and a SND indication for pacing, in whom a high percentage of ventricular pacing is expected,
an indication for CRT or HBP should be evaluated (see section 6 on
CRT and section 7 on HBP).
The role of pacing algorithms for preventing AF has been the subject of controversy. A series of algorithms for preventing/suppressing
AF has been tested, such as dynamic atrial overdrive pacing, atrial pacing in response to atrial premature beats, pacing in response to exercise, and post-mode-switch pacing. The clinical evaluation of these algorithms, also applied at different atrial pacing sites, is not convincing and no clinical benefit with regard to major clinical endpoints has been demonstrated.160,161
Atrial antitachycardia pacing [ATP; i.e. delivery of atrial stimuli at high frequencies to convert an atrial tachyarrhythmia to sinus rhythm
(SR)] has also been tested for reducing the atrial tachyarrhythmia burden and counteracting the tendency over time towards progression to permanent AF.162 Conventional delivery of atrial ATP in a way that mirrors the delivery of ventricular ATP (bursts/ramp at arrhythmia onset) has a relatively low success rate, and indeed the trials based on conventional atrial ATP showed no benefit on AF burden or clinical events.163 A new form of ATP delivery has been


<!-- PAGE 25 -->

### Page 25

......................
proposed, specifically aimed at reducing atrial tachyarrhythmias, and its efficacy in reducing the progression to permanent AF was validated in an RCT.162,164
In this trial,164 the primary composite outcome at 2 years (death,
cardiovascular hospitalizations, or permanent AF) was significantly reduced in patients with a device combining ATP and algorithms for minimizing RV pacing [36% relative risk reduction compared with conventional DDD(R)]. The positive effect on the primary endpoint was due to a lower rate of progression to permanent AF. A post-hoc analysis indicated that this form of atrial ATP was an independent predictor of permanent or persistent AF reduction.162,164,165 In
CHD, where re-entrant atrial arrhythmias are very common, use of
DDD(R) pacemakers with atrial ATP may be considered (see section
8 on pacing in CHD).
SND
Persistent or paroxysmal
DDD(R)a
Optimal pacing mode in sinus node dysfunction and atrio-ventricular block
Y
N
Sinus rhythm:
DDD + AVM
AF: VVI +
rate hysteresis
DDDR
+ AVM
Single chamber 
AAI(R)a
VVI(R)a
Any reason to avoid 2
leadsb
Significant comorbidity
Default option
DDD
+ AVM
DDD(R)a
+ AVM
Single chamber
AAIR
Single chamber
AAI
VVIR
VVI
VVI + rate hysteresis
DDD
VVIR
VVI(R)a
VDD
VVI
VDD
VVI +
rate hysteresis
Chronotropic incompetence?
Persistent or paroxysmal no SND
AF
AV block
SND
Paroxysmal
Persistent
Persistent
Paroxysmal
Figure 5 Optimal pacing mode and algorithm selection in sinus node dysfunction and atrioventricular block. AF = atrial fibrillation; AV = atrioventricular;
AVM = atrioventricular management [i.e. AV delay programming (avoiding values >230 ms) or specific algorithms to avoid/reduce unnecessary ventricular pacing]; CRT = cardiac resynchronization therapy; SND = sinus node dysfunction. a(R) indicates that the programming of such a pacing mode is preferred only in the case of chronotropic incompetence. bReasons to avoid two leads include young age and limited venous access. Note: in patients who are candidates for a VVI/VDD pacemaker, a leadless pacemaker may be considered (see section 7). For combined CRT indications, see section 6. Adapted from
Brignole et al.62
ESC Guidelines
25


<!-- PAGE 26 -->

### Page 26

.............................................................................................................................................................................
5.2 Pacing for atrioventricular block
5.2.1
Indications for pacing
Treatment of AVB aims at ameliorating symptoms and preventing syncope and sudden cardiac death (SCD). First-degree AVB is usually asymptomatic. Syncope and dizziness are mainly observed in highdegree and complete AVB, especially in the paroxysmal forms. HF
symptoms are more common in chronic AVB with permanent bradycardia, but can also be observed in first-degree AVB with a very prolonged PR interval. Given the commonly advanced age at onset of
AVB, manifestations of fatigue, exertional intolerance, and HF are sometimes underestimated. Deterioration of cognitive functions is often only speculative so that the possibilities of improvement after implantation of a pacemaker are unpredictable and unlikely. Death in patients with untreated AVB is due not only to HF secondary to low cardiac output, but also to SCD caused by prolonged asystole or bradycardia-triggered ventricular tachyarrhythmia. Although RCTs of pacing in AVB have not been performed, it is clear from several observational studies that pacing prevents recurrence of syncope and improves survival.1012
5.2.1.1 First-degree atrioventricular block
Usually the prognosis is good in the absence of structural heart disease, and progression to high-degree block is uncommon.175 The indication for pacing relies on an established correlation between symptoms and AVB. There is weak evidence to show that marked PR
prolongation (i.e. >_300 ms), particularly when it persists or is prolonged during exercise, can lead to symptoms similar to pacemaker syndrome and/or that these can improve with pacing.176 Symptom correlation is crucial, although it may be difficult if these are nonspecific and subtle. In the absence of a clear correlation, a pacemaker is generally not indicated.
5.2.1.2 Second-degree type I atrioventricular block (Mobitz type I or
Wenckebach)
In addition to the presence or absence of symptoms, the risk of progression to higher degrees of AVB should be considered. Supranodal block has a benign course, and the risk of progression to type II or a higher degree of AV block is low. Small, retrospective studies have suggested that, over the long term, this type of AVB carries a higher risk of death in patients aged >_45 years in the absence of pacemaker implantation.177,178 Infranodal block (rare in this form of block) carries a high risk of progression to complete heart block, syncope, and sudden death, and warrants pacing even in the absence of symptoms.179,180
5.2.1.3 Second-degree Mobitz type II, 2:1, and advanced atrioventricular block (also named high-grade atrioventricular block, where the P:QRS
ratio is 3:1 or higher), third-degree atrioventricular block
In the absence of a reversible cause, due to the risk of occurrence of severe symptoms and/or possible progression towards a more severe or complete AVB, patients should receive a pacemaker even in the absence of symptoms. In asymptomatic patients in whom a 2:1
AVB is found incidentally, the decision for implantation should be made on a case by case basis including distinction between nodal and infranodal AVB. This distinction may be based on observations such as PR or PP interval prolongation before AVB, the effect of exercise on AV conduction, and an EPS.
5.2.1.4 Paroxysmal atrioventricular block
Because of the risk of syncope and SCD and of the potential progression to permanent AVB, the indications for pacing are the same for paroxysmal as for permanent AVB. It is crucial to rule out a reversible cause and to recognize the reflex forms of AVB, which may not need pacing. Documentation of infranodal block by EPS or the documentation of initiation of the block by atrial or ventricular premature beats,
or increased heart rate (tachy-dependent AVB) or decreased heart
Recommendations for pacing in sinus node dysfunction
Recommendations
Classa
Levelb
In patients with SND and a DDD pacemaker,
minimization of unnecessary ventricular pacing through programming is recommended.144,151,159,164,166169
I
A
Pacing is indicated in SND when symptoms can clearly be attributed to bradyarrhythmias.14,128131
I
B
Pacing is indicated in symptomatic patients with the bradycardiatachycardia form of SND in order to correct bradyarrhythmias and enable pharmacological treatment, unless ablation of the tachyarrhythmia is preferred.17,20,21,136138,170,171
I
B
In patients who present chronotropic incompetence and have clear symptoms during exercise,
DDD with rate-responsive pacing should be considered.172,173
IIa
B
AF ablation should be considered as a strategy to avoid pacemaker implantation in patients with
AF-related bradycardia or symptomatic preautomaticity pauses, after AF conversion, taking into account the clinical situation.136139,174
IIa
C
In patients with the bradycardiatachycardia variant of SND, programming of atrial ATP may be considered.164,165
IIb
B
In patients with syncope, cardiac pacing may be considered to reduce recurrent syncope when asymptomatic pause(s) >6 s due to sinus arrest is documented.133,134
IIb
C
Pacing may be considered in SND when symptoms are likely to be due to bradyarrhythmias,
when the evidence is not conclusive.
IIb
C
Pacing is not recommended in patients with bradyarrhythmias related to SND that are asymptomatic or due to transient causes that can be corrected and prevented.33
III
C
ATP = antitachycardia pacing; DDD = dual-chamber, atrioventricular pacing;
SND = sinus node dysfunction.
aClass of recommendation.
bLevel of evidence.
ESC 2021


<!-- PAGE 27 -->

### Page 27

.....................................................
rate (brady-dependent AVB), support a diagnosis of intrinsic infranodal AVB.27
5.2.2
Pacing mode and algorithm selection
5.2.2.1 Dual-chamber vs. ventricular pacing
Large, randomized, parallel trials that included patients with only
AVB181 or with AVB and/or SND140 failed to show superiority of
DDD over ventricular pacing with regard to mortality, and have not consistently shown superiority in terms of quality of life or morbidity
(including stroke or transient ischaemic attack and AF).20,140,181 Dualchamber pacing is beneficial over ventricular pacing due to the avoidance of pacemaker syndrome, which occurred in up to a quarter of patients with AVB in these trials. In a meta-analysis of 20 crossover trials, DDD was associated with an improved exercise capacity compared with ventricular pacing. However, the effect was driven by non-rate-modulated ventricular pacemakers, and no benefit was observed from the comparison of DDD with VVIR pacing.182
Pacemaker syndrome is associated with reduction in quality of life and may require a reintervention for upgrading, justifying the preference for DDD when reasonable (i.e. in patients who do not present with significant frailty, very advanced age, significant comorbidities limiting their life expectancy, or a very limited mobility). Another consideration is the diagnosis of AF, which is more reliable from device data in patients with DDD pacemakers. On a case by case basis, in frail elderly patients, and/or when AVB is paroxysmal and pacing anticipated to be infrequent, VVIR pacing may be considered as it carries a lower complication rate.140
There is strong evidence to show that chronic conventional RV
pacing may be deleterious in some patients and may lead to LV dysfunction and HF,148 even when AV synchrony is maintained.183 This effect is only partly explained by the abnormal activation sequence and may involve myocardial perfusion, and humoral, cellular, and molecular changes.184,185 Compared with a matched control cohort,
patients with a pacemaker and an RV lead have an increased risk of
HF, which is also associated with older age, previous MI, kidney disease, and male sex.186 Pacing-induced cardiomyopathy occurs in
1020% of patients after 24 years of RV pacing.186188 It is associated with a >20% RV pacing burden.187190 However, there are no data to support that any percentage of RV pacing can be considered as defining a true limit below which RV pacing is safe and beyond which RV pacing is harmful. For discussion of potential indications for
CRT and/or HBP to prevent pacing-induced cardiomyopathy, please refer to sections 6 and 7.
5.2.2.2 Atrioventricular block in the case of permanent atrial fibrillation
In the presence of AF, AVB should be suspected if the ventricular rate is slow and the ventricular rhythm regular. During prolonged monitoring, long ventricular pauses may be detected.191 In patients with AF and no permanent AVB or symptoms, there is no identifiable,
minimum pause duration as an indication for pacing. In the absence of a potentially reversible cause, bradycardia or inappropriate chronotropic response (due to either intermittent or complete AVB) associated or reasonably correlated with symptoms is an indication for cardiac pacing. Any high-degree or infranodal block is also an indication for pacing, even in the absence of symptoms. In the absence of symptoms due to bradycardia and of high-degree or infranodal block,
pacing is unlikely to be beneficial and is not indicated.
In patients with AF who undergo atrioventricular junction (AVJ)
ablation to control rapid ventricular rates, there is evidence to show that AVJ ablation plus RV pacing improves symptoms and quality of life.192 In contrast, neutral results were found regarding the progression of HF, hospitalization, and mortality,193 except in one study.194
Compared with pharmacological rate control, AVJ ablation and CRT
reduced the risks of death due to HF, hospitalization due to HF, or worsening HF by 62%, and improved specific symptoms of AF by
36% in elderly patients with permanent AF and narrow QRS.195 In other studies, this beneficial effect was limited to patients with HF or reduced ejection fraction (EF).166,196 For further discussion of the role of CRT following AVJ ablation, refer to section 6. There is weak evidence to support a benefit from para-Hisian and Hisian pacing after AVJ ablation for refractory AF.197200 For further discussion,
refer to section 7.
Recommendations for pacing for atrioventricular block
Recommendations
Classa
Levelb
Pacing is indicated in patients in SR with permanent or paroxysmal third- or second-degree type 2, infranodal 2:1, or high-degree AVB, irrespective of symptoms.c 912
I
C
Pacing is indicated in patients with atrial arrhythmia (mainly AF) and permanent or paroxysmal third- or high-degree AVB irrespective of symptoms.
I
C
In patients with permanent AF in need of a pacemaker, ventricular pacing with rate response function is recommended.201204
I
C
Pacing should be considered in patients with second-degree type 1 AVB that causes symptoms or is found to be located at intra- or infra-His levels at EPS.177180
IIa
C
In patients with AVB, DDD should be preferred over single-chamber ventricular pacing to avoid pacemaker syndrome and to improve quality of life.20,140,181,182
IIa
A
Permanent pacemaker implantation should be considered for patients with persistent symptoms similar to those of pacemaker syndrome and clearly attributable to ﬁrst-degree AVB (PR
>0.3 s).205207
IIa
C
Pacing is not recommended in patients with AVB
due to transient causes that can be corrected and prevented.
III
C
AF = atrial ﬁbrillation; AVB = atrioventricular block; DDD = dual-chamber, atrioventricular pacing; EPS = electrophysiology study; SR = sinus rhythm.
aClass of recommendation.
bLevel of evidence.
cIn asymptomatic narrow QRS complex and 2:1 AVB, pacing may be avoided if supra-Hisian block is clinically suspected (concomitant Wenckebach is observed and block disappears with exercise) or demonstrated at EPS.
ESC 2021
...................................................................................................................
ESC Guidelines
27


<!-- PAGE 28 -->

### Page 28

...............................................................
In patients with AF, compared with fixed rate pacing, rateresponsive pacing is associated with better exercise performance,
improved daily activities, a decrease in symptoms of shortness of breath, chest pain, and palpitations, and improved quality of life.201203 It has also been shown to improve heart rate and blood pressure response to mental stress compared with fixed rate pacing.204 Therefore, rate-adaptive pacing is the pacing mode of first choice. Fixed-rate VVI pacing should be reserved for older sedentary patients who have very limited activity. Commonly, the minimum rate is programmed higher (e.g. 70 b.p.m.) than for patients in SR in an attempt to compensate for loss of active atrial filling.
5.3 Pacing for conduction disorders without atrioventricular block
This section focuses on patients with 1:1 AV conduction and QRS
abnormalities caused by delayed or blocked conduction of the
HisPurkinje system: BBB, fascicular block in isolation or in combination with BBB, and non-specific intraventricular delay. Bifascicular block is defined as LBBB or the combination of RBBB and with left anterior or posterior fascicular block.
Isolated fascicular block and BBB are rarely associated with symptoms; however, their presence may be a marker for underlying structural heart disease. The presence or absence of symptoms referable to intermittent bradycardia will guide the evaluation of these patients.
5.3.1
Indications for pacing
5.3.1.1 Bundle branch block and unexplained syncope
Although syncope is not associated with an increased incidence of sudden death in patients with preserved cardiac function, a high incidence of total deaths (about one-third sudden) was observed in patients with BBB and HF, previous MI, or low EF.208210 Indeed, in those with low EF, syncope is a risk factor for death.211
Unfortunately, ventricular-programmed stimulation does not seem to identify these patients correctly; therefore, an ICD or a defibrillator with CRT (CRT-D) is indicated in patients with BBB and LVEF
<35% for the prevention of SCD (Figure 6).63
5.3.1.2 Bundle branch block, unexplained syncope, and abnormal electrophysiological study
Electrophysiological assessment includes measurement of the
HV at baseline, with stress by incremental atrial pacing or by
Decision algorithm for patients with unexplained syncope and BBB
Bifascicular block
LVEF ≤ 35%
Elderly and frail patients at risk of traumatic recurrrences
ICD/CRT-D
Clinical follow-up
Adapted therapy
Pacemaker implant
EPS/CSM
ILR
N
N
No diagnosis
Y
Y
Diagnosis
No diagnosis
Diagnosis
Figure 6 Decision algorithm for patients with unexplained syncope and bundle branch block. BBB = bundle branch block; CRT-D = defibrillator with cardiac resynchronization therapy; CSM = carotid sinus massage; EPS = electrophysiology study; ICD = implantable cardioverter-defibrillator; ILR =
implantable loop recorder; LVEF = left ventricular ejection fraction.


<!-- PAGE 29 -->

### Page 29

........................................................................
pharmacological provocation (ajmaline, procainamide, or flecainide).
Scheinman et al. studied the prognostic value of the HV: the progression rate to AVB at 4 years was 4% in patients with HV <70 ms, 12%
in patients with HV between 70 and 100 ms, and 24% in patients with
HV >100 ms.121 Development of intra- or infra-His block at incremental atrial pacing or by pharmacological stress test increases the sensitivity and positive predictive value of the EPS to identify patients who will develop AVB.116118,120,122,212 A positive EPS yielded a positive predictive value as high as 80% to identify patients who develop
AVB. This finding has been indirectly confirmed by a study that showed a significant reduction in syncopal recurrences in patients with positive EPS treated with a pacemaker, compared with a control group of untreated patients with a negative EPS.119 In patients with unexplained syncope and bifascicular block, EPS is highly sensitive in identifying patients with intermittent or impending high-degree AVB.
However, a negative EPS cannot rule out intermittent/paroxysmal
AVB as the cause of syncope. Indeed, in patients with a negative EPS,
intermittent or stable AVB was documented by ILR in 50% of cases.
Therefore, elderly patients with bifascicular block and unexplained syncope might benefit from an empirical pacemaker, especially in unpredictable and recurrent syncope that exposes the patient to a high risk of traumatic recurrences. The decision to implant a pacemaker in these patients should be based on individual riskbenefit evaluation.213
5.3.1.3 Alternating bundle branch block
This rare condition refers to situations in which there is clear ECG
evidence for block in all three fascicles on successive ECGs; examples are LBBB and RBBB morphologies on successive ECGs, or RBBB
with associated left anterior fascicular block on one ECG and left posterior fascicular block on another ECG.214 There is general consensus that this phenomenon is associated with significant infranodal disease and that patients will progress rapidly toward AVB.
Therefore, a pacemaker should be implanted as soon as the alternating BBB is detected, even in the absence of symptoms.
5.3.1.4 Bundle branch block without symptoms
Permanent pacemaker implantation is not indicated for BBB without symptoms, with the exception of alternating BBB, because only a minority of these patients will develop
AVB
(12%
per year).115,121,215 The risks of pacemaker implantation and long-term transvenous lead complications are higher than the benefits of pacemaker implantation.216,217
5.3.1.5 Patients with neuromuscular diseases
In patients with neuromuscular diseases, cardiac pacing should be considered, as any degree of fascicular block can progress unpredictably, even in the absence of symptoms (see section 8.5).
5.3.2
Pacing mode and algorithm selection
In intermittent bradycardia, pacing may be required only for short periods. In this situation, the benefits of bradycardia and pause prevention must be weighed against the detrimental effects of permanent pacing,
particularly pacing-induced
HF.
Low base-rate programming to achieve backup pacing, and manual adaptation of AV
interval, programming AV hysteresis, or other specific algorithms preventing unnecessary RV pacing, play a particularly important role in this patient group.144,148
In patients in SR, the optimal pacing mode is DDD. The strong evidence of superiority of DDD vs. VVI pacing is limited to improvement in symptoms and quality of life. Conversely, there is strong evidence of non-superiority with regard to survival and morbidity.20
Therefore, in elderly or frail patients with intermittent bradycardia,
the decision regarding the pacing mode should be made on an individual basis, taking into consideration the increased complication risk and costs of DDD (Figure 5).
VDD may be a pacing mode alternative for patients with advanced
AV conduction abnormalities and spared sinus node function. In comparison with DDD, VDD system implantation is associated with fewer complications, shorter procedure and fluoroscopy times, and a high incidence of atrial undersensing.218 Potential atrial undersensing is contributing to the low use of this system as most operators are aiming for AV synchrony.
Recommendations for pacing in patients with bundle branch block
Recommendations
Classa
Levelb
In patients with unexplained syncope and bifascicular block, a pacemaker is indicated in the presence of either a baseline HV of >_70 ms, second- or third-degree intra- or infra-Hisian block during incremental atrial pacing, or an abnormal response to pharmacological challenge.119,120
I
B
Pacing is indicated in patients with alternating
BBB with or without symptoms.
I
C
Pacing may be considered in selected patients with unexplained syncope and bifascicular block without EPS (elderly, frail patients, high-risk and/
or recurrent syncope).213
IIb
B
Pacing is not recommended for asymptomatic
BBB or bifascicular block.115,121,215
III
B
BBB
=
bundle branch block;
EPS
=
electrophysiology study;
HV
=
Hisventricular interval.
aClass of recommendation.
bLevel of evidence.
ESC 2021
..........................................................................
ESC Guidelines
29


<!-- PAGE 30 -->

### Page 30

......................................................
5.4 Pacing for reflex syncope
Permanent pacemaker therapy may be effective if asystole is a dominant feature of reflex syncope. Establishing a relationship between symptoms and bradycardia should be the goal of the clinical evaluation of patients with syncope and a normal baseline ECG. The efficacy of pacing depends on the clinical setting. The fact that pacing is effective does not mean it is always necessary. In patients with reflex syncope, cardiac pacing should be the last resort and should only be considered in highly selected patients [i.e. those >40 years of age
(mostly >60 years), affected by severe forms of reflex syncope with frequent recurrences associated with a high risk of injury, often without a prodrome]. The 2018 ESC Guidelines on syncope62 give a detailed description of the diagnostic pathway and indications for pacing, and provide the evidence from trials that support such recommendations. Figure 7 summarizes the suggested decision pathway.
The algorithm shown in Figure 7 has been prospectively validated in a multicentre pragmatic study, which showed a low recurrence rate of syncope with pacing of 15% at 2 years, significantly lower than the 37% rate observed in unpaced controls.219 The 3-year recurrence rate was similar in patients with cardioinhibitory carotid sinus syndrome (16%), asystolic tilt response (23%), and spontaneous asystole documented by ILR (24%), suggesting similar indications and similar results for the three forms of reflex syncope.220
Whilst some scepticism prevails over the diagnostic accuracy of tilt testing for the diagnosis of syncope, emerging evidence supports the use of tilt testing in the assessment of reflex hypotensive susceptibility.107,221 Thus, tilt testing may be considered to identify patients with an associated usually antecedent hypotensive response that would be less likely to respond to permanent cardiac pacing. Patients with hypotensive susceptibility need measures directed to counteract hypotensive susceptibility in addition to cardiac pacing (e.g. physical counterpressure manoeuvres, discontinuation/reduction of hypotensive drugs, and administration of fludrocortisone or midodrine).
Management of cardiac pacing in patients with reflex syncope
Severe, recurrent, unpredictable syncopes, age > 40 years
Cardioinhibitory carotid 
sinus syndrome 
Perform carotid sinus massage and tilt table test
Pacing not indicated
(Class III)
N
Y
Y
Positive tilt-test
Y
Y
Asystolic tilt-test
Implantable loop recorder
Asystole
Positive tilt-test
N
N
N
Y
Implant a DDD PM
and counteract hypotensive susceptibility
(Class I)
Y
Y
Implant a DDD PM
(Class I)
N
N
Figure 7 Decision pathway for cardiac pacing in patients with reflex syncope. DDD = dual-chamber, atrioventricular pacing. Note: cardioinhibitory carotid sinus syndrome is defined when the spontaneous syncope is reproduced by the carotid sinus massage in the presence of an asystolic pause >3 s;
asystolic tilt positive test is defined when the spontaneous syncope is reproduced in the presence of an asystolic pause >3 s. A symptomatic asystolic pause(s) >3 s or asymptomatic pause(s) >6 s due to sinus arrest, atrioventricular block, or the combination of the two similarly define asystole detected by implantable loop recorder. Figure adapted from Brignole et al.62


<!-- PAGE 31 -->

### Page 31

....................................................................................
5.4.1
Indications for pacing
This Task Force found sufficient evidence in the literature to recommend pacing in highly selected patients with reflex syncope (i.e. those
>40 years of age with severe recurrent unpredictable syncopal episodes when asystole has been documented, induced by either CSM
or tilt testing, or recorded through a monitoring system)133,222228
(see Supplementary Table 7). There is sufficient evidence that DDD
pacing should be considered in order to reduce recurrence of syncope in patients with dominant cardioinhibitory CSS (asystolic pause
>3 s and spontaneous syncope during CSM) and in those in whom there is a correlation between spontaneous symptoms and ECG
who are >40 years of age and have severe recurrent unpredictable syncope.62 Permanent pacemaker therapy may be effective if asystole is a dominant feature of reflex syncope. Establishing a correlation between symptoms and bradycardia should be the goal of the clinical evaluation of patients with syncope and a normal baseline ECG. The efficacy of pacing depends on the clinical setting. A comparison of results in different settings is presented in Supplementary Table 8.
Since the publication of the 2018 ESC Guidelines on syncope,62
some trials have added relevant information regarding the subset of patients with tilt-induced asystolic vasovagal syncope. The SPAIN trial was a multicentre, randomized, controlled, crossover study, performed in 46 patients aged >40 years affected by severely recurrent
(>5 episodes during life) syncope and cardioinhibitory tilt test response (defined as bradycardia <40 b.p.m. lasting >10 s or asystole
>3 s).226 During the 24-month follow-up, syncope recurred in 4 (9%)
patients treated with a DDD pacemaker with closed loop stimulation vs. in 21 (46%) patients who had received a sham pacemaker programmed off (P = 0.0001). In a propensity score-matched comparison study,229 the 5-year actuarial syncope-free rate was 81% in the pacing group and 53% in propensity-matched patients (P = 0.005; HR
= 0.25). Finally, the BioSync CLS trial was a multicentre RCT that investigated the usefulness of the tilt-table test to select candidates for cardiac pacing.228 Patients aged >_40 years who had at least two episodes of unpredictable severe reflex syncope during the past year and a tilt-induced syncope with an asystolic pause >3 s were randomized to receive either an active (63 patients) or an inactive (64
patients) dual-chamber pacemaker with close loop stimulation. The study showed that, after a median follow-up of 11.2 months, syncope occurred in significantly fewer patients in the pacing group than in the control group [10 (16%) vs. 34 (53%), respectively; HR 0.23; P =
0.00005). This study supports inclusion of tilt testing as a useful method to select patients with reflex syncope for cardiac pacing.
Based on the results of the above studies, sufficient evidence exists to upgrade from IIb to I the indication for pacing in patients aged >40
years with asystolic tilt response >3 s. Figure 8 summarizes the recommended indication for pacing. Although there is also a rationale for pacing in patients aged <_40 years who have the same severity criteria as those >40 years, this Task Force cannot make any recommendation due to the lack of evidence from trials addressing this specific population.
There is weak evidence that DDD may be useful in reducing recurrences of syncope in patients with the clinical features of adenosinesensitive syncope.62 In a small multicentre trial performed in 80 highly
Indications for pacing in patients above age 40 with reflex syncope
Spontaneous asystolic pause(s)
Y
Y
N
N
Test-induced asystolic pause(s)
Extrinsic (functional)
vagally-mediated or adenosine-sensitive
Pacing indicated
(Class I)
CI-CSS
Pacing indicated
(Class I)
Asystolic tilt
Pacing indicated
(Class I)
Adenosine induced
AV block > 10 sec 
Pacing indicated
(Class IIb)
Undocumented syncope
Pacing not indicated
(Class III)
Figure 8 Summary of indications for pacing in patients >40 years of age with reflex syncope. CI-CSS = cardioinhibitory carotid sinus syndrome. Note:
spontaneous asystolic pause = 3 s symptomatic or 6 s asymptomatic. Adapted from Brignole et al.62
ESC Guidelines
31


<!-- PAGE 32 -->

### Page 32

.....................................................
selected elderly patients with unexplained unpredictable syncope who had induction of third-degree AVB of >_10 s to intravenous injection of a bolus of 20 mg of adenosine triphosphate, DDD significantly reduced the 2-year syncope recurrence rate from 69% in the control group to 23% in the active group.230 Finally, cardiac pacing is not indicated in the absence of a documented cardioinhibitory reflex.231,232
5.4.2
Pacing mode and algorithm selection
Even if the quality of evidence is weak, DDD pacing is widely preferred in clinical practice to single-chamber RV pacing in counteracting blood pressure fall and preventing symptom recurrences. In patients with tilt-induced vasovagal syncope, DDD was used mostly with a rate-drop response feature that provides rapid DDD if the device detects a rapid decrease in heart rate. A comparison between
DDD closed-loop stimulation and conventional DDD has been performed by means of a crossover design in two small studies. Both studies showed fewer syncope recurrences with closed-loop stimulation, both in the acute setting during repeated tilt testing233 and during 18-month clinical follow-up.227 However, until a formal parallel trial is performed, no recommendation can be given regarding the selection of the pacing mode (i.e. DDD with rate-drop response or
DDD with closed-loop stimulation) and its programming.
5.5 Pacing for suspected
(undocumented) bradycardia
In patients with recurrent unexplained syncope or falls at the end of the conventional work-up, ILR monitoring should be considered in an attempt to document a spontaneous relapse instead of embarking on empiric cardiac pacing.62
5.5.1
Recurrent undiagnosed syncope
In patients with unexplained syncope at the end of a complete workup and absence of any conduction disturbance, the lack of a rationale and the negative results of small studies234,235 give sufficient evidence of inefficacy of cardiac pacing. Thus, cardiac pacing is not recommended until a diagnosis is made (Figure 8).
5.5.2
Recurrent falls
Between 15% and 20% of unexplained falls may be syncopal in nature,
possibly bradyarrhythmic. Retrograde amnesia, which is frequent in the falling elderly, is responsible for misinterpretation of the event.62
The management of unexplained falls should be the same as that for unexplained syncope (see section 5.4.1). In a randomized doubleblind trial,236 cardiac pacing was ineffective in preventing recurrences in patients with an unexplained fall in whom carotid sinus hypersensitivity was unable to induce syncope.
6 Cardiac resynchronization therapy
6.1 Epidemiology, prognosis, and pathophysiology of heart failure suitable for cardiac resynchronization therapy by biventricular pacing
The prevalence of HF in the developed world approximates 12%
of the adult population, rising to >_10% among people aged >70
years.237 The prevalence of HF is increasing (by 23% over the past decade according to one estimate) mainly due to the ageing of the population, with the age-specific incidence actually declining.238241
There are three distinct phenotypes of HF based on the measurement of LVEF [<40%, HF with reduced EF (HFrEF); 4049%, HF
with mildly reduced EF (HFmrEF); and >_50%, HF with preserved EF
(HFpEF)].242 CRT is clinically useful mainly for patients with HFrEF
and LVEF <_35%. Patients with HFrEF constitute 50% of the entire
Recommendations for pacing for reﬂex syncope
Recommendations
Classa
Levelb
Dual-chamber cardiac pacing is indicated to reduce recurrent syncope in patients aged >40
years, with severe, unpredictable, recurrent syncope who have:
• spontaneous documented symptomatic asystolic pause(s) >3 s or asymptomatic pause(s)
>6 s due to sinus arrest or AVB; or
• cardioinhibitory carotid sinus syndrome; or
• asystolic syncope during tilt testing.62,219,220,226,228,229
I
A
Dual-chamber cardiac pacing may be considered to reduce syncope recurrences in patients with the clinical features of adenosine-sensitive syncope.230
IIb
B
Cardiac pacing is not indicated in the absence of a documented cardioinhibitory reﬂex.231,232
III
B
AVB = atrioventricular block.
aClass of recommendation.
bLevel of evidence.
ESC 2021
Recommendations for cardiac pacing in patients with suspected (undocumented) syncope and unexplained falls
Recommendations
Classa
Levelb
In patients with recurrent unexplained falls, the same assessment as for unexplained syncope should be considered.62
IIa
C
Pacing is not recommended in patients with unexplained falls in the absence of any other documented indication.236
III
B
Pacing is not recommended in patients with unexplained syncope without evidence of SND
or conduction disturbance.234,235
III
C
SND = sinus node dysfunction.
aClass of recommendation.
bLevel of evidence.
ESC 2021
...................................................................................................................


<!-- PAGE 33 -->

### Page 33

.............................................................................................................................................................................
population with HF, and HFrEF is less prevalent among individuals aged 70 years or older. The prognosis of HF varies according to the defined population. In contemporary clinical trials of HFrEF, 1-year mortality rates of 6% are seen, whereas in large registry-based surveys, 1-year mortality rates exceed 20% in patients recently hospitalized for HF, but are closer to 6% in those recruited with stable outpatient HF.243 The concept of CRT is based on the fact that in patients with HF and LV systolic dysfunction, high-grade intraventricular conduction delays are frequently observed, with a prevalence of
QRS duration >120 ms in 2550% of patients and of LBBB in
1527% of cases. Moreover, in such patients, AV dyssynchrony is also often present with prolonged PR on the surface ECG in up to
52% of cases.244246 These electrical abnormalities may result in AV,
interventricular, and intra-LV mechanical dyssynchrony.247,248
Recommendations for CRT are based on the results of the major
RCTs of CRT, most of which have been restricted to the 60% of
HFrEF patients who are in SR. CRT is recommended (in addition to guideline-directed medical therapy) in only defined subsets of the HF
patient population, the majority being symptomatic HF patients in SR
with a reduced LVEF and a QRS duration >_130 ms. Other smaller groups that may be considered for CRT include New York Heart
Association (NYHA) class III or IV HF patients in AF with a reduced
LVEF and a QRS duration >_130 ms, provided a strategy to ensure biventricular capture is in place or the patient is expected to return to SR, and occasionally as an upgrade from a conventional pacemaker or an ICD in HFrEF patients who develop worsening HF with a high rate of ventricular pacing. A recent survey in the USA, which derived a nationally representative estimate of the entire US population of hospitalized patients, found that over a 10-year period (20032012),
there were an estimated 378 247 CRT-D implantations, representing
40 000 per year, or roughly 135 per million per year.249 In Europe,
previous estimates have reported that 400 patients per million population per year might be suitable for CRT. This was based on an estimated prevalence of 35% for LVEF <_35% in a representative HF
population, of which 41% of patients were estimated to have a QRS
duration >_120 ms. The change to a higher threshold of QRS duration of 130 ms will reduce these estimates modestly.250,251 In Sweden, a recent survey of 12 807 HFrEF patients showed that 7% had received
CRT and 69% had no indication for CRT, but 24% had an indication and had not received CRT. These data highlight the underuse of
CRT.252,253 Finally, the Task Force stresses the point that the decision to implant CRT requires a shared decision-making with the patient.
6.2 Indication for cardiac resynchronization therapy: patients in sinus rhythm
CRT improves cardiac function, symptoms, and well-being, and reduces morbidity and mortality in an appropriately selected group of HF patients. CRT also improves quality-adjusted life-years among patients with moderate to severe HF. The beneficial effects of CRT
have been extensively proven in patients with NYHA class II, III, and
IV.37,39,40,254266 In contrast, there is rather limited evidence of CRT
benefit in patients with NYHA functional class I and ischaemic cardiomyopathy.40,265
In the
Multicenter
Automatic
Defibrillator
Implantation with Cardiac Resynchronization Therapy (MADITCRT) study,265 a total of 265 (7.8%) of 1820 patients were class I and had an ischaemic cardiomyopathy. At 7-year follow-up, the subgroup of patients with LBBB, NYHA functional class I, and ischaemic cardiomyopathy showed a non-significant trend towards lower risk of death from any cause [relative risk 0.66, 95% confidence interval (CI)
0.301.42; P = 0.29]. Therefore, present CRT recommendations are applicable to all patients in NYHA functional class IIIV of any aetiology.
The MUltisite STimulation In Cardiomyopathies (MUSTIC),256,257
Multicenter Insync RAndomized Clinical Evaluation (MIRACLE),
PAcing THerapies in Congestive Heart Failure (PATH-CHF) I and
II,58,254,255,259
COmparison of
Medical therapy,
PAcing aNd defibrillatION (COMPANION),260 and CArdiac REsynchronization in
Heart Failure (CARE-HF)39,261 trials compared the effect of CRT vs.
guideline-directed medical therapy in NYHA functional class III or IV; in contrast, most recent trials have compared CRT-D with ICD on top of best medical therapy in NYHA functional class II.37,40,262266 Few studies have compared CRT-pacemaker (CRT-P) with conventional pacing.190,267,268 Most studies of CRT have specified that LVEF should be
<_35%,
but
MADIT-CRT40
and the
Resynchronization
Defibrillation for Ambulatory Heart Failure Trial (RAFT)37 considered an LVEF <_30%, and the REsynchronization reVErses Remodelling in
Systolic left vEntricular dysfunction (REVERSE) trial262 specified <_40%.
Relatively few patients with an LVEF of 3540% have been randomized, but an individual participant data meta-analysis suggests no diminution of the effect of CRT in this group.33
Not all patients respond favourably to CRT. Several characteristics predict reduction in ventricular volume (reverse remodelling) and improvement in morbidity and mortality. QRS width predicts CRT
response and was the inclusion criterion in all randomized trials (for
ECG criteria for LBBB and RBBB, see Supplementary Table 1). QRS
morphology has been related to a beneficial response to CRT.
Several studies have shown that patients with LBBB morphology are more likely to respond favourably, whereas there is less certainty about patients with non-LBBB morphology. Sipahi et al.269,270 performed a meta-analysis in which they examined 33 clinical trials investigating the effect of QRS morphology on CRT, but only four
(COMPANION, CARE-HF, MADIT-CRT, and RAFT) included outcomes according to QRS morphology. When they evaluated the effect of CRT on composite adverse clinical events in 3349 patients with LBBB at baseline, they observed a 36% reduction in risk with the use of CRT (relative risk 0.64, 95% CI 0.520.77; P < 0.00001).
However, such benefit was not observed in patients with non-LBBB
conduction abnormalities (relative risk 0.97, 95% CI 0.821.15; P <
0.75). When the analysis was limited to trials without ICD (CARE-HF
and COMPANION), the benefit of CRT was still observed only in patients with LBBB (P < 0.000001). In a meta-analysis excluding
COMPANION and MADIT-CRT, LBBB was not found to be a predictor of mortality, in contrast to QRS duration.266 In a recent large meta-analysis of five RCTs (COMPANION, CARE-HF, MADIT-CRT,
RAFT, and REVERSE) including 6523 participants (1766 with nonLBBB QRS morphology), CRT was not associated with a reduction in death and/or HF hospitalization in patients with non-LBBB QRS morphology (HR 0.99, 95% CI 0.82- 1.2).271 As patients have been aggregated in the non-LBBB category in nearly all studies and post-hoc analyses on the beneficial effect of QRS morphology in CRT, it is not possible to provide a separate recommendation for CRT in patients presenting with diffuse intraventricular conduction disturbance and
ESC Guidelines
33


<!-- PAGE 34 -->

### Page 34

.............................................................
RBBB.272277 Patients with RBBB do not benefit from CRT278 unless they show a so-called masked LBBB on ECG,277 characterized by a broad, slurred, sometimes notched R wave on leads I and aVL,
together with a leftward axis deviation. Individualized positioning of the LV lead is crucial in these patients.
An important recent notion is the possible role played by a prolonged PR in HF patients with non-LBBB. A few single-centre studies and two post-hoc analyses of large RCTs (COMPANION and
MADIT-CRT) indicated a potential benefit of implanting CRT in this patient subgroup.244,279,280 In MADIT-CRT, the subgroup of nonLBBB patients who had a prolonged PR did benefit from CRT-D, with a 73% reduction in the risk of HF or death and an 81% reduction in the risk of all-cause mortality compared with ICD-only therapy.279 In non LBBB patients with normal PR, CRT-D was associated with a trend towards an increased risk of HF or death and a >2-fold higher mortality compared with ICD therapy, suggesting a bidirectional significant interaction. However, the data are too limited to give a recommendation.279
The results of the MADIT-CRT, REVERSE, and RAFT trials suggest that in patients with LBBB, there is likely to be potential benefit in all patients with LBBB regardless of QRS duration, and that no cut-off point can be identified clearly to exclude patients who will not respond according to the QRS duration.272,273,275 In contrast, any benefit of CRT in patients with non-LBBB is evident mostly in those with a QRS duration >_150 ms. Importantly, as shown in the MADITCRT long-term study and RAFT, the benefit in patients with QRS
<150 ms appeared later during follow-up.265,273
The
Echocardiography
Guided
Cardiac
Resynchronization
Therapy (Echo-CRT) trial suggested possible harm from CRT when baseline echocardiographic mechanical dyssynchrony in patients with
QRS duration <130 ms is used.264,281 Therefore, selection of CRT
patients based solely on the use of cardiac imaging data is strongly discouraged in patients with so-called ‘narrow’ QRS (i.e. <130 ms).
Individual patient data pooled from three CRT-D vs. ICD trials enrolling predominantly patients with NYHA class II HF showed that women are more likely to respond than men.282 In the US Food and
Drug Administration meta-analysis of patient-level data, Zusterzeel et al.283 found that the main difference occurred in patients with LBBB
and a QRS of 130149 ms. In this group, women had a 76% reduction in HF or death [absolute CRT-D to ICD difference, 23% (HR
0.24, 95% CI 0.110.53; P < 0.001)] and a 76% reduction in death alone [absolute difference 9% (HR 0.24, 95% CI 0.060.89; P =
0.03)], whereas there was no significant benefit in men for HF or death [absolute difference 4% (HR 0.85, 95% CI 0.601.21; P =
0.38)] or death alone [absolute difference 2% (HR 0.86, 95% CI
0.491.52; P = 0.60)]. A possible explanation for the greater benefit of CRT in women has been attributed to sex difference in LV size, as sex-specific differences in response disappear when QRS duration is normalized to LV end-diastolic volume.284 Recently, computer modelling confirmed that sex differences in the LV size account for a significant proportion of the sex difference in QRS duration, and provided a possible mechanistic explanation for the sex difference in
CRT response.285,286 Simulations accounting for the smaller LV size in female CRT patients predict 9 - 13 ms lower QRS duration thresholds for females. As with other ECG parameters (e.g. duration of QT
and corrected QT), it is conceivable that QRS duration also has to reflect sex difference.
ECG criteria of intraventricular conduction disturbance, LBBB, and non-LBBB have not been consistently defined and reported in any of the past CRT studies.287,288 Similarly, the modality of QRS measurement (automatic or manual, and ECG recording machine) was not reported in CRT studies. However, the selection of ECG criteria appears to influence hard endpoints.287290 Similarly, ECG recording modality and ECG manufacturer have been shown to possibly affect the automatically measured QRS duration.
Finally, CRT is considered in patients on optimal medical treatment
(OMT), including beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers, and mineralocorticoid receptor antagonists. However, a study raises the question of the timing of CRT, because the efficacy of the medical treatment can be limited in patients with LBBB, suggesting considering CRT sooner.291
Moreover, whereas everyday clinical practice supports the use of sacubitril/valsartan, ivabradine, and sodiumglucose co-transporter2 inhibitors, it must be emphasized that in the landmark trials documenting the efficacy of these drugs, very few patients had an indication for CRT. Thus, there are no strong data to support the mandatory use of these drugs before considering CRT.292295
Recommendations for cardiac resynchronization therapy in patients in sinus rhythm
Recommendations
Classa
Levelb
LBBB QRS morphology
CRT is recommended for symptomatic patients with HF in SR with LVEF <_35%, QRS duration
>_150 ms, and LBBB QRS morphology despite
OMT, in order to improve symptoms and reduce morbidity and mortality.37,39,40,254266,283,284
I
A
CRT should be considered for symptomatic patients with HF in SR with LVEF <_35%, QRS
duration 130149 ms, and LBBB QRS morphology despite OMT, in order to improve symptoms and reduce morbidity and mortality.37,39,40,254266,283,284
IIa
B
Non-LBBB QRS morphology
CRT should be considered for symptomatic patients with HF in SR with LVEF <_35%, QRS
duration >_150 ms, and non-LBBB QRS morphology despite OMT, in order to improve symptoms and reduce morbidity.37,39,40,254266,283,284
IIa
B
CRT may be considered for symptomatic patients with HF in SR with LVEF <_35%, QRS
duration 130149 ms, and non-LBBB QRS morphology despite OMT, in order to improve symptoms and reduce morbidity.273278,281
IIb
B
QRS duration
CRT is not indicated in patients with HF and
QRS duration <130 ms without an indication for
RV pacing.264,282
III
A
CRT = cardiac resynchronization therapy; HF = heart failure; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; OMT = optimal medical therapy; SR = sinus rhythm.
aClass of recommendation.
bLevel of evidence.
ESC 2021
................................................................................................................


<!-- PAGE 35 -->

### Page 35

.............................................................................................................................................................................
6.3 Patients in atrial fibrillation
This section considers indications for CRT in patients with permanent AF or persistent AF unsuitable for AF ablation or after unsuccessful AF ablation. AF ablation has been reported to improve LVEF
and reduce the HF hospitalization rate in selected patients. In particular, AF ablation is recommended for reversing LV dysfunction in AF
patients when tachycardia-induced cardiomyopathy is highly probable, regardless of symptoms.296 Therefore, CRT should be considered in those patients with persistent AF and HFrEF when AF
ablation cannot be performed or is declined by the patient. With regard to indications for rate control therapy and in particular to AVJ
ablation, refer to the ESC Guidelines for the management of AF.296
6.3.1
Patients with atrial fibrillation and heart failure who are candidates for cardiac resynchronization therapy
A major determinant of the success of CRT is the effective delivery of biventricular pacing. A particular aspect of AF patients is that AF
rhythm with fast ventricular rate and irregularity may interfere with adequate biventricular pacing delivery. AF may reduce the rate of effective biventricular capture by creating spontaneous, fusion, or pseudo-fusion beats. A high rate of biventricular pacing is not reached in two-thirds of patients with persistent or permanent AF.297
Data from large registries show that AF patients undergoing CRT
have an increased risk of mortality even after adjusting for several clinical variables.297299 In most AF patients with intact AV conduction, an adequate biventricular pacing delivery can be achieved only by means of AVJ ablation.300302 A substudy of the RAFT trial300 was unable to show benefit of CRT without AVJ ablation with regard to the combined endpoint of death or hospitalization for HF; notably,
only 47% of the patients had a biventricular capture >90%. The decision to perform AVJ ablation is still a matter of debate, but most studies have shown improvements in LV function, functional capacity,
exercise capacity, and survival (with the same magnitude as in patients with SR).301 Gasparini et al.302 compared total mortality of
443 AF patients who received AVJ ablation (n = 443) and of 895 AF
patients who received rate-slowing drugs with the mortality of 6046
patients who were in SR. The long-term survival after CRT among patients with AF and AVJ ablation was similar to that observed among patients in SR (HR 0.93); the mortality was higher for AF patients treated with rate-slowing drugs (HR 1.52). The most common ratecontrolling drugs used in AF are beta-blockers; although safe even in the context of AF and HFrEF, they do not necessarily have the same benefit as in patients with SR303 and the benefitrisk ratio is influenced by other cardiovascular comorbidities.304,305 In a systematic review and meta-analysis,306 AVJ ablation, compared with no AVJ
ablation, reduced mortality by 37% and reduced the rate of nonresponse by 59% in patients with biventricular pacing <90%, but showed no benefit in those with >_90% biventricular pacing. Similarly,
Tolosana et al. observed the same rate of responders (defined as
>_10% decrease in end-systolic volume) in AF patients who received
AVJ ablation or rate-slowing drugs and patients in SR who had adequate biventricular pacing (97, 94, and 97%, respectively).307
Importantly, AVJ ablation did not improve survival for patients in AF
treated with CRT compared with those treated with rate-slowing drugs when an adequate biventricular pacing was achieved either with ablation (97%) or with drugs (94%).308
In conclusion, despite the weak evidence due to lack of large,
randomized trials, the prevailing opinion of experts is in favour of the usefulness of CRT in patients with permanent AF and NYHA class III
and IV with the same indications as for patients in SR, provided that
AVJ ablation is added in those patients with incomplete (<90 - 95%)
biventricular capture due to AF (Figure 9). However, there are other causes for incomplete biventricular pacing such as frequent premature ventricular beats, which may need to be treated (with drugs or ablation) before considering AVJ ablation. Importantly, evaluation of the biventricular pacing percentage is mainly given by the percentage of biventricular pacing using device memory, which does not reflect exactly the rate of effective biventricular capture. Holter monitoring may help to assess the real biventricular capture percentage.309,310 A
new algorithm has been developed that can continuously assess the effective biventricular pacing.311
For patients with permanent AF, there are no data supporting the difference in the magnitude of response to CRT according to the
QRS morphology or a QRS duration cut-off of 150 ms.
It is important to remember that limited data are available for patients in NYHA class II.
6.3.2
Patients with uncontrolled heart rate who are candidates for atrioventricular junction ablation
(irrespective of QRS duration)
AVJ ablation should be considered to control heart rate in patients unresponsive or intolerant to intensive rate and rhythm control therapy, or who are ineligible for AF ablation, accepting that these patients will become pacemaker dependent.296 In particular, AVJ
ablation combined with CRT may be preferred to AF ablation in severely symptomatic patients with permanent AF and at least one hospitalization for HF.296
AVJ ablation and permanent pacing from the RV apex provides highly efficient rate control and regularization of the ventricular response in AF, and improves symptoms in selected patients.192 A
large study with a propensity score-matched control group194
showed a 53% reduction in total mortality in patients who underwent
AVJ ablation compared with those treated with pharmacological rate control therapy. A class IIa indication is provided in the 2020 ESC
Guidelines on AF.296
The downside of RV pacing, however, is that it induces LV dyssynchrony in 50% of patients,312 and that this may lead to worsening of
HF symptoms in a minority. In the majority of patients, AVJ ablation improves LVEF even with RV apical (RVA) pacing due to amelioration of tachycardia-induced LV dysfunction, which commonly exists in these patients. CRT may prevent RV pacing-induced LV dyssynchrony. The multicentre, randomized, prospective Ablate and Pace in
Atrial Fibrillation (APAF) trial313 included 186 patients in whom a
CRT or RV pacing device was implanted, followed by AVJ ablation.
During a median follow-up of 20 months, CRT significantly reduced by 63% the primary composite endpoint of death due to HF, hospitalization due to HF, or worsening of HF. The beneficial effects of CRT
were similar in patients with an EF <_35%, NYHA class >_III, and QRS
width >_120 ms, and in other patients with EF>35% or NYHA class
< III or narrow QRS. Compared with the RV pacing group, responders increased from 63% to 83% (P ¼ 0.003).314 A meta-analysis of
696
patients from five trials showed a
62%
reduction in
ESC Guidelines
35


<!-- PAGE 36 -->

### Page 36

.............................................
hospitalization for HF and a modest improvement in LVEF compared with RV pacing, but not in 6-min walked distance and quality of life assessed by means of the Minnesota Living with Heart Failure questionnaire.315 In the APAF-CRT RCT, 102 elderly patients (mean age
72 years) with permanent AF, a narrow QRS (<_110 ms), and at least one hospitalization for HF in the previous year were randomized to
AVJ ablation and CRT or to pharmacological rate control therapy.195
After a median follow-up of 16 months, the primary composite outcome of HF death, hospitalization due to HF, or worsening HF had occurred in 10 patients (20%) in the ablation (AVJ) plus CRT arm and in 20 patients (38%) in the drug control arm (HR 0.38; P = 0.013). The results were mostly driven by a reduction in hospitalization for HF.
The HR was 0.18 (P = 0.01) in patients with LVEF <_35% and 0.62 (P =
0.36) in those with LVEF >35%. Furthermore, patients undergoing AVJ
ablation and CRT had a 36% reduction in the specific symptoms and physical limitations of AF at 1-year follow-up (P = 0.004). In contrast to the main composite endpoint, the greatest symptomatic improvements were observed in patients with LVEF >35% (P = 0.0003).
In conclusion, there is evidence from randomized trials of an additional benefit of performing CRT pacing in patients with reduced EF,
who are candidates for AVJ ablation for rate control to reduce hospitalization and improve quality of life. There is evidence that CRT is superior to RV pacing in relieving symptoms, but not mortality and hospitalization in patients with mid-range reduced systolic function
(Figure 9).
6.3.3
Emerging novel modalities for CRT: role of conduction system pacing
HBP, alone or in conjunction with coronary sinus pacing, is a promising novel technique for delivering CRT, useful in AF patients
OR
Controlled heart rate
Candidate for CRT
Candidate for AVJ ablation
Management of atrio-ventricular junction ablation in patients with:
Y
N
Persistent AF unsuitable for atrial fibrillation ablation 
Permanent AF 
OR
CRT
if QRS ≥ 130 ms
(Class IIa)
BiV
> 90 – 95%a
BiV
< 90 – 95%a
No AVJ
ablation
AVJ ablation
(Class IIa)
CRT
(Class I)
CRT
(Class IIa)
CRT
(Class IIb)
LVEF
< 40%
(HFrEF)
40% ≤LVEF 
LVEF < 50%
(HFmrEF)
LVEF < 50%
HBP
(Class IIb)
AVJ ablation
Y
N
RV pacing
(Class IIa)
HBP
(Class IIb)
Figure 9 Indication for atrioventricular junction ablation in patients with symptomatic permanent atrial fibrillation or persistent atrial fibrillation unsuitable for atrial fibrillation ablation. AF = atrial fibrillation; AVJ = atrioventricular junction; BiV = biventricular; CRT = cardiac resynchronization therapy; ESC
= European Society of Cardiology; HBP = His bundle pacing; HFmrEF = heart failure with mildly reduced ejection fraction; HFrEF = heart failure with reduced ejection fraction; LVEF = left ventricular ejection fraction; QRS = Q, R, and S waves; RV = right ventricular/right ventricle. aDue to a rapid ventricular response. Note: the figure is based on the recommendations in the ESC Guidelines on AF.296


<!-- PAGE 37 -->

### Page 37

......................................................................................................................
undergoing AVJ ablation.198,199,316318 Non-conventional CRT using
HBP coronary sinus pacing (so-called ‘His-optimized CRT’) or left bundle branch area pacing, in comparison with conventional CRT,
can achieve a narrower QRS with a ‘quasi-normal’ axis morphology,
echocardiographic improvement of mechanical resynchronization indexes, and a better short-term clinical outcome.319321 In general,
the potential benefit of HBP depends on the ability to achieve a narrow QRS complex that is similar to the native QRS complex,
rather than on the LVEF. Widespread adoption of this technique relies upon further validation of its efficacy in large RCTs and improvements in lead design, delivery tools, and devices (see section 7).
6.4 Patients with conventional pacemaker or implantable cardioverter defibrillator who need upgrade to cardiac resynchronization therapy
Several studies have demonstrated the deleterious effect of chronic
RV pacing with respect to an increased risk of HF symptoms or hospitalizations, which may be reduced by programming to maximize intrinsic conduction or prevented by CRT.148,183,190,324 Previously,
the benefit of CRT upgrade had been investigated only by observational controlled trials and registries,325339 mainly comparing upgrade with de novo CRT; in early, small, observational pre- vs. post-CRT
studies;340346 and in crossover trials,347350 providing only limited clinical outcome data.
Based on a recent meta-analysis of observational studies, mostly single-centre,351 echocardiographic and functional response as well as the risk of mortality or HF events was similar in patients after de novo vs. upgrade CRT; however, in previous subgroup analyses from large, randomized, prospective trials such as RAFT,37 morbidity or mortality benefit was not confirmed.
Clinical outcomes are also influenced by the clinical characteristics of patients referred to CRT upgrade. Based on data from the
European CRT Survey II,352 a high-volume registry, and clinical characteristics from previous studies,351 patients referred for a CRT
upgrade differ from patients referred for de novo CRT implantation:
they are older (even compared with those in RCTs), mainly male patients, and have more comorbidities such as AF, ischaemic heart disease, anaemia, and renal failure.
On average, the number of upgrade procedures reaches 23% of total CRT implantations, 60% from a conventional device and 40%
from an ICD352 in ESC countries, showing significant regional differences regarding the type of implanted device, such as CRT-P or
CRT-D.352,353
Regarding procedure-related complications,
several studies described a higher burden during upgrade procedures, ranging from
6.8% to 20.9% compared with de novo implantations.339,354 This was not confirmed in a recent analysis of registry data, where upgrades had similar complication rates to de novo implantations.352 Notably,
82% of these procedures were performed in high-volume centres.
However, data on the long-term infection rates or lead revisions after
CRT upgrade are scarce.354,355
The first prospective, randomized trial, the BUDAPEST CRT
Upgrade study, is still ongoing, but may clarify these questions.356
Recommendations for cardiac resynchronization therapy in patients with persistent or permanent atrial
ﬁbrillation
Recommendations
Classa
Levelb
1) In patients with HF with permanent AF who are candidates for CRT:
1A) CRT should be considered for patients with
HF and LVEF <_35% in NYHA class III or IV
despite OMT if they are in AF and have intrinsic
QRS >_130 ms, provided a strategy to ensure biventricular capture is in place, in order to improve symptoms and reduce morbidity and mortality.302,306,307,322
IIa
C
1B) AVJ ablation should be added in the case of incomplete biventricular pacing (<9095%) due to conducted AF.297302
IIa
B
2) In patients with symptomatic AF and an uncontrolled heart rate who are candidates for AVJ ablation (irrespective of QRS
duration):
2A) CRT is recommended in patients with
HFrEF.196,197,306,308
I
B
2B) CRT rather than standard RV pacing should be considered in patients with HFmrEF.
IIa
C
2C) RV pacing should be considered in patients with HFpEF.188,196,323
IIa
B
2D) CRT may be considered in patients with
HFpEF.
IIb
C
AF = atrial ﬁbrillation; AVJ = atrioventricular junction; CRT = cardiac resynchronization therapy; EF = ejection fraction; HF = heart failure; HFrEF = heart failure with reduced ejection fraction (<40%); HFmrEF = heart failure with mildly reduced ejection fraction (40- 49%); HFpEF = heart failure with preserved ejection fraction (>_50%)
according to the 2021 ESC HF Guidelines;242 LVEF = left ventricular ejection fraction;
NYHA = New York Heart Association; RV = right ventricular.
aClass of recommendation.
bLevel of evidence.
Recommendation for upgrade from right ventricular pacing to cardiac resynchronization therapy
Recommendation
Classa
Levelb
Patients who have received a conventional pacemaker or an ICD and who subsequently develop symptomatic HF with LVEF <_35% despite OMT,
and who have a signiﬁcantc proportion of RV
pacing, should be considered for upgrade to
CRT.37,148,185,190,324352
IIa
B
CRT = cardiac resynchronization therapy; HF = heart failure; ICD = implantable cardioverter-deﬁbrillator; LVEF = left ventricular ejection fraction; OMT = optimal medical therapy; RV = right ventricular.
aClass of recommendation.
bLevel of evidence.
cA limit of 20% RV pacing for considering interventions for pacing-induced HF is supported by observational data. However, there are no data to support that any percentage of RV pacing can be considered as deﬁning a true limit below which
RV pacing is safe and beyond which RV pacing is harmful.
ESC 2021
ESC 2021
.......................................................
ESC Guidelines
37


<!-- PAGE 38 -->

### Page 38

.............................................................................................................................................................................
6.5 Pacing in patients with reduced left ventricular ejection fraction and a conventional indication for antibradycardia pacing
Three randomized trials proved the superiority of biventricular pacing over RV pacing in patients with moderate to severe systolic dysfunction who required antibradycardia pacing to improve quality of life, NYHA class, and echocardiographic response.190,357,358 In the
Biventricular versus RV pacing in patients with AV block (BLOCK
HF) trial, 691 patients with AVN disease and an indication for pacemaker with a mildly reduced EF (<50% by inclusion criteria, average
42.9% in the pacemaker group) were randomized to biventricular or
RV pacing with or without an ICD, and followed for an average of 37
months.190 The primary endpoint (a composite of >_15% increase in the LV end-systolic volume, HF events, or mortality) was significantly improved in those assigned to CRT. CRT response is high among patients with systolic dysfunction and expected frequent RV pacing.
Based on the MOde Selection Trial in Sinus-Node Dysfunction
(MOST),183 at least 40% RV pacing is associated with an increased risk of HF hospitalization or AF.
For patients with normal or preserved EF, data on benefit of CRT
are conflicting with respect to hospitalization, and no mortality benefit was shown.166,268,323,359 However, adverse remodelling caused by
RV pacing was prevented by biventricular pacing, especially during long-term follow up.323,359,360 A single-centre study showed that
>20% RV pacing was associated with deleterious LV remodelling in patients with AVB and preserved LVEF.188 Frailty should also be taken into account in deciding on CRT implantation, because of the higher costs and high complication rates of this procedure.
6.6 Benefit of adding implantable cardioverter defibrillator in patients with indications for cardiac resynchronization therapy
The mortality benefit of CRT-D over CRT-P is still unclear, mostly because no head to head RCTs have been designed to compare these two treatments. While CRT-D may further improve survival over CRT-P by reducing arrhythmic death, it does also add ICDspecific risks such as lead failure and inappropriate shocks, as well as costs.
COMPANION is the only trial to randomize patients to CRT-P or
CRT-D, but was designed to assess the effects of CRT compared with OMT.260 Crucially, it was not designed to compare CRT-D and
CRT-P. CRT-P was associated with a marginally non-significant reduction in the risk of all-cause mortality (HR 0.76, 95% CI
0.58 - 1.01; P = 0.06), whereas CRT-D was associated with a significant, 36% risk reduction (HR 0.64, 95% CI 0.480.86; P = 0.004).
Analysis of cause-specific mortality showed that SCD was significantly reduced by CRT-D (HR 0.44, 95% CI 0.23 - 0.86; P = 0.02) but not
CRT-P (HR 1.21, 95% CI 0.72.07; P = 0.50).363
Nevertheless, the CARE-HF extension study proved that CRT-P
alone reduced the risk of dying suddenly by 5.6%.261 In line with these findings, subgroup analyses from RCTs in mild HF consistently found a reduction in ventricular arrhythmias with CRT.364368 These effects were especially observed among CRT responders, suggesting that the reduction in SCD risk is related to the extent of reverse LV
remodelling with CRT.
Meta-analyses have drawn different conclusions on the matter. In the study by Al-Majed et al.,369 the survival benefit of CRT was largely driven by a reduction in HF-related mortality, but SCD was not reduced. Lam et al.370 showed that CRT-D significantly reduced mortality compared with medical therapy alone [odds ratio (OR) 0.57,
95% CI 0.400.80], but not when compared with ICD without CRT
(OR 0.82, 95% CI 0.571.18) or CRT-P (OR 0.85, 95% CI
0.601.22). However, more recently, a network meta-analysis of 13
randomized trials including >12 000 patients found that CRT-D
reduced total mortality by 19% (95% CI 133%, unadjusted) compared with CRT-P.275
Some recent large observational studies highlighted the importance of HF aetiology in the assessment of potential benefits of CRTD over CRT-P.371373 CRT-D was associated with a significant risk reduction in all-cause mortality compared with CRT-P in patients with ischaemic cardiomyopathy. However, this difference was not found in patients with non-ischaemic cardiomyopathy.
These findings are consistent with the results from the DANISH
study, which assigned 1116 patients with HF and non-ischaemic cardiomyopathy to receive either a primary prophylactic ICD or usual clinical care alone.374 In both groups, 58% of patients also had CRT.
Subgroup analysis showed that CRT-D was not superior to CRT-P in reducing the primary outcome of all-cause mortality (HR 0.91, 95%
CI 0.641.29; P = 0.59) after a median follow-up of 67.6 months.
However, in a large multicentre registry of >50 000 patients, CRT-D
was associated with a significantly lower observed mortality.375
Similar results were found in a recent propensity-matched cohort,
where CRT-D was associated with a significantly lower all-cause mortality than CRT-P in patients with ischaemic aetiology and in patients with non-ischaemic HF under 75 years old.376 Furthermore,
the CeRtiTuDe Cohort study377 showed better survival in CRT-D
vs. CRT-P mainly due to a reduction of non-SCD. In an Italian multicentre CRT registry, the only independent predictor of mortality was the lack of an ICD.378 Whereas these studies are limited by their observational design, important novel information on the issue of
CRT-D vs. CRT-P is expected to come from an ongoing randomized trial, Re-evaluation of Optimal Re-synchronisation Therapy in
Recommendation for patients with heart failure and atrioventricular block
Recommendation
Classa
Levelb
CRT rather than RV pacing is recommended for patients with HFrEF (<40%) regardless of NYHA
class who have an indication for ventricular pacing and high-degree AVB in order to reduce morbidity. This includes patients with
AF.183,190,196,268,313,323,357359,361,362
I
A
AF = atrial ﬁbrillation; AVB = atrioventricular block; CRT = cardiac resynchronization therapy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction (<40%) according to the 2021 ESC HF Guidelines;242 NYHA = New
York Heart Association; RV = right ventricular.
aClass of recommendation.
bLevel of evidence.
ESC 2021


<!-- PAGE 39 -->

### Page 39

..........................................................................................................................................................................
Patients with Chronic Heart Failure (RESET-CRT; ClinicalTrials.gov
Identifier NCT03494933).
In conclusion, prospective randomized trials are lacking, and available data are insufficient to firmly prove a superiority of CRT-D over
CRT-P. However, it is important to consider that CRT trials in mild
HF almost exclusively included patients with an ICD,37,40,262 and that survival benefit of CRT without an ICD is uncertain in this particular group. Furthermore, observational data point towards significant survival benefits by CRT-D over CRT-P in patients with ischaemic cardiomyopathy, while no clear benefit has been shown in those with non-ischaemic cardiomyopathy.
Further predictive power concerning the risk of ventricular arrhythmia may be derived by contrast-enhanced CMR-guided scar characterization.379,380 When discussing the choice between CRT-D
and CRT-P, it is particularly important to consider general predictors of ICD effectiveness such as age and comorbidities associated with a mortality risk that competes with sudden arrhythmic death. Thus, the addition of ICD to CRT should be considered, especially in younger patients with a good survival prognosis, ischaemic aetiology, and a favourable comorbidity profile or presence of myocardial fibrosis
(Figure 10). Moreover, the benefit of the ICD is governed by the balance between the risk of SCD and the risk of death from other causes, as well as comorbidities. Generally, the rate of sudden arrhythmic death in primary prevention appears to be declining (1%/
year).
Owing to the complexity of the matter and the lack of clear evidence, it is particularly important that the choice between CRT-P
and CRT-D is guided by a process of shared decision-making between patients and clinicians, taking into account both medical facts and patient values.
6.7 Factors influencing the efficacy of cardiac resynchronization therapy: role of imaging techniques
The role of cardiac imaging in selecting HF patients for CRT has been evaluated mostly in observational analyses. Cardiac dyssynchrony,384386 myocardial scar,387,388 and site of latest activation of the LV in relation to the LV lead position389,390 have been associated with response to CRT. LVEF is the only parameter included in the guidelines for the selection of patients for CRT and is key to define the type of HF (<40%, HFrEF; 4049%, HFmrEF; and >_50%,
HFpEF).242 Echocardiography is the imaging technique of first choice for the assessment of LVEF. However, when intravenous contrast is not available and the acoustic window does not allow accurate assessment of LVEF, CMR or nuclear imaging should be considered.242 Strain imaging (based on echocardiography or CMR) to quantify LV systolic function has shown incremental prognostic value in
HF,
and allows assessment of
LV
mechanical dyssynchrony.384,391393 CMR with LGE techniques (which show the presence of myocardial scar tissue) provide the best resolution to differentiate ischaemic cardiomyopathy and non-ischaemic cardiomyopathy.394 The location (posterolateral) and extent (transmural vs.
non-transmural and percentage of LV mass) of LGE on CMR or with nuclear techniques has been associated with the benefit from
CRT.380,387,395,396 Severe mitral regurgitation,397 lack of significant electromechanical LV dyssynchrony,384,385,392 and RV systolic dysfunction398 have been associated with less improvement in clinical symptoms and reduced survival after CRT. Several imaging techniques have been tested to assess LV mechanical dyssynchrony, but most measures of LV dyssynchrony have not been tested in randomized trials including patients with HFrEF and wide QRS.399 The presence of septal flash and apical rocking,400 time differences based on radial strain and patterns of regional longitudinal strain,384,392,401403
non-invasive and invasive ECG mapping,385,404 and vector-cardiography405 have been proposed as novel techniques to predict response to CRT. Furthermore, LV myocardial work assessed with speckletracking echocardiography has been associated with survival in CRT
recipients.406 Coronary sinus venography is commonly performed to detect a suitable coronary vein in which to deploy an LV lead.
Randomized trials have not systematically demonstrated that the guidance of LV lead implantation based on imaging (assessing myocardial scar or site of latest activation) is superior to standard practice.389,390,407,408 Initial experience on using artificial intelligence to combine clinical, electrical, and imaging parameters to define phenotypes of patients that will benefit from CRT is promising, but more data are needed.409
Significant (moderate to severe and severe) secondary mitral regurgitation is frequent among candidates for CRT and has been shown to affect long-term survival as well as response to therapy.406,410 CRT can improve mitral regurgitation in as many as 40% of patients.406 However, in 60% of patients, significant mitral regurgitation is not corrected and, at long-term follow-up, progression of the underlying disease may lead to further deterioration of mitral valve function and poor prognosis. Transcatheter edge-to-edge mitral valve repair has been demonstrated to improve the response to CRT
in registries.411414 However, results from recent RCTs including patients with symptomatic severe secondary mitral regurgitation despite guideline-directed medical therapy (including CRT when indicated) have not consistently shown a benefit from transcatheter edge-to-edge mitral valve repair.415,416
Therefore, selection of patients for CRT based on imaging is limited to the measurement of LVEF, whereas the assessment of other factors such as extent of myocardial scar, presence of mitral
Recommendations for adding a deﬁbrillator with cardiac resynchronization therapy
Recommendations
Classa
Levelb
In patients who are candidates for an ICD and who have CRT indication, implantation of a
CRT-D is recommended.260,369,370,381
I
A
In patients who are candidates for CRT, implantation of a CRT-D should be considered after individual risk assessment and using shared decision-making.382,383
IIa
B
CRT = cardiac resynchronization therapy; CRT-D = deﬁbrillator with cardiac resynchronization therapy; ICD = implantable cardioverter-deﬁbrillator.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC Guidelines
39


<!-- PAGE 40 -->

### Page 40

......................................................................................
regurgitation, or RV systolic function is important in identifying potential non-responders that may need additional treatment (mitral valve intervention, for example).
Alternatives to conventional coronary sinus pacing for CRT (epicardial, endocardial) are described in section 6.1 in the Supplementary data.
7 Alternative pacing strategies and sites
Alternative RV pacing sites (as opposed to RVA pacing) include pacing from the RV outflow tract (RVOT), the mid and high RV septum
(RVS), HBP, para-Hisian pacing, and left bundle branch area pacing,
which includes LV septal pacing and left bundle branch pacing.
7.1 Septal pacing
Since the 2013 ESC Guidelines,33 two randomized trials found no difference in clinical outcomes between RVS and RVA pacing in the setting of AVB417 or CRT,418 respectively. A meta-analysis reported an echocardiographic benefit of RVS pacing in patients with pre-existing reduced LVEF.419 In an observational study, RVS pacing was associated with a lower risk of perforation.420 However, true RVS pacing is not easily obtained and ascertained,421 and neither beneficial nor harmful effects of RVS pacing compared with RVA pacing have been shown on relevant clinical endpoints (Supplementary Table 9).
Current evidence does not support systematically recommending either RVS or RVA pacing for all patients.
7.2 His bundle pacing
HBP was first reported in humans in 2000,199 and is steadily gaining interest for providing a more physiological alternative to RV pacing. It may also correct intraventricular conduction delay in a subset of patients, thereby providing an alternative to biventricular pacing for treating HF. The advent of new tools has greatly facilitated implantation, which has become routine in a growing number of centres. HBP
is used in lieu of RV pacing, in lieu of biventricular pacing, and as Hisoptimized CRT (HOT-CRT),319 which exploits a synergistic effect between HBP and RV pacing, LV pacing, or biventricular pacing to improve synchrony. There is growing evidence, mainly from observational studies, that HBP may be safe and effective in these settings
(Supplementary Table 10), although large RCTs and long-term followup are still lacking.422 With more data on safety and effectiveness,
HBP is likely to play a growing role in pacing therapy in the future.
7.2.1
Implantation and follow-up
The use of guiding catheters to deliver leads has facilitated implantation, with success rates exceeding 80%.422 In an international registry,
implant success was 87% after a learning curve of 40 cases.423
Selective HBP is easily recognized by an isoelectric interval (corresponding to the HV) between the pacing spike and QRS onset,
whereas with non-selective HBP, a ‘pseudo-delta’ wave is observed due to capture of local myocardium.424 In addition, correction of BBB
may be observed (Figure 11). It is important to distinguish nonselective HBP from para-Hisian pacing (where there is no capture of conduction tissue) by evaluating transitions in QRS morphology by reducing pacing output or with pacing manoeuvres.425
Patient with indication for CRT
CRT-P
CRT-D
+
-
Myocardial Fibrosis on CMR
Age
-
+
Other factors in favor of choosing 
CRT-P rather than CRT-D:
Non-ischaemic cardiomyopathy
Short life expectancy
Major comorbidities
Poor renal function
Patient preference
Shared decision making
Shared decision making
Age
-
+
Figure 10 Patient’s clinical characteristics and preference to be considered for the decision-making between cardiac resynchronization therapy pacemaker or defibrillator. CRT-P = cardiac resynchronization therapy-pacemaker; CRT-D = defibrillator with cardiac resynchronization therapy; CMR = cardiovascular magnetic resonance.


<!-- PAGE 41 -->

### Page 41

0
1
2
3
4
5
6
7
8
NS-HBP
S-HBP
LOC
NS-HBP
S-HBP corrS-HBP corr+
Myo
LOC
LOC
A
B
C
Thresholds
His
Myocardium
Bundle branch
NS-HBP
S-HBP
V
NS-HBP
Myo
V
S-HBP corr+
S-HBP corrV
A
B
C
Output  (V/0.5ms)
Figure 11 Three patients with different types of transitions in QRS morphology with His bundle pacing and decrementing pacing output. BBB = bundle branch block; Corr± = with/without correction of bundle branch block; LBBB = left bundle branch block; LOC = loss of capture; Myo = myocardium;
NSHBP = non-selective His bundle pacing; S-HBP = selective His bundle pacing. (A) Non-selective to selective His capture. Note the presence of a
‘pseudo-delta’ wave with non-selective capture and an isoelectric interval after the pacing spike with selective capture. (B) Non-selective His capture to myocardial capture only. (C) Selective His capture with correction of BBB to selective His capture with LBBB. Note: the graph on the right of the panel shows a schematic representation of the different thresholds in the three instances.
ESC Guidelines
41


<!-- PAGE 42 -->

### Page 42

.............................................................................................................................................................................
Compared with RV pacing, HBP capture thresholds are on average higher and sensing amplitudes lower. A recent observational study raised concern with regard to increasing HBP pacing thresholds with intermediate follow-up.426 The higher capture thresholds lead to shorter battery longevity (at 5 years there were 9% generator changes with HBP compared with 1% with RVP).427 Capture thresholds of HBP at implantation should aim to be <2.0 V/1 ms (or <2.5 V/
0.4 ms) and bipolar R-wave sensing amplitude >2.0 mV. With experience, thresholds decrease as implanters gain confidence to reposition leads. Sensing issues include not only ventricular undersensing, but also oversensing of atrial or His potentials (which may be potentially lethal in a pacemaker-dependent patient).
An RV backup lead should be considered if the implanter is inexperienced, or if there are high capture thresholds or sensing issues in pacemaker-dependent patients, in those scheduled for AVN ablation
(where there is a risk of compromising HBP), or in patients with highdegree or infranodal block. Pros and cons are listed in Table 9.
Several series have shown that the rate of mid-term lead revision is relatively high at 7%,318,423,427,428 (and reported to be as high as
11%426), and is higher than RV pacing, which is 23%.427,429
Therefore, it is advisable to follow-up these patients at least once every 6 months or place them on remote monitoring (ensuring that automatic threshold measurements correspond to those measured manually, as this may not be the case and depends on device configuration).430 Device programming should take into account specific requirements for HBP, which are covered in detail elsewhere.431,432
7.2.2
Indications
7.2.2.1 Pacing for bradycardia
One study reported that in patients with AVB and normal baseline
LVEF, the incidence of RV pacing-induced cardiomyopathy was
12.3% and the risk was increased if the percentage of ventricular pacing was >_20% (HR 6.76; P = 0.002).188 However, there are no data to support that any percentage of RV pacing can be considered as defining a true limit below which RV pacing is safe and beyond which RV
pacing is harmful. Observational data indicate that patients with HBP
fare better in terms of HF hospitalizations than patients with RV pacing if the percentage of ventricular pacing is >20% (HR 0.54; P =
0.01).42 Of note, the average baseline LVEF in patients with HBP in that study was 55% and the average QRS duration was 105 ms. HBP
may therefore avoid clinical deterioration in these patients, particularly if the intrinsic QRS is narrow or if BBB is corrected by HBP.
In a series of 100 patients with AVB undergoing HBP by experienced operators, implantation was successful in 41/54 (76%) patients with infranodal AVB and higher in the case of nodal block (93%; P <
0.05).433 Over a mean follow-up of 19 ± 12 months, lead revision was necessary in 2/41 (5%) patients with infranodal block and in 3/43
(7%) with nodal block. Notably, the average LVEF in this series was
54%, and there are no data reported specifically on HBP in patients with AVB and reduced LVEF. HBP is an option in patients with a narrow QRS or if HBP corrects BBB, but otherwise biventricular pacing is indicated.
There is a need for RCTs to compare the safety and efficacy of
HBP with RV pacing. It is important to balance the potential benefits of HBP with the aforementioned issues of higher capture thresholds and shorter battery longevity, a higher rate of lead revision, and more frequent sensing issues, compared with RV pacing. It is also important to consider the operator’s experience and expertise with HBP, and whether a backup ventricular pacing lead is indicated. The patient’s safety should be first and foremost in decision-making.
7.2.2.2 Pace and ablate
Seven observational series, totalling >240 patients treated with a
‘pace-and-ablate’ strategy for rapidly conducted AF, found an improvement in LVEF and NYHA class compared with baseline with
HBP.197199,434 Long-term results with a median of 3 years of followup have been reported, with favourable outcomes.434 A singleblinded, randomized, crossover study in 16 patients compared HBP
with RVA pacing over 6 months and found better NYHA and 6-min walk distance with HBP, without differences in echocardiographic parameters.200 However, only four patients in this study had confirmed HBP (with para-Hisian pacing in the remaining patients).
These studies included patients with reduced as well as preserved
LVEF,197,198 and QRS width was on average <120 ms. HBP is of particular interest in patients with a normal baseline QRS morphology as it preserves intrinsic ventricular synchrony, However, a caveat is that
AVJ ablation may result in an increase in HBP capture thresholds or in lead dislodgments in a minority of patients.197,199,318,426 Owing to these issues and risk of HBP lead failure, a backup RV lead should be considered.
7.2.2.3 Role in cardiac resynchronization therapy
In 1977, Narula showed that pacing of the His bundle can correct
LBBB in a subset of patients, implying a proximal site of conduction disturbance with longitudinal dissociation within the His bundle.435 A
recent mapping study reported intra-Hisian block in 46% of patients with LBBB, in whom 94% were corrected by temporary HBP.436 HBP
may therefore be used in lieu of biventricular pacing for HBP-based
CRT, as some data have shown that results are comparable (see
Supplementary Table 10).437439 Nevertheless, especially in CRT candidates with LBBB, biventricular pacing has more solid evidence of efficacy and safety, and therefore remains first-line therapy. However,
HBP should be considered as a bailout solution in the case of failed
Table 9
Advantages and disadvantages of a ‘backup’
ventricular lead with His bundle pacing
Advantages
• Increased safety (in case of loss of capture of the HBP lead)
• Can be used for sensing (lower risk of ventricular undersensing, no risk of His or atrial oversensing)
• Programming of pacing output with lower safety margins
• May serve to narrow the QRS with fusion pacing in the case of selective-HBP with uncorrected RBBB
Disadvantages
• Higher cost
• More transvenous hardware
• Risk associated with the additional lead (e.g. ventricular perforation)
• More complex programming
• “Off-label” use (current regulatory approval and MRI-conditionality for HBP is only granted for His leads connected to the RV port)
HBP = His bundle pacing; MRI = magnetic resonance imaging; RBBB = right bundle branch block.
ESC 2021


<!-- PAGE 43 -->

### Page 43

..........................................................................................................................................
LV lead implantation along with other options such as surgical epicardial leads424,440 (see section 6.7). An interesting population is patients with RBBB, who are known to respond less well to biventricular pacing, in whom HBP has shown promising preliminary results in a series of 37 patients.441 HBP may sometimes incompletely correct BBB, and can be used in conjunction with RV, LV, or biventricular pacing, as in the HOT-CRT study.319 This is of particular interest in patients with permanent AF, in whom a His lead may be connected to the vacant atrial port, thus offering additional therapeutic options.
7.3 Left bundle branch area pacing
With left bundle branch area pacing, the lead is implanted slightly distal to the His bundle and is screwed deep in the LV septum, ideally to capture the left bundle branch.442 Advantages of this technique are that electrical parameters are usually excellent, it may be successful in blocks that are too distal to be treated with HBP, and it also facilitates AVJ ablation, which may be challenging with HBP. However,
although the technique is very promising, data on this modality are still scarce (Supplementary Table 11), and there is concern regarding long-term lead performance and feasibility of lead extraction.
Recommendations for using left bundle branch area pacing cannot therefore be formulated at this stage. However, conduction system pacing (which includes HBP and left bundle branch area pacing) is very likely to play a growing role in the future, and the current recommendations will probably need to be revised once more solid evidence of safety and efficacy (from randomized trials) is published. A
comparison of RV pacing, HBP, and left bundle branch area pacing is provided in Supplementary Table 12.
7.4 Leadless pacing
Leadless pacemakers have been developed to address limitations typically related to pulse generator pocket and transvenous leads of conventional pacemaker systems. Currently, two leadless pacemaker systems have been studied in clinical trials, of which one is currently available for clinical use. Both are inserted into the RV cavity by a femoral venous approach using a specially designed catheter-based delivery system.
A number of prospective registries have reported that implantation success rates are high, with adequate electrical results both at implant and at follow-up (Supplementary Table 13). ‘Real-world’
results of one leadless pacemaker system, including 1817 patients,
reported serious adverse events in 2.7% of patients.50 The prevalence of leadless device infections is low as the principal sources of infection
(i.e. the subdermal surgical pocket and pacemaker leads) are absent.
However, during the initial operator experience, there was a higher incidence of peri-operative major complications (6.5%), including perforation and tamponade, vascular complications, ventricular arrhythmias, and death.445 These data highlight the importance of adequate training and supervision in this domain when starting with leadless pacemaker implantation. In addition, implanting physicians should have the same competency and accreditation as those required for standard transvenous pacing to be able to offer the most suitable system for a given patient. Implantation of leadless pacemakers should be performed in an adequate setting (i.e. with highresolution multiplane fluoroscopy) and with cardiac surgery available on site due to the risk of tamponade, which may be more difficult to manage than with standard pacing.446,447
Leadless pacemakers that only function in the VVI(R) mode restrict indications to patients with AF or very infrequent pacing (e.g.
paroxysmal AVB). Recently, VDD pacing (by detection of atrial contraction by the accelerometer) has been introduced, which extends indications to patients with AVB with preserved sinus node function.
AV synchrony is maintained 7090% of the time, depending on the patient’s position and activity, based on data from two studies including 73 patients in SR and high-degree AV block.448 There may in future be an alternative to standard DDD pacemakers in selected patients if the potential benefits of leadless pacing outweigh the potential benefits of 100% AV synchrony, atrial pacing, and atrial arrhythmia monitoring.
Indications for leadless pacemakers include obstruction of the venous route used for standard pacemaker implantation (e.g. bilateral venous thoracic outlet syndrome or chronic obstruction of the superior vena cava), pocket issues (e.g. in the case of cachexia or dementia), or particularly increased infection risk [e.g. in the case of dialysis
Recommendations for using His bundle pacing
Recommendations
Classa
Levelb
In patients treated with HBP, device programming tailored to speciﬁc requirements of HBP is recommended.430,431
I
C
In CRT candidates in whom coronary sinus lead implantation is unsuccessful, HBP should be considered as a treatment option along with other techniques such as surgical epicardial lead.318,424,440,443
IIa
B
In patients treated with HBP, implantation of an
RV lead used as ‘backup’ for pacing should be considered in speciﬁc situations (e.g. pacemaker dependency, high-grade AVB, infranodal block,
high pacing threshold, planned AVJ ablation) or for sensing in the case of issues with detection
(e.g. risk of ventricular undersensing or oversensing of atrial/His potentials).423,426,444
IIa
C
HBP with a ventricular backup lead may be considered in patients in whom a ‘pace-and-ablate’
strategy for rapidly conducted supraventricular arrhythmia is indicated, particularly when the intrinsic QRS is narrow.197,199,200,318
IIb
C
Continued
HBP may be considered as an alternative to RV
pacing in patients with AVB and LVEF >40%,
who are anticipated to have >20% ventricular pacing.42,433
IIb
C
AVB = atrioventricular block; AVJ = atrioventricular junction; CRT = cardiac resynchronization therapy; HBP = His bundle pacing; LVEF = left ventricular ejection fraction; RV = right ventricular.
aClass of recommendation.
bLevel of evidence.
ESC 2021
.................................
ESC Guidelines
43


<!-- PAGE 44 -->

### Page 44

................................................................................
or previous cardiovascular implantable electronic device (CIED)
infection]. Observational data showed that a leadless pacemaker was a safe pacing alternative in patients with previous device infection and explant, and in patients on chronic haemodialysis. Whereas observational data indicate high efficacy and low complication rates with leadless pacemakers,50 there are currently no data from RCTs documenting the long-term safety and efficacy of leadless vs. standard transvenous pacemakers, and therefore the indication for a leadless pacemaker should be carefully considered on a case by case basis.
The absence of long-term data on leadless pacemaker performance and limited data on retrievability and end-of-life strategy449 require careful consideration before selecting leadless pacemaker therapy,
especially for younger patients (e.g. with a life expectancy >20 years).
8 Indications for pacing in specific conditions
8.1 Pacing in acute myocardial infarction
In patients with acute MI, significant bradyarrhythmia may occur due to autonomic influences or damage of the conduction system by ischaemia and/or reperfusion. The right coronary artery supplies the sinus node in 60% and the AVN and His bundle in 90%
of patients.451,452 AVB is located above the His bundle in most patients with inferior infarction, but is usually infra-Hisian and preceded by intraventricular conduction disturbances in anterior infarction.451,453457
The incidence of high-degree AVB in patients with ST-segment elevation MI has declined to 34% in the primary percutaneous coronary intervention era.458460 High-degree AVB is most frequent in inferior or inferolateral infarctions.455,458461
Patients with high-degree AVB have higher clinical risk and larger infarctions especially when AVB complicates an anterior infarction.458460,462,463 New-onset intraventricular conduction disturbance is also associated with larger infarctions.464467
Sinus bradycardia and AVB at presentation can be vagally mediated and may respond to atropine.455,468 Revascularization is recommended in patients with AVB who have not yet received reperfusion therapy.469 AVB may require temporary pacing in the presence of refractory symptoms or haemodynamic compromise,
but most often resolves spontaneously within a few days and only a minority of patients require permanent pacing.451,454,456,458,462 In patients with persistent intraventricular conduction abnormalities and transient AVB in whom permanent pacing was recommended in the past, there is no evidence that permanent cardiac pacing improves outcome.454,470 These patients frequently have HF and poor LV function, and should be evaluated for ICD, CRT-P, or CRTD rather than conventional pacing if an early device implantation is considered.471
If AVB does not resolve within 10 days, a permanent pacemaker should be implanted. In the absence of robust scientific data, the waiting period before pacemaker implantation has to be decided individually. It may last up to 10 days but can be shortened to 5 days depending on the occluded vessel, time delay, and success of revascularization. Conditions favouring consideration of earlier pacemaker implantation include unsuccessful or late revascularization, anterior
MI, bifascicular block or AV block before MI, and progression of AV
block within the first days after MI. Sick sinus syndrome after occlusion of the right coronary artery resolves in most cases. If revascularization is incomplete, pacemaker implantation can usually still be postponed and implantation only be performed if symptoms due to sinus bradycardia persist.
8.2 Pacing after cardiac surgery and heart transplantation
8.2.1
Pacing after coronary artery bypass graft and valve surgery
AVB may occur in 14% of cases after cardiac surgery and in
8% after repeat valve surgery.472476 SND may occur after right lateral atriotomy or transseptal superior approaches to the mitral valve.473,474
Recommendations for using leadless pacing (leadless pacemaker)
Recommendations
Classa
Levelb
Leadless pacemakers should be considered as an alternative to transvenous pacemakers when no upper extremity venous access exists or when risk of device pocket infection is particularly high, such as previous infection and patients on haemodialysis.45,4750,450
IIa
B
Leadless pacemakers may be considered as an alternative to standard single-lead ventricular pacing, taking into consideration life expectancy and using shared decision-making.45,4750
IIb
C
aClass of recommendation.
bLevel of evidence.
ESC 2021
Recommendations for cardiac pacing after acute myocardial infarction
Recommendations
Classa
Levelb
Implantation of a permanent pacemaker is indicated with the same recommendations as in a general population (section 5.2) when AVB does not resolve within a waiting period of at least 5
days after MI.
I
C
In selected patients with AVB in the context of anterior wall MI and acute HF, early device implantation (CRT-D/CRT-P) may be considered.471
IIb
C
Pacing is not recommended if AVB resolves after revascularization or spontaneously.454456,458
III
B
AVB = atrioventricular block; CRT-D = deﬁbrillator with cardiac resynchronization therapy; CRT-P = cardiac resynchronization therapy-pacemaker; MI = myocardial infarction.
aClass of recommendation.
bLevel of evidence.
ESC 2021
..........................................................................................


<!-- PAGE 45 -->

### Page 45

........................................................................................................................................................
Pacemaker implantation is more frequent after valvular than after coronary artery bypass graft (CABG) surgery.477 In clinical practice,
an observation period of 37 days is usually applied before implanting a permanent pacemaker473 to allow regression of transient bradycardias. The ideal timing of pacemaker implantation after cardiac surgery remains a topic of controversy, due to the fact that 6070%
of patients implanted for SND and up to 25% of those implanted for
AVB are not pacemaker dependent at follow-up.473,478 In the case of complete AVB occurring within the first 24 h after valvular surgery and persisting for 48 h, resolution within the next 12 weeks is unlikely and earlier implantation of a pacemaker may be considered.479,480 The same approach appears reasonable for complete
AVB with a low rate of escape rhythm.473 The situation in CHD surgery and in children may be different (see section 8.4).
In valvular endocarditis, predictors of AVB after surgery are preoperative conduction abnormalities, Staphylococcus aureus infection,
intracardiac abscess, tricuspid valve involvement, and previous valvular surgery.481 In patients with endocarditis and peri-operative AVB,
early pacemaker implantation is reasonable, especially when one or more predicting factors are present. In light of the infected state of the patient, intra-operative implantation of an epicardial pacemaker system during valvular surgery may be reasonable despite the absence of solid data on infection rates of epicardial vs. transvenous pacemaker systems.
8.2.2
Pacing after heart transplantation
SND is common and leads to permanent pacemaker implantation after heart transplantation in 8% of patients.473 Possible causes of
SND include surgical trauma, sinus node artery damage, or ischaemia and prolonged cardiac ischaemic times.482,483 AVB is less common,
and is probably related to inadequate preservation of the donor heart.473,483,484 Chronotropic incompetence is always present following standard orthotopic heart transplantation, as a result of loss of autonomic control. As sinus node and AVN function improve during the first few weeks after transplantation, an observation period before pacemaker implantation may allow spontaneous improvement of bradycardia.485 There is general consensus that patients in whom symptomatic bradycardia persists after the third postoperative week may require permanent pacemaker implantation.
DDD(R) mode with minimized ventricular pacing in the case of intact
AVN conduction is recommended.483
8.2.3
Pacing after tricuspid valve surgery
An underestimated aspect of the surgical management of tricuspid valve disease is to address trans-tricuspid pacemaker or ICD leads.
Such leads can interfere with the function of a repaired tricuspid valve or tricuspid valve prosthesis.
Placing an epicardial RV lead at the time of tricuspid valve surgery is the most straightforward alternative in cases with type II secondor third-degree AVB. There have been doubts about the long-term performance of epicardial leads, but recent data indicate, at least for epicardial LV leads, performance comparable with transvenous leads.486
Ventricular pacing after mechanical tricuspid valve replacement using a coronary sinus lead appears safe and feasible, but only results from small patient cohorts have been published. Procedural success of implantation was 100% in 23 patients; after 5.3 ± 2.8 years, 96% of leads were functional with stable pacing and sensing parameters.487
HBP is emerging as a more physiological method of ventricular pacing and may evolve into a possible solution in patients with AV
conduction disease after tricuspid valve surgery. One study investigating 30 patients with HBP after cardiac valve operations reported successful permanent HBP in 93% of these patients.488 This study included 10 patients with tricuspid valve annuloplasty.
After replacement by a mechanical valve, transvalvular lead placement is contraindicated, and implanting either a coronary sinus lead for ventricular pacing or epicardial leads, which may be placed minimally invasively, is recommended. To avoid damaging a repaired tricuspid valve or a tricuspid bioprosthesis, the optimal solution in patients needing ventricular pacing after such surgery should not include transvalvular lead implantation. Implanting a coronary sinus lead for ventricular pacing or minimally invasively placed epicardial leads is judged to be the preferred choice.
However, as indicated in observational reports, transvalvular lead implantation was used with acceptable results,489 and still may be considered in selected patients after tricuspid valve annuloplasty,
other types of repair, and replacement of a tricuspid valve by a bioprosthesis.
Performing tricuspid valve replacement in a patient with an existing RV lead, removal of the old RV lead and implantation of an epicardial RV lead should be preferred over sewing in the existing lead between a bioprosthesis and annulus. The reasons are that sewing in the lead may be associated with higher risk of lead failure and, in the case of future need for lead extraction, such a procedure is likely to require open heart surgery, which will be a reintervention with higher operative risk. In cases of tricuspid valve repair with a current annuloplasty ring with an open segment and without concomitant leaflet procedures, an existing RV lead may be left in place without sewing it in between the ring and the annulus. However, even in isolated annuloplasty procedures, an existing RV lead should ideally be removed to avoid future lead-related complications to the repaired tricuspid valve and an epicardial RV lead should be implanted. Particularly in patients not in need of a dual-chamber device, the use of a leadless pacemaker for ventricular pacing may serve as a feasible future alternative after tricuspid valve repair or replacement by a bioprosthesis. However, experience is very limited, and no long-term data are available in this cohort. Crossing a mechanical tricuspid valve with the delivery sheath and a leadless pacemaker is contraindicated.
ESC Guidelines
45


<!-- PAGE 46 -->

### Page 46

..................................................................................................................................................
8.3 Pacing after transcatheter aortic valve implantation
For extended literature on patients with pre-procedural RBBB and post-procedural
LBBB
see sections
8.3.1
and
8.3.2
in the
Supplementary data.
Rates of permanent pacemaker implantation after TAVI range between 3.4% and 25.9% in randomized trials and large registries.490502 Whereas the association between pacing after TAVI and outcome is controversial,503509 RV pacing may lead to deterioration in LV function.183,510,511 Thus, efforts to minimize unnecessary permanent pacing are warranted.
Predictors for permanent pacing (Table 10 and supplementary table
14), especially RBBB, which has been identified as the most consistent and powerful predictor for permanent pacemaker implantation,
should be incorporated into procedural planning including transcatheter heart valve selection, implantation height, and balloon inflations.
Patients with pre-existing advanced conduction system disease who may have an indication for permanent pacing irrespective of the
TAVI procedure need consultation with an electrophysiologist before the procedure. There is currently no evidence to support permanent pacemaker implantation as a ‘prophylactic’ measure before
TAVI in asymptomatic patients or in patients who do not meet the standard indications for pacemaker implantation.
A recommended approach for the management of conduction abnormalities after TAVI is detailed in Figure 12. Patients without new conduction disturbances post-TAVI are at very low risk of developing high-degree AVB.533535 Conversely, management of patients with persistent complete or high-degree AVB should follow standard guidelines. Permanent pacemaker implantation appears warranted in patients with intraprocedural AVB that persists for 24- 48 h after
TAVI or appears later. Data to guide the management of patients with other conduction abnormalities at baseline or post-procedure are more limited.
Given the close anatomical proximity of the aortic valve and the left bundle branch, the most frequent conduction abnormality after
TAVI is new-onset LBBB.504,536538 Only a small minority of these patients require pacemaker implantation.536,537 Thus, EPS539541 or long-term monitoring536 in lieu of pacemaker implantation may be considered542,543 (see section 8 in the Supplementary data). Several high-risk subgroups of patients with new LBBB have been identified
(see Figure 12, and section 8 in the Supplementary data). In such patients with dynamic progression of conduction abnormalities after
TAVI (new BBB with dynamic prolongation of QRS and/or PR), an extended monitoring period in hospital of up to 5 days should be considered. Conversely, patients with new-onset LBBB but QRS
Recommendations for cardiac pacing after cardiac surgery and heart transplantation
Recommendations
Classa
Levelb
1) High-degree or complete AVB after cardiac surgery
A period of clinical observation of at least 5
days is indicated to assess whether the rhythm disturbance is transient and resolves.
However, in the case of complete AVB with low or no escape rhythm when resolution is unlikely, this observation period can be shortened.473,478
I
C
2) Surgery for valvular endocarditis and intraoperative complete AVB
Immediate epicardial pacemaker implantation should be considered in patients with surgery for valvular endocarditis and complete AVB if one of the following predictors of persistence is present: pre-operative conduction abnormality,
Staphylococcus aureus infection, intracardiac abscess, tricuspid valve involvement, or previous valvular surgery.481
IIa
C
3) SND after cardiac surgery and heart transplantation
Before permanent pacemaker implantation, a period of observation of up to 6 weeks should be considered.473
IIa
C
4) Chronotropic incompetence after heart transplantation
Cardiac pacing should be considered for chronotropic incompetence persisting for >6 weeks after heart transplantation to improve quality of life.485
IIa
C
5) Patients requiring pacing at the time of tricuspid valve surgery
Transvalvular leads should be avoided and epicardial ventricular leads used. During tricuspid valve surgery, removal of pre-existing transvalvular leads should be considered and preferred over sewing in the lead between the annulus and a bioprosthesis or annuloplasty ring. In the case of an isolated tricuspid annuloplasty based on an individual riskbeneﬁt analysis, a preexisting RV lead may be left in place without jailing it between ring and annulus.
IIa
C
6) Patients requiring pacing after biological tricuspid valve replacement/tricuspid valve ring repair
When ventricular pacing is indicated, transvenous implantation of a coronary sinus lead or minimally invasive placement of an epicardial ventricular lead should be considered and preferred over a transvenous transvalvular approach.487
IIa
C
Continued
7) Patients requiring pacing after mechanical tricuspid valve replacement
Implantation of a transvalvular RV lead should be avoided.
III
C
AVB = atrioventricular block; RV = right ventricular; SND = sinus node dysfunction.
aClass of recommendation.
bLevel of evidence.
ESC 2021
...........................


<!-- PAGE 47 -->

### Page 47

Table 10
Predictors for permanent pacing after transcatheter aortic valve implantation
Characteristics
